1) Virmani R, Kolodgie FD, Burke AP et al:Lessons from sudden coronary death:A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20(5):1262-1275, 2000
循環器内科学レビュー 2022-’23
特記事項：
商品紹介
循環器内科学のエキスパートによって選別された、直近2年間を中心に国内外で発表された最新の文献レビューです。広く循環器内科関連の最近のトピックスを把握でき、循環器内科医だけでなく、専門医を目指す方にも役立つ1冊です。
目次
- I章 冠動脈疾患
1．冠動脈硬化と急性冠症候群の成因
2．安定冠動脈疾患のカテーテル室での機能的評価
3．冠動脈疾患の血管内イメージング
4．冠動脈疾患の画像診断
5．血行再建治療 vs 至適薬物療法
6．PCI vs CABG
7．薬物溶出性ステントupdate
8．冠動脈疾患と抗血栓療法
9．冠動脈患者に対する積極的脂質低下療法
II章 不整脈
10．不整脈と抗血栓療法
11．心房細動アブレーション
12．心室性不整脈アブレーション
13．心臓突然死とデバイス治療
14．遺伝性不整脈
15．不整脈とAI診療
16．不整脈検出デバイス
17．房室結節周囲の最新知見
18．不整脈症例の非薬物的抗血栓療法
III章 心不全
19．急性心不全の急性期治療戦略
20．慢性心不全―LVEFの低下した心不全(HFrEF)患者の薬物療法
21．慢性心不全―LVEFの保たれた心不全(HFpEF)患者の治療戦略
22．わが国における心臓移植の現況
23．心不全における緩和ケア
4．心不全と糖尿病 双方を意識した治療戦略
IV章 弁膜症
25．大動脈弁狭窄症に対するカテーテル治療（TAVI）
26．僧帽弁閉鎖不全症に対するカテーテル治療（MitraClip®）
27．大動脈弁閉鎖不全症・僧帽弁閉鎖不全症に対する外科的治療
28．僧帽弁狭窄症の治療の適応と介入のタイミング
29．三尖弁閉鎖不全、肺動脈弁閉鎖不全に対するカテーテル治療
V章 原発性心筋症・心筋炎・心膜疾患・心臓腫瘍
30．拡張型心筋症における最新の話題
31．肥大型心筋症における最新の話題
32．不整脈原性右室心筋症における最新の話題
33．たこつぼ症候群のトピックス
34．心筋炎・心膜疾患・心臓腫瘍のトピックス
VI章 二次性心筋症（アミロイドーシス、サルコイドーシス、ファブリーなど）
35．心臓サルコイドーシスの診断と治療
36．心アミロイドーシスの診断と治療
37．ファブリー病の診断と治療
38．抗癌剤による薬剤性心筋症の診断と治療
39．周産期心筋症の最近の話題
VII章 大動脈疾患
40．大動脈疾患の診断・内科治療
41．大動脈疾患の外科治療
42．大動脈疾患の血管内治療―特に、大動脈解離に対するTEVERについて
VIII章 末梢血管疾患
43．末梢動脈疾患における至適薬物治療
44．末梢動脈疾患の血行再建術（血管内治療）
45．末梢動脈疾患の血行再建術（バイパス手術）
46．急性下肢虚血の血栓溶解療法とカテーテル治療
47．腎動脈狭窄症に対するカテーテル治療
IX章 先天性心疾患
48．成人先天性心疾患に対するカテーテル治療の適応と現状
（心房中隔欠損、卵円孔開存、動脈管開存）
49．成人期川崎病の管理と治療
50．成人期を迎えた先天性心疾患術後患者の管理と治療
（ファロー四徴、修正大血管転位、フォンタン循環など）
51．成人先天性心疾患に合併した心不全の予後と治療
X章 生活習慣病
52．高血圧の診断と治療 up-to-date
53．心血管疾患予防のためのLDLコレステロール低下療法
54．糖尿病と心血管イベント
55．心血管イベントの残余リスクとそのコントロール
XI章 心肺蘇生術・集中治療・管理
56．心エコー図法による血行動態モニタリング
57．心肺蘇生と心停止後症候群
58．心原性ショックに対する補助循環デバイス
59．循環器救急における集中治療管理
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
I章 冠動脈疾患
P.2 掲載の参考文献
P.3 掲載の参考文献
2) Shibutani H, Fujii K, Ueda D et al:Automated classification of coronary atherosclerotic plaque in optical frequency domain imaging based on deep learning. Atherosclerosis 328:100-105, 2021
3) Nakashima Y, Chen YX, Kinukawa N et al:Distributions of diffuse intimal thickening in human arteries:Preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch 441(3):279-288, 2002
4) Nakashima Y, Fujii H, Sumiyoshi S et al:Early human atherosclerosis:Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infil-tration. Arterioscler Thromb Vasc Biol 27(5):1159-1165, 2007
P.4 掲載の参考文献
5) Back M, Yurdagul A, Tabas I et al:Inflammation and its resolution in atherosclerosis:Mediators and therapeutic opportunities. Nat Rev Cardiol 16:389-406, 2019
6) Kolodgie FD, Gold HK, Burke AP et al:Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349(24):2316-2325, 2003
7) Guo L, Akahori H, Harari E et al:CD163+ macrophages promote angiogenesis and vascular permeability accompanied by in-flammation in atherosclerosis. J Clin Invest 128(3):1106-1124, 2018
8) Fernandez-Friera L, Penalvo JL, Fernan-dez-Ortiz A et al:Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort the PESA(Progression of Early Subclinical Atherosclerosis)study. Circulation 131(24):2104-2113, 2015
9) Mori H, Torii S, Kutyna M et al:Coronary artery calcification and its progression:What does it really mean? JACC Cardio-vasc Imaging 11(1):127-142, 2018
P.5 掲載の参考文献
10) Motoyama S, Sarai M, Harigaya H et al:Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 54(1):49-57, 2009
11) Burke AP, Farb A, Malcom GT et al:Coronary risk factors and plaque morphol-ogy in men with coronary disease who died suddenly. N Engl J Med 336(18):1276-1282, 1997
12) Nakano M, Yahagi K, Yamamoto H et al:Additive value of integrated backscatter IVUS for detection of vulnerable plaque by optical frequency domain imaging. JACC Cardiovasc Imaging 9(2):163-172, 2016
13) Sugizaki Y, Otake H, Kawamori H et al:Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fi-broatheroma:An ALTAIR Trial Report. JACC Cardiovasc Imaging 13:1452-1454, 2020
14) Ota H, Omori H, Kawasaki M et al:Clini-cal impact of PCSK9 inhibitor on stabiliza-tion and regression of lipid-rich coronary plaques:A near-infrared spectroscopy study. Eur Heart J Cardiovasc Imaging, 2021[online ahead of print]
15) Kubo T, Ino Y, Mintz GS et al:Optical coherence tomography detection of vul-nerable plaques at high risk of developing acute coronary syndrome. Eur Heart J Cardiovasc Imaging, 2021[online ahead of print]
P.6 掲載の参考文献
16) van der Wal AC, Becker AE, van der Loos CM et al:Site of intimal rupture or erosion of thrombosed coronary athero-sclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89(1):36-44, 1994
17) Farb A, Burke AP, Tang AL et al:Coro-nary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Cir-culation 93(7):1354-1363, 1996
18) Nagasawa A, Otake H, Kawamori H et al:Relationship among clinical characteristics, morphological culprit plaque features, and long-term prognosis in patients with acute coronary syndrome. Int J Cardiovasc Im-aging, 2021[online ahead of print]
19) Cao M, Zhao L, Ren X et al:Pancoro-nary plaque characteristics in STEMI caused by culprit plaque erosion versus rupture:3-vessel OCT study. JACC Car-diovasc Imaging 14(6):1235-1245, 2021
20) Kato A, Minami Y, Asakura K et al:Characteristics of carotid atherosclerosis in patients with plaque erosion. J Thromb Thrombolysis, 2021[online ahead of print]
21) Kramer MCA, Rittersma SZH, de Winter RJ et al:Relationship of thrombus healing to underlying plaque morphology in sud-den coronary death. J Am Coll Cardiol 55(2):122-132, 2010
22) Shin E-S, Ann SH, Singh GB et al:OCT-defined morphological characteristics of coronary artery spasm sites in vasospastic angina. JACC Cardiovasc Imaging 8(9):1059-1067, 2015
23) Tashiro K, Mori H, Sone H et al:Con-firmed coronary spasm at the culprit ves-sel of plaque erosion in a patient with new-onset ventricular fibrillation. Coron Artery Dis 29(7):603-604, 2018
24) Jia H, Dai J, Hou J et al:Effective anti-thrombotic therapy without stenting:Intravascular optical coherence tomogra-phy-based management in plaque erosion (the EROSION study). Eur Heart J 38(11):792-800, 2017
25) He L, Qin Y, Xu Y et al:Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion:4-year outcomes of the EROSION study. EuroIntervention, 2020[online ahead of print]
P.7 掲載の参考文献
26) Torii S, Sato Y, Otsuka F et al:Eruptive calcified nodules as a potential mechanism of acute coronary thrombosis and sudden death. J Am Coll Cardiol 77(13):1599-1611, 2021
27) Lee T, Mintz GS, Matsumura M et al:Prevalence, predictors, and clinical pre-sentation of a calcified nodule as assessed by optical coherence tomography. JACC Cardiovasc Imaging 10(8):883-891, 2017
28) Mori H, Finn AV, Atkinson JB et al:Cal-cified nodule:An early and late cause of in-stent failure. JACC Cardiovasc Interv 9(13):e125-e126, 2016
29) Mann J, Davies MJ:Mechanisms of progression in native coronary artery disease:Role of healed plaque disruption. Heart 82(3):265-268, 1999
30) Burke AP, Kolodgie FD, Farb A et al:Healed plaque ruptures and sudden coro-nary death:Evidence that subclinical rupture has a role in plaque progression. Circulation 103(7):934-940, 2001
31) Fracassi F, Crea F, Sugiyama T et al:Healed culprit plaques in patients with acute coronary syndromes. J Am Coll Car-diol 73(18):2253-2263, 2019
32) Shimokado A, Matsuo Y, Kubo T et al:In vivo optical coherence tomography imag-ing and histopathology of healed coronary plaques. Atherosclerosis 275:35-42, 2018
P.9 掲載の参考文献
1) Lee JM, Choi KH, Park J et al:Physi-ological and clinical assessment of resting physiological indexes. Circulation 139:889-900, 2019
2) Johnson NP, Li W, Chen X et al:Diastolic pressure ratio:New approach and valida-tion vs. the instantaneous wave-free ratio. Euro Heart J 40:2585-2594, 2019
3) Lee JM, Lee SH, Hwang D et al:Long-term clinical outcomes of nonhyperemic pressure ratios:Resting full-cycle ratio, diastolic pressure ratio, and instantaneous wave-free ratio. J Am Heart Assoc 9:e016818, 2020
4) Volz S, Dworeck C, Redfors B et al:Survival of patients with angina pectoris undergoing percutaneous coronary inter-vention with intracoronary pressure wire guidance. J Am Coll Cardiol 75:2785-2799, 2020
P.10 掲載の参考文献
5) Parikh RV, Liu G, Plomondon ME et al:Utilization and outcomes of measuring fractional flow reserve in patients with stable ischemic heart disease. J Am Coll Cardiol 75:409-419, 2020
6) Kuramitsu S, Matsuo H, Shinozaki T et al:Two-year outcomes after deferral of revascularization based on fractional flow reserve:The J-CONFIRM Registry. Circ Cardiovasc Interv 13:e008355, 2020
7) Escaned J, Collet C, Ryan N et al:Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease:1-year results of the SYNTAX II study. Eur Heart J 38:3124-3134, 2017
8) Serruys PW, Kogame N, Katagiri Y et al:Clinical outcomes of state-of-the-art per-cutaneous coronary revascularisation in patients with three-vessel disease:Two-year follow-up of the SYNTAX II study. EuroIntervention 15:e244-e252, 2019
P.11 掲載の参考文献
9) Hamilos M, Muller O, Cuisset T et al:Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 120:1505-1512, 2009
10) Mallidi J, Atreya AR, Cook J et al:Long-term outcomes following fractional flow reserve-guided treatment of angiographi-cally ambiguous left main coronary artery disease:A meta-analysis of prospective cohort studies. Catheter Cardiovasc Interv 86:12-18, 2015
11) Warisawa T, Cook CM, Rajkumar C et al:Safety of revascularization deferral of left main stenosis based on instantaneous wave-free ratio evaluation. J Am Coll Car-diol Intv 13:1655-1664, 2020
P.12 掲載の参考文献
12) El Hajj SC, Toya T, Warisawa T et al:Correlation of intravascular ultrasound and instantaneous wave-free ratio in patients with intermediate left main coronary artery disease. Circ Cardiovasc Interv 14:e009830, 2021
P.13 掲載の参考文献
13) Warisawa T, Cook CM, Howard JP et al:Physiological pattern of disease assessed by Pressure-Wire Pullback has an influ-ence on fractional flow reserve/instanta-neous wave-free ratio discordance. Circ Cardiovasc Interv 12:e007494, 2019
14) Cook CM, Jeremias A, Petraco R et al:Fractional flow reserve/instantaneous wave-free ratio discordance in angiograph-ically intermediate coronary stenoses:An analysis using doppler-derived coronary flow measurements. J Am Coll Cardiol Intv 10:2514-2524, 2017
P.14 掲載の参考文献
15) Sen S, Ahmad Y, Dehbi HM et al:Clinical events after deferral of LAD revascular-ization following physiological coronary assessment. J Am Coll Cardiol 73:444-453, 2019
16) Warisawa T, Cook CM, Seligman H et al:Per-vessel level analysis of fractional flow reserve and instantaneous wave-free ratio discordance-Insights from the AJIP Reg-istry. Circ J 84:1034-1038, 2020
P.15 掲載の参考文献
17) Matsuo A, Kasahara T, Ariyoshi M et al:Utility of angiography-physiology coregis-tration maps during percutaneous coronary intervention in clinical practice. Cardiovasc Interv Ther 36:208-218, 2021
18) Warisawa T, Howard JP, Cook CM et al:Inter-observer differences in interpreta-tion of coronary pressure-wire pullback data by non-expert interventional cardiolo-gists. Cardiovasc Interv Ther 36:289-297, 2021
19) Collet C, Sonck J, Vandeloo B et al:Mea-surement of hyperemic pullback pressure gradients to characterize patterns of coro-nary atherosclerosis. J Am Coll Cardiol 74:1772-1784, 2019
20) Cook CM, Warisawa T, Howard JP et al:Algorithmic versus expert human inter-pretation of instantaneous wave-free ratio coronary pressure-wire pull back data. J Am Coll Cardiol Intv 12:1315-1324, 2019
P.16 掲載の参考文献
21) Kikuta Y, Cook CM, Sharp ASP et al:Pre-angioplasty instantaneous wave-free ratio pullback predicts hemodynamic outcome in humans with coronary artery disease:Primary results of the International Mul-ticenter iFR GRADIENT Registry. J Am Coll Cardiol Intv 11:757-767, 2018
22) Higashioka D, Yasutsugu Shiono, Takashi Kubo et al:The inter-study reproduc-ibility of instantaneous wave-free ratio and angiography coregistration. J Cardiol 75:507-512, 2020
23) Warisawa T, Howard JP, Kawase Y et al:Difference in functional assessment of indi-vidual stenosis severity in serial coronary lesions between resting and hyperemic pressure-wire pullback:Insights from the GIFT registry. Int J Cardiol 312:10-15, 2020
24) Omori H, Kawase Y, Mizukami T et al: Comparisons of nonhyperemic pressure ratios:Predicting functional results of coronary revascularization using longitu-dinal vessel interrogation. J Am Coll Car-diol Intv 13:2688-2698, 2020
25) Candreva A, Mizukami T, Sonck J et al:Hyperemic hemodynamic characteristics of serial coronary lesions assessed by pull-back pressure gradients. Catheter Cardio-vasc Interv, 2021[online ahead of print]
P.17 掲載の参考文献
26) Jeremias A, Davies JE, Maehara A et al:Blinded physiological assessment of resid-ual ischemia after successful angiographic percutaneous coronary intervention:The DEFINE PCI study. J Am Coll Cardiol Intv 12:1991-2001, 2019
27) van Zandvoort LJC, Masdjedi K, Witberg K et al:Explanation of postprocedural fractional flow reserve below 0.85. Circ Cardiovasc Interv 12:e007030, 2019
28) Fournier S, Ciccarelli G, Toth GG et al:Association of improvement in fractional flow reserve with outcomes, including symptomatic relief, after percutaneous coronary intervention. JAMA Cardiol 4:370-374, 2019
29) Yang HM, Lim HS, Yoon MH et al:Use-fulness of the trans-stent fractional flow reserve gradient for predicting clinical outcomes. Catheter Cardiovasc Interv 95:E123-E129, 2020
30) Shin D, Lee SH, Lee JM et al:Prognostic implications of post-intervention resting pd/pa and fractional flow reserve in pa-tients with stent implantation. J Am Coll Cardiol Intv 13:1920-1933, 2020
31) Lauri F, Macaya F, Mejia-Renteria H et al:Angiography-derived functional as-sessment of nonculprit coronary stenoses during primary percutaneous coronary intervention for ST-elevation myocardial infarction. EuroIntervention 15:e1594-e1601, 2020
32) Mejia-Renteria H, Nombela-Franco L, Para-dis JM et al:Angiography-based quan-titative flow ratio versus fractional flow reserve in patients with coronary artery disease and severe aortic stenosis. EuroIn-tervention 16:e285-e292, 2020
P.18 掲載の参考文献
33) Witberg G, Bruyne BD, Fearon WF et al:Diagnostic performance of angiogram-derived fractional flow reserve:A pooled analysis of 5 prospective cohort studies. J Am Coll Cardiol Intv 13:488-497, 2020
34) Emori H, Kubo T, Shiono Y et al:Com-parison of optical flow ratio and fractional flow ratio in stent-treated arteries imme-diately after percutaneous coronary inter-vention. Circ J 84:2253-2258, 2020
35) Wada T, Shiono Y, Kubo T et al:Impact of instantaneous wave-free ratio on graft failure after coronary artery bypass graft surgery. Int J Cardiol 324:23-29, 2021
36) Fournier S, Toth GG, Bruyne BD et al:Changes in surgical revascularization strategy after fractional flow reserve. Catheter Cardiovasc Interv, 2021[online ahead of print]
37) Bainey KR, Engstrom T, Smits PC et al:Complete vs Culprit-Lesion-Only Revascu-larization for ST-Segment Elevation Myo-cardial Infarction:A systematic review and meta-analysis. JAMA Cardiol 5:881-888, 2020
38) Cerrato E, Mejia-Renteria H, Dehbi HM et al:Revascularization deferral of nonculprit stenoses on the basis of fractional flow re-serve:1-year outcomes of 8,579 patients. J Am Coll Cardiol Intv 13:1894-1903, 2020
39) Puymirat E, Cayla G, Simon T et al:Multivessel PCI guided by FFR or angiog-raphy for myocardial infarction. N Engl J Med 385:297-308, 2021
P.20 掲載の参考文献
1) Konstantinides SV, Torbicki A, Agnelli G et al:2014 ESC guidelines on the diagnosis and management of acute pulmonary em-bolism. Eur Heart J 35:3033-3069, 2014
P.21 掲載の参考文献
2) Neumann FJ, Sousa-Uva M, Ahlsson A et al:2018 ESC/EACTS Guidelines on myo-cardial revascularization. Eur Heart J 40:87-165, 2019
3) Yamagishi M, Tamaki N, Akasaka T et al:JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. Circ J 85:402-572, 2021
4) Kurogi K, Ishii M, Sakamoto K et al:Opti-cal coherence tomography-guided percu-taneous coronary intervention with low-molecular-weight dextran-effect on renal function. Circ J 84:917-925, 2020
5) Kobayashi N, Shibata Y, Okazaki H et al:A novel technique of low molecular weight dextran infusion followed by catheter push(D-PUSH)for optical coherence tomography. EuroIntervention 17:e149-e151, 2021
6) Mizuno K, Arai T, Satomura K et al:New percutaneous transluminal coronary an-gioscope. J Am Coll Cardiol 13:363-368, 1989
P.22 掲載の参考文献
7) Mentias A, Sarrazin MV, Saad M et al:Long-Term outcomes of coronary stent-ing with and without use of intravascular ultrasound. JACC Cardiovasc Interv 13:1880-1890, 2020
8) Witzenbichler B, Maehara A, Weisz G et al:Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents:the assessment of dual antiplatelet therapy with drug-eluting stents(ADAPT-DES)study. Cir-culation 129:463-470, 2014
9) Buccheri S, Franchina G, Romano S et al:Clinical outcomes following intravascular imaging-guided versus coronary angi-ography-guided percutaneous coronary intervention with stent implantation:A systematic review and Bayesian network meta-analysis of 31 studies and 17,882 pa-tients. JACC Cardiovasc Interv 10:2488-2498, 2017
10) Hong SJ, Mintz GS, Ahn CM et al:Effect of intravascular ultrasound-guided drug-eluting stent implantation:5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv 13:62-71, 2020
11) Darmoch F, Alraies MC, Al-Khadra Y et al:Intravascular ultrasound imaging-guided versus coronary angiography-guid-ed percutaneous coronary intervention:A systematic review and meta-analysis. J Am Heart Assoc 9:e013678, 2020
12) Park SJ, Kim YH, Park DW et al:Impact of intravascular ultrasound guidance on long-term mortality in stenting for unpro-tected left main coronary artery stenosis. Circ Cardiovasc Interv 2:167-177, 2009
13) Kinnaird T, Johnson T, Anderson R et al:Intravascular imaging and 12-month mortality after unprotected left main stem PCI:An analysis from the British Cardio-vascular Intervention Society Database. JACC Cardiovasc Interv 13:346-357, 2020
14) Zhou J, Liew D, Duffy SJ et al:Intra-vascular ultrasound versus angiography-guided drug-eluting stent implantation:A health economic analysis. Circ Cardiovasc Qual Outcomes 14:e006789, 2021
15) Shlofmitz E, Torguson R, Zhang C et al:Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coro-nary InterventioN in Complex Lesions (iOPEN Complex). Am Heart J 221:74-83, 2020
P.23 掲載の参考文献
16) Kim BK, Shin DH, Hong MK et al:Clinical impact of intravascular ultrasound-guided chronic total occlusion intervention with zotarolimus-eluting versus biolimus-eluting stent implantation:Randomized study. Circ Cardiovasc Interv 8:e002592, 2015
17) Doi H, Maehara A, Mintz GS et al:Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents:An integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv 2:1269-1275, 2009
18) Fujii K, Carlier SG, Mintz GS et al:Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation:An intravascular ultrasound study. J Am Coll Cardiol 45:995-998, 2005
19) Kobayashi N, Mintz GS, Witzenbichler B et al:Prevalence, features, and prognostic importance of edge dissection after drug-eluting stent implantation:An ADAPT-DES intravascular ultrasound substudy. Circ Cardiovasc Interv 9:e003553, 2016
20) Zhang J, Gao X, Kan J et al:Intravascular ultrasound versus angiography-guided drug-eluting stent implantation:The UL-TIMATE Trial. J Am Coll Cardiol 72:3126-3137, 2018
21) Jones DA, Rathod KS, Koganti S et al:An-giography alone versus angiography plus optical coherence tomography to guide percutaneous coronary intervention:Out-comes from the Pan-London PCI Cohort. JACC Cardiovasc Interv 11:1313-1321, 2018
22) Kubo T, Shinke T, Okamura T et al:Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention(OPINION trial):One-year angiographic and clinical results. Eur Heart J 38:3139-3147, 2017
23) Ali ZA, Maehara A, Genereux P et al:Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent im-plantation(ILUMIEN III:OPTIMIZE PCI):A randomised controlled trial. Lan-cet 388:2618-2628, 2016
24) Ali ZA, Karimi Galougahi K, Mintz GS et al:Intracoronary optical coherence tomography:State of the art and future directions. EuroIntervention 17:e105-e123, 2021
P.24 掲載の参考文献
25) Chamie D, Costa JR, Jr., Damiani LP et al:Optical coherence tomography versus intravascular ultrasound and angiography to guide percutaneous coronary interven-tions:The iSIGHT Randomized Trial. Circ Cardiovasc Interv 14:e009452, 2021
26) Ali ZA, Karimi Galougahi K, Maehara A et al:Outcomes of optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation:One-year re-sults from the ILUMIEN III:OPTIMIZE PCI trial. EuroIntervention 16:1085-1091, 2021
27) Ali ZA, Landmesser U, Karimi Galougahi K et al:Optical coherence tomography-guided coronary stent implantation com-pared to angiography:A multicentre ran-domised trial in PCI-design and rationale of ILUMIEN IV:OPTIMAL PCI. EuroIn-tervention 16:1092-1099, 2021
28) Holm NR, Andreasen LN, Walsh S et al:Rational and design of the European ran-domized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial(OCTOBER). Am Heart J 205:97-109, 2018
29) Nissen SE, Nicholls SJ, Sipahi I et al:Ef-fect of very high-intensity statin therapy on regression of coronary atherosclero-sis:The ASTEROID trial. JAMA 295:1556-1565, 2006
30) Ako J, Hibi K, Tsujita K et al:Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome- The ODYSSEY J-IVUS Trial. Circ J 83:2025-2033, 2019
31) Takano M, Mizuno K, Yokoyama S et al:Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin:Serial evaluation by coronary angioscopy. J Am Coll Cardiol 42:680-686, 2003
32) Sugizaki Y, Otake H, Kawamori H et al:Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fi-broatheroma:An ALTAIR Trial Report. JACC Cardiovasc Imaging 13:1452-1454, 2020
P.26 掲載の参考文献
1) OECD health care activities 2021 https://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_REAC
2) MDsave https://www.mdsave.com/procedures/cardiac-ct-coronary-angiography/d786ffc8
3) 循環器疾患診療実態調査 http://www.j-circ.or.jp/jittai_chosa/#tensai
4) Inohara T, Kohsaka S, Spertus JA et al:Comparative trends in percutaneous coro-nary intervention in Japan and the United States, 2013 to 2017. J Am Coll Cardiol 76:1328-1340, 2020
5) Volz S, Dworeck C, Redfors B et al:Survival of patients with angina pectoris undergoing percutaneous coronary inter-vention with intracoronary pressure wire guidance. J Am Coll Cardiol 75:2785-2799, 2020
6) 厚生労働省保健局 医療課:平成30年度診療報酬改定の概要 医科II https://www.mhlw.go.jp/file/06-Seisaku-jouhou-12400000-Hokenkyoku/0000197984.pdf
7) Maron DJ, Hochman JS, Reynolds HR et al:ISCHEMIA Research Group. Initial in-vasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395-1407, 2020
8) 医薬・生活衛生局 医療機器審査管理課:審議結果報告書. (平成28年9月21日) https://www.pmda.go.jp/medical_devic-es/2016/M20161031002/641250000_22800BZX00418000_A100_1.pdf
P.27 掲載の参考文献
9) 「特掲診療料の施設基準等の一部を改正する件」(令和2年3月5日 厚生労働省告示第59号)「特掲診療料の施設基準等及びその届出に関する手続きの取扱いについて」(令和2年3月5日 保医発第0305第3号) https://www.mhlw.go.jp/content/12400000/000603894.pdf
10) NICE:HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography;Medical technologies guid-ance. 13 February 2017 www.nice.org.uk/guidance/mtg32
11) Miller JM, Rochitte CE, Dewey M et al:Diagnostic performance of coronary an-giography by 64-row CT. N Engl J Med 359:2324-2336, 2008
12) Newby DE, Adamson PD, Berry C et al;SCOT-HEART Investigators: Coronary CT angiography and 5-year risk of myo-cardial infarction. N Engl J Med 379(10):924-933, 2018
13) Lopes RD, Alexander KP, Stevens SR et al:Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction:Insights from the ISCHEMIA Trial. Circu-lation 142:1725-1735, 2020
14) Velazquez EJ, Lee KL, Jones RH et al;STICHES Investigators:Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374:1511-1520, 2016
15) Romero J, Xue X, Gonzalez W et al:CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease:a meta-analy-sis of prospective trials. JACC Cardiovasc Imaging 5:494-508, 2012
16) NSFとガドリニウム造影剤使用に関する合同委員会(日本医学放射線学会・日本腎臓学会):腎障害患者におけるガドリニウム造影剤使用に関するガイドライン(第2版:2009年9月2日改訂)
17) Dastidar AG, Harries I, Pontecorboli G et al:Native T1 mapping to detect extent of acute and chronic myocardial infarction:comparison with late gadolinium enhance-ment technique. Int J Cardiovasc Imaging 35:517-527, 2019
18) Dilsizian V, Bacharach SL, Beanlands RS et al:ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography nuclear cardiology proce-dures. J Nucl Cardiol 23:1187-1226, 2016
P.28 掲載の参考文献
19) O'Meara E, Mielniczuk LM, Wells GA et al;IMAGE HF investigators:Alterna-tive imaging modalities in ischemic heart failure(AIMI-HF)IMAGE HF Project I-A:study protocol for a randomized con-trolled trial. Trials 14:218, 2013
20) OECD:health care activities 2021 https://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT
21) Narula J, Chandrashekhar Y, Ahmadi A et al:SCCT 2021 expert consensus docu-ment on coronary computed tomographic angiography:a report of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 15:192-217, 2021
22) Williams MC, Moss AJ, Dweck M et al:Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study. J Am Coll Cardiol 73(3):291-301, 2019
23) Hecht HS, Cronin P, Blaha MJ et al:2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans:a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. J Car-diovasc Comput Tomogr 11:74-84, 2017
P.29 掲載の参考文献
24) Nishimura T, Nakajima K, Kusuoka H et al:Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial per-fusion SPECT:J-ACCESS study. Eur J Nucl Med Mol Imaging 35:319-328, 2008
25) Shah SJ, Lam CSP, Svedlund S et al:Prev-alence and correlates of coronary micro-vascular dysfunction in heart failure with preserved ejection fraction:PROMIS-HFpEF. Eur Heart J 39:3439-3450, 2018
26) D'Amario D, Migliaro S, Borovac JA et al:Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol 10:1347, 2019
27) Murphy VL, Naya M, Foster CR et al:Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 124:2215-2224, 2011
P.30 掲載の参考文献
1) 日本循環器学会, 日本冠疾患学会, 日本胸部外科学会 他:急性冠症候群ガイドライン(2018年改訂版). 2019 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_kimura.pdf
P.31 掲載の参考文献
2) Mehta SR, Wood DA, Storey RF et al:Complete revascularization with multives-sel PCI for myocardial infarction. N Engl J Med 381:1411-1421, 2019
3) Gershlick AH, Banning AS, Parker E et al:Long-term follow-up of complete ver-sus lesion-only revascularization in STEMI and multivessel disease:The CvLPRIT Trial. J Am Coll Cardiol 74:3083-3094, 2019
4) Bainey KR, Alemayehu W, Armstrong PW et al:Long-term outcomes of com-plete revascularization with percutaneous coronary intervention in acute coronary syndromes. JACC Cardiovasc Interv 13:1557-1567, 2020
5) Sheth T, Pinilla-Echeverri N, Moreno R et al:Nonculprit lesion severity and out-come of revascularization in patients with STEMI and multivessel coronary disease. J Am Coll Cardiol 76:1277-1286, 2020
6) Puymirat E, Cayla G, Simon T et al:Multivessel PCI guided by FFR or angiog-raphy for myocardial infarction. N Engl J Med 385:297-308, 2021
7) Cerrato E, Mejia-Renteria H, dehbi hm et al:revascularization deferral of non-culprit stenoses on the basis of fractional flow reserve:1-year outcomes of 8,579 pa-tients. JACC Cardiovasc Interv 13:1894-1903, 2020
8) 日本循環器学会, 日本冠疾患学会, 日本冠動脈外科学会 他:安定冠動脈疾患の血行再建ガイドライン(2018年改訂版). 2019 https://www.j-circ.or.jp/cms/wp-content/uploads/2018/09/JCS2018_nakamura_yaku.pdf
9) Maron DJ, Hochman JS, Reynolds HR et al:Initial invasive or conservative strat-egy for stable coronary disease. N Engl J Med 382:1395-1407, 2020
P.32 掲載の参考文献
10) 木村一雄, 中村正人, 石原正治 他:2020年JCSガイドラインフォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Naka-mura.pdf
11) 日本高血圧学会高血圧治療ガイドライン作成委員会 編:高血圧治療ガイドライン2019. 日本高血圧学会, 2019 https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf
12) 日本糖尿病学会 編:糖尿病診療ガイドライン2019. 2019
13) McGuire DK, Zinman B, Inzucchi SE et al:Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardio-vascular disease:A secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol 8:949-959, 2020
14) 日本動脈硬化学会:動脈硬化性疾患予防ガイドライン2017年版. 2017
P.33 掲載の参考文献
15) Xaplanteris P, Fournier S, Pijls NHJ et al:Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379:250-259, 2018
16) Bangalore S, Maron DJ, O'Brien SM et al:Management of coronary disease in patients with advanced kidney disease. N Engl J Med 382:1608-1618, 2020
17) Chaitman BR, Alexander KP, Cyr DD et al:Myocardial infarction in the ISCH-EMIA Trial:Impact of different defini-tions on incidence, prognosis, and treat-ment comparisons. Circulation 143:790-804, 2021
P.34 掲載の参考文献
18) Lopes RD, Alexander KP, Stevens SR et al:Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction:Insights from the ISCHEMIA Trial. Circu-lation 142:1725-1735, 2020
19) Navarese EP, Lansky AJ, Kereiakes DJ et al:Cardiac mortality in patients ran-domised to elective coronary revasculari-sation plus medical therapy or medical therapy alone:A systematic review and meta-analysis. Eur Heart J, 2021[online ahead of print]
20) Spertus JA, Jones PG, Maron DJ et al:Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 382:1408-1419, 2020
21) Spertus JA, Jones PG, Maron DJ et al:Health status after invasive or conserva-tive care in coronary and advanced kidney disease. N Engl J Med 382:1619-1628, 2020
P.35 掲載の参考文献
22) Fournier S, Kobayashi Y, Fearon WF et al:Asymptomatic patients with abnormal fractional flow reserve treated with medi-cation alone or with PCI. J Am Coll Cardiol 74:1642-1644, 2019
23) Waksman R, Di Mario C, Torguson R et al:Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging:A prospective, co-hort study. Lancet 394:1629-1637, 2019
24) Erlinge D, Maehara A, Ben-Yehuda O et al:Identification of vulnerable plaques and patients by intracoronary near-infra-red spectroscopy and ultrasound(PROS-PECT II):A prospective natural history study. Lancet 397:985-995, 2021
25) Lee JM, Choi KH, Koo BK et al:Prognos-tic implications of plaque characteristics and stenosis severity in patients with coronary artery disease. J Am Coll Cardiol 73:2413-2424, 2019
26) Stone GW, Maehara A, Ali ZA et al:Per-cutaneous coronary intervention for vul-nerable coronary atherosclerotic plaque. J Am Coll Cardiol 76:2289-2301, 2020
P.36 掲載の参考文献
1) 日本循環器学会, 日本冠疾患学会, 日本冠動脈外科学会 他:安定冠動脈疾患の血行再建ガイドライン(2018年改訂版). 2019
2) Doenst T, Haverich A, Serruys P et al:PCI and CABG for treating stable coro-nary artery disease:JACC review topic of the week. J Am Coll Cardiol 73(8):964-976, 2019
P.37 掲載の参考文献
3) Hannan EL, Zhong Y, Walford G et al:Coronary artery bypass graft surgery ver-sus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 64(25):2717-2726, 2014
4) Matsoukis IL, Karanasos A, Patsa C et al:Long-term clinical outcomes of coronary artery bypass graft surgery compared to those of percutaneous coronary interven-tion with second generation drug eluting stents in patients with stable angina and an isolated lesion in the proximal left an-terior descending artery. Catheter Cardio-vasc Interv, 2020[online ahead of print]
5) Neumann FJ, Sousa-Uva M, Ahlsson A et al:2018 ESC/EACTS Guidelines on myo-cardial revascularization. Eur Heart J 40(2):87-165, 2019
6) Gada H, Kirtane AJ, Kereiakes DJ et al:Meta-analysis of trials on mortality after percutaneous coronary intervention com-pared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. Am J Cardiol 115(9):1194-1199, 2015
7) Serruys PW, Morice MC, Kappetein AP et al:Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961-972, 2009
8) Thuijs D, Kappetein AP, Serruys PW et al:Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease:10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 394(10206):1325-1334, 2019
9) Ono M, Serruys PW, Hara H et al:10-year follow-up after revascularization in elderly patients with complex coronary artery disease. J Am Coll Cardiol 77(22):2761-2773, 2021
P.38 掲載の参考文献
10) Takahashi K, Serruys PW, Fuster V et al:Redevelopment and validation of the SYNTAX score II to individualise deci-sion making between percutaneous and surgical revascularisation in patients with complex coronary artery disease:Second-ary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet 396(10260):1399-1412, 2020
11) Farkouh ME, Domanski M, Sleeper LA et al:Strategies for multivessel revascular-ization in patients with diabetes. N Engl J Med 367(25):2375-2384, 2012
12) Farkouh ME, Domanski M, Dangas GD et al:Long-term survival following multives-sel revascularization in patients with dia-betes:The FREEDOM Follow-On study. J Am Coll Cardiol 73(6):629-638, 2019
13) Stone GW, Sabik JF, Serruys PW et al:Everolimus-eluting stents or bypass sur-gery for left main coronary artery disease. N Engl J Med 375(23):2223-2235, 2016
P.39 掲載の参考文献
14) Stone GW, Kappetein AP, Sabik JF et al:Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 381(19):1820-1830, 2019
15) Mack M, Holmes DR:Randomised trials in left main disease:a NOBLE effort. Lan-cet 388(10061):2715-2716, 2016
16) Holm NR, Makikallio T, Lindsay MM et al:Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis:updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 395(10219):191-199, 2020
17) Ahmad Y, Howard JP, Arnold AD et al:Mortality after drug-eluting stents vs. cor-onary artery bypass grafting for left main coronary artery disease:A meta-analysis of randomized controlled trials. Eur Heart J 41(34):3228-323, 2020
18) Takahashi K, Serruys PW, Gao C et al:Ten-year all-cause death according to com-pleteness of revascularization in patients with three-vessel disease or left main coronary artery disease:Insights from the SYNTAX Extended Survival Study. Circu-lation, 2021[online ahead of print]
P.40 掲載の参考文献
19) Tonino PA, De Bruyne B, Pijls NH et al:Fractional flow reserve versus angiogra-phy for guiding percutaneous coronary intervention. N Engl J Med 360(3):213-224, 2009
20) De Bruyne B, Fearon WF, Pijls NH et al:Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371(13):1208-1217, 2014
21) Xaplanteris P, Fournier S, Pijls NHJ et al:Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379(3):250-259, 2018
22) Toth G, De Bruyne B, Casselman F et al:Fractional flow reserve-guided versus an-giography-guided coronary artery bypass graft surgery. Circulation 128(13):1405-1411, 2013
23) Zimmermann FM, De Bruyne B, Pijls NH et al:Rationale and design of the Fraction-al Flow Reserve versus Angiography for Multivessel Evaluation(FAME)3 Trial:A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary ar-tery disease. Am Heart J 170(4):619-626. e2, 2015
24) 日本循環器学会, 日本冠疾患学会, 日本胸部外科学会 他:急性冠症候群ガイドライン(2018年改訂版). 2019
25) Mehta SR, Wood DA, Storey RF et al:Complete revascularization with multives-sel PCI for myocardial infarction. N Engl J Med 381(15):1411-1421, 2019
26) Gaba P, Gersh BJ, Ali ZA et al:Complete versus incomplete coronary revasculariza-tion:Definitions, assessment and outcomes. Nat Rev Cardiol 18(3):155-168, 2021
27) Bainey KR, Engstrom T, Smits PC et al:Complete vs Culprit-Lesion-Only Revascu-larization for ST-Segment Elevation Myo-cardial Infarction:A systematic review and meta-analysis. JAMA Cardiol 5(8):881-888, 2020
28) Stone GW, Witzenbichler B, Guagliumi G et al:Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358(21):2218-2230, 2008
P.41 掲載の参考文献
29) Thiele H, Akin I, Sandri M et al:PCI strategies in patients with acute myocar-dial infarction and cardiogenic shock. N Engl J Med 377(25):2419-2432, 2017
30) Hage A, Giambruno V, Jones P et al:Hy-brid coronary revascularization versus off-pump coronary artery bypass grafting:Comparative effectiveness analysis with long-term follow-up. J Am Heart Assoc 8(24):e014204, 2019
31) Moreno PR, Stone GW, Gonzalez-Lengua CA et al:The hybrid coronary approach for optimal revascularization:JACC re-view topic of the week. J Am Coll Cardiol 76(3):321-333, 2020
P.42 掲載の参考文献
1) Saito Y, Kobayashi Y:Contemporary coronary drug-eluting and coated stents:A mini-review. Cardiovasc Interv Ther 36(1):20-22, 2021
P.43 掲載の参考文献
2) Kandzari DE, Koolen JJ, Doros G et al:Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization:3-year outcomes from the randomized BIOFLOW V trial. JACC Cardiovasc Interv 13(11):1343-1353, 2020
3) Pilgrim T, Muller O, Heg D et al:Biode-gradable- versus durable-polymer drug-eluting stents for STEMI:Final 2-year outcomes of the BIOSTEMI trial. JACC Cardiovasc Interv 14(6):639-648, 2021
P.44 掲載の参考文献
4) Kerkmeijer LSM, Chandrasekhar J, Kalk-man DN et al:Final five-year results of the REMEDEE Registry:Real-world experience with the dual-therapy COMBO stent. Catheter Cardiovasc Interv 1-8, 2020
5) Jakobsen L, Christiansen EH, Freeman P et al:Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting combo stent with the sirolimus-eluting orsiro stent in patients treated with percutaneous coronary inter-vention:The SORT OUT X Trial. Circula-tion 143(22):2155-2165, 2021
6) Otaegui I, Perez de Prado A, Massotti M et al:Intrapatient randomization to study strut coverage in polymer-free versus biodegradable-polymer sirolimus-eluting stent Implantations. JACC Cardiovasc In-terv 13(7):899-900, 2020
7) Kufner S, Ernst M, Cassese S et al:10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents. J Am Coll Cardiol 76(2):146-158, 2020
P.45 掲載の参考文献
8) 木村一雄, 中村正人(班長):2020年 JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020 https://www.j-circ.or.jp/guideline/guideline-series/
9) Windecker S, Latib A, Kedhi E et al:Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 382(13):1208-1218, 2020
10) Watanabe H, Domei T, Morimoto T et al:Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiv-ing PCI:The STOPDAPT-2 randomized clinical trial. JAMA 321(24):2414-2427, 2019
11) Urban P, Mehran R, Colleran R et al:De-fining high bleeding risk in patients under-going percutaneous coronary intervention. A consensus document from the Academic Research Consortium for high bleeding risk. Circulation 140:240-261, 2019
12) Watanabe H, Domei T, Morimoto T et al:Details on the effect of very short dual an-tiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk:insight from the STOPDAPT-2 trial. Cardiovasc Interv Ther, 2020(in press)
P.46 掲載の参考文献
13) De Luca G, Damen SA, Camaro C et al:Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent(RE-DUCE trial). EuroIntervention 15(11):e990-e998, 2019
14) Giacoppo D, Matsuda Y, Fovino LN et al:Short dual antiplatelet therapy fol-lowed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents:A systematic review and meta-analysis of randomized clinical trials. Eur Heart J 42(4):308-319, 2021
15) Madhavan MV, Howard JP, Naqvi A et al:Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents:A systematic review and meta-analysis of randomized controlled trials. Eur Heart J, 2021[online ahead of print]
P.47 掲載の参考文献
16) Torii S, Jinnouchi H, Sakamoto A et al:Drug-eluting coronary stents:Insights from preclinical and pathology studies. Nat Rev Cardiol 17(1):37-51, 2020
17) Kimura T, Saito S, Ando K et al:Final 5-year results in randomized Japanese patients implanted with a thin-strut, bioab-sorbable, polymer-coated, everolimus-elut-ing SYNERGY stent(from the EVOLVE II Study). Circ Rep 3(1):9-17, 2020
18) Buiten RA, Ploumen EH, Zocca P et al:Thin, very thin, or ultrathin strut biode-gradable or durable polymer-coated drug-eluting stents:3-year outcomes of BIO-RESORT. JACC Cardiovasc Interv 12(17):1650-1660, 2019
19) Buccheri S, James S, Lindholm D et al:Clinical and angiographic outcomes of bio-absorbable vs. permanent polymer drug-eluting stents in Sweaden:A report from the Swedish Coronary and Angioplasty Registry(SCAAR). Eur Heart J 40:2607-2615, 2019
20) Iglesias JF, Muller O, Heg D et al:Biodegradable polymer sirolimus-eluting stents versus durable polymer everoli-mus-eluting stents in patients with ST-segment elevation myocardial infarction(BIOSTEMI):A single-blind, prospective, randomised superiority trial. Lancet 394(10205):1243-1253, 2019
21) Choe JC, Cha KS, Lee JG et al:Long-term outcomes of biodegradable versus second-generation durable polymer drug-eluting stent implantations for myocardial infarc-tion. JACC Cardiovasc Interv 13:97-111, 2020
P.48 掲載の参考文献
22) Natsuaki M, Morimoto T, Shiomi H et al:Application of the Academic Research Consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. Circ Cardiovasc Interv 12(11):e008307, 2019
23) Nakamura M, Kadota K, Nakao K et al:High bleeding risk and clinical outcomes in East Asian patients undergoing per-cutaneous coronary intervention:The PENDULUM registry. EuroIntervention 16(14):1154-1162, 2021
P.50 掲載の参考文献
1) Tada T, Byrne RA, Simunovic I et al:Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents:results from a registry of 18,334 patients. JACC Cardiovasc Interv 6:1267-1274, 2013
2) Mauri L, Kereiakes DJ, Yeh RW et al:Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155-2166, 2014
3) Bonaca MP, Bhatt DL, Cohen M et al:Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791-1800, 2015
4) Palmerini T, Benedetto U, Bacchi-Reggiani L et al:Mortality in patients treated with extended duration dual antiplatelet thera-py after drug-eluting stent implantation:A pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385:2371-2382, 2015
5) Urban P, Mehran R, Colleran R et al:Defining high bleeding risk in patients undergoing percutaneous coronary inter-vention:A consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 40:2632-2653, 2019
6) Urban P, Mehran R, Colleran R et al:Defining High bleeding risk in patients undergoing percutaneous coronary inter-vention. Circulation 140:240-261, 2019
7) Natsuaki M, Morimoto T, Shiomi H et al:application of the academic research con-sortium high bleeding risk criteria in an all-comers registry of percutaneous coro-nary intervention. Circ Cardiovasc Interv 12:e008307, 2019
P.51 掲載の参考文献
8) 木村一雄, 中村正人, 石原正治 他:2020年JCSガイドラインフォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020
9) Nakamura M, Kimura K, Kimura T et al:JCS 2020 Guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J 84:831-865, 2020
10) Natsuaki M, Morimoto T, Yamaji K et al:Prediction of thrombotic and bleeding events after percutaneous coronary inter-vention:CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 7, 2018
11) Valgimigli M, Bueno H, Byrne RA et al:2017 ESC focused update on dual anti-platelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet ther-apy in coronary artery disease of the Eu-ropean Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS). Eur Heart J 39:213-260, 2018
P.52 掲載の参考文献
12) Vranckx P, Valgimigli M, Juni P et al:Ti-cagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monother-apy for 12 months after implantation of a drug-eluting stent:A multicentre, open-label, randomised superiority trial. Lancet 392:940-949, 2018
13) Tomaniak M, Chichareon P, Onuma Y et al:Benefit and risks of aspirin in ad-dition to ticagrelor in acute coronary syndromes:A post hoc analysis of the Randomized GLOBAL LEADERS Trial. JAMA Cardiol 4:1092-1101, 2019
14) Watanabe H, Domei T, Morimoto T et al:Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI:The STOPDAPT-2 Randomized Clinical Trial. JAMA 321:2414-2427, 2019
P.53 掲載の参考文献
15) Watanabe H, Domei T, Morimoto T et al:Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk:Insight from the STOPDAPT-2 Trial. Circulation 140:1957-1959, 2019
16) Windecker S, Latib A, Kedhi E et al:polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 382:1208-1218, 2020
17) Urban P, Meredith IT, Abizaid A et al:Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373:2038-2047, 2015
18) Mehran R, Baber U, Sharma SK et al:Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381:2032-2042, 2019
P.54 掲載の参考文献
19) Kim BK, Hong SJ, Cho YH et al:Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovas-cular events in patients with acute coro-nary syndrome:The TICO Randomized Clinical Trial. JAMA 323:2407-2416, 2020
20) Dewilde WJ, Oirbans T, Verheugt FW et al:Use of clopidogrel with or without aspirin in patients taking oral anticoagu-lant therapy and undergoing percutane-ous coronary intervention:An open-label, randomised, controlled trial. Lancet 381:1107-1115, 2013
21) Gibson CM, Mehran R, Bode C et al:Pre-vention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423-2434, 2016
22) Cannon CP, Bhatt DL, Oldgren J et al:Dual antithrombotic therapy with dabiga-tran after PCI in atrial fibrillation. N Engl J Med 377:1513-1524, 2017
23) Lopes RD, Heizer G, Aronson R et al:An-tithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509-1524, 2019
24) Vranckx P, Valgimigli M, Eckardt L et al:Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in pa-tients with atrial fibrillation(ENTRUST-AF PCI):A randomised, open-label, phase 3b trial. Lancet 394:1335-1343, 2019
P.55 掲載の参考文献
25) Gargiulo G, Goette A, Tijssen J et al:Safety and efficacy outcomes of double vs. triple an-tithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention:A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 40:3757-3767, 2019
26) Lip GY, Windecker S, Huber K et al:Man-agement of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing per-cutaneous coronary or valve interventions:A joint consensus document of the Euro-pean Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association(EHRA), European Association of Percutaneous Cardiovascular Interven-tions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155-3179, 2014
27) Matsumura-Nakano Y, Shizuta S, Komasa A et al:Open-label randomized trial compar-ing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 139:604-616, 2019
28) Yasuda S, Kaikita K, Akao M et al:An-tithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381:1103-1113, 2019
P.57 掲載の参考文献
1) Kimura K, Kimura T, Ishihara M et al:JCS 2018 Guideline on diagnosis and treat-ment of acute coronary syndrome. Circ J 83:1085-1196, 2019
2) Yamashita S, Masuda D, Matsuzawa Y:Pemafibrate, a new selective PPARalpha Modulator:Drug concept and its clinical applications for dyslipidemia and meta-bolic diseases. Curr Atheroscler Rep 22(1):5-21, 2020
P.58 掲載の参考文献
3) Pradhan AD, Paynter NP, Everett BM et al:Rationale and design of the Pemafi-brate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes(PROMINENT)study. Am Heart J 206:80-93, 2018
4) Bhatt DL, Steg PG, Miller M et al:Car-diovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 380:11-22, 2019
5) Nicholls SJ, Lincoff AM, Garcia M et al:Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk:The STRENGTH Randomized Clini-cal Trial. JAMA 324(22):2268-2280, 2020
6) Bowman L, Mafham M, Wallendszus K et al:Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379(16):1540-1550, 2018
7) Manson JE, Cook NR, Lee I et al:Marine n-3 fatty acids and prevention of cardio-vascular disease and cancer. N Engl J Med 380(1):23-32, 2019
8) Kodera S, Morita H, Kiyosue A et al:Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coro-nary artery disease in Japan. Circ J 82(10):2602-2608, 2018
9) Wilson PWF, Polonsky TS, Miedema MD et al:Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cho-lesterol:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e1144, 2019
10) Polack FP, Thomas SJ, Kitchin N et al:Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603-2615, 2020
12) Nakamura M, Imamura T, Kinugawa K:Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloido-sis. J Cardiol Cases 23(4):177-180, 2021
P.59 掲載の参考文献
13) Nanavati C, McMullen G, Yu R et al:Interspecies scaling of human clearance and plasma trough exposure for antisense oligonucleotides:A retrospective analysis of triantennary N-Acetyl galactosamine-conjugated and unconjugated-antisense oligonucleotides. Nucleic Acid Ther, 2021[online ahead of print]
14) Blom DJ, Raal FJ, Santos RD et al:Lomitapide and mipomersen-inhibiting microsomal triglyceride transfer protein(MTP) and apoB100 synthesis. Curr Ath-eroscler Rep 21(12):48, 2019
15) Wright RS, Ray KK, Raal FJ et al:Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterol-emia or atherosclerosis. J Am Coll Cardiol 77(9):1182-1193, 2021
16) Fitzgerald K, White S, Borodovsky A et al:A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41-51, 2017
17) Cordero A, Santos-Gallego CG, Facila L et al:Estimation of the major cardiovascular events prevention with Inclisiran. Athero-sclerosis 313:76-80, 2020
18) Lekuona I, Pinto X:Clinical development of bempedoic acid:phase 2 and phase 3 clinical trials. Clin Investig Arterioscler 33 Suppl 1:58-64, 2021
P.60 掲載の参考文献
19) Ahmad Z, Pordy R, Rader DJ et al:Inhibi-tion of angiopoietin-like protein 3 with evi-nacumab in subjects with high and severe hypertriglyceridemia. J Am Coll Cardiol 78(2):193-195, 2021
20) Tsimikas S, Moriarty PM, Stroes ES:Emerging RNA therapeutics to lower blood levels of Lp(a):JACC Focus Semi-nar 2/4. J Am Coll Cardiol 77(12):1576-1589, 2021
II章 不整脈
P.62 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2020年改訂版 不整脈薬物治療ガイドライン. 2020 https://www.j-circ.or.jp/old/guideline/pdf/JCS2020_Ono.pdf
P.63 掲載の参考文献
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2021年JCS/JHRSガイドライン フォーカスアップデート版 不整脈非薬物治療. 2021 https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Kurita_No-gami.pdf
3) 木村一雄, 中村正人, 石原正治 他:2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Naka-mura.pdf
4) January CT, Wann LS, Calkins H et al:2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibril-lation:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Col-laboration With the Society of Thoracic Surgeons. Circulation 140:e125-e151, 2019
5) Izumi C, Miyake M, Amano M et al:Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves:A retrospective observational study. J Cardiol 76:44-50, 2020
6) Guimaraes PO, Pokorney SD, Lopes RD et al:Efficacy and safety of apixaban vs war-farin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair:Insights from the ARISTO-TLE trial. Clin Cardiol 42:568-571, 2019
P.64 掲載の参考文献
7) Okumura K, Tomita H, Nakai M et al:Risk factors associated with ischemic stroke in Japanese patients with nonval-vular atrial fibrillation. JAMA Netw Open 3:e202881, 2020
8) Okumura K, Tomita H, Nakai M et al:A novel risk stratification system for isch-emic stroke in Japanese patients with non-valvular atrial fibrillation. Circ J 85:1254-1262, 2021
P.65 掲載の参考文献
9) 小谷英太郎:心房細動患者に対する血圧管理の重要性. Cardio-Coagulation 7:36-41, 2020
10) Kodani E, Inoue H, Atarashi H et al:Impact of blood pressure visit-to-visit vari-ability on adverse events in patients with nonvalvular atrial fibrillation:Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc 10:e018585, 2021
11) Nakamura K, Naito S, Sasaki T et al:Un-interrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation:A prospective randomized single-centre study on post-ab-lation thrombo-embolic and haemorrhagic events. Europace 21:259-267, 2019
P.66 掲載の参考文献
12) Asmarats L, Cruz-Gonzalez I, Nombela-Franco L et al:Recurrence of device-related thrombus after percutaneous left atrial appendage closure. Circulation 140:1441-1443, 2019
P.67 掲載の参考文献
13) Matsumura-Nakano Y, Shizuta S, Komasa A et al:Open-label randomized trial com-paring oral anticoagulation with and with-out single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coro-nary stent implantation. Circulation 139:604-616, 2019
14) Yasuda S, Kaikita K, Akao M et al:An-tithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381:1103-1113, 2019
15) Inoue H, Uchiyama S, Atarashi H et al:Effectiveness and safety of long-term dabi-gatran among patients with non-valvular atrial fibrillation in clinical practice:J-dabigatran surveillance. J Cardiol 73:507-514, 2019
16) Ikeda T, Ogawa S, Kitazono T et al:Real-world outcomes of the Xarelto Post-Autho-rization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation(XAPASS). J Cardiol 74:60-66, 2019
P.68 掲載の参考文献
17) Sakuma I, Uchiyama S, Atarashi H et al:Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban:the EXPAND Study sub-analysis. Heart Ves-sels 34:1839-1851, 2019
18) Inoue H, Umeyama M, Yamada T et al:Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fi-brillation in clinical practice:A regulatory postmarketing surveillance, the STAN-DARD study. J Arrhythm 35:506-514, 2019
19) Inoue H, Umeyama M, Yamada T et al:Safety and effectiveness of reduced-dose apixaban in Japanese patients with non-valvular atrial fibrillation in clinical prac-tice:A sub-analysis of the STANDARD study. J Cardiol 75:208-215, 2020
20) Yamashita T, Koretsune Y, Nagao T et al:Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation(ETNA-AF-Japan):One-year safety and effectiveness analyses. J Arrhythm 36:395-405, 2020
21) Kato ET, Goto S, Giugliano RP:Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 49:115-124, 2019
22) Kodani E, Akao M:Atrial fibrillation and stroke prevention:state of the art-epidemiology and pathophysiology:New risk factors, concepts and controversies. Eur Heart J Suppl 22:O1-O13, 2020
23) Yamashita T, Suzuki S, Inoue H et al:Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation:Results from the All Nippon AF In the Elderly(ANAFIE)Registry. Eur Heart J Qual Care Clin Outcomes, 2021[online ahead of print]
24) Okumura K, Yamashita T, Suzuki S et al:A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibril-lation patients(J-ELD AF Registry). Clin Cardiol 43:251-259, 2020
25) Okumura K, Akao M, Yoshida T et al:Low-dose edoxaban in very elderly pa-tients with atrial fibrillation. N Engl J Med 383:1735-1745, 2020
P.69 掲載の参考文献
26) Akao M, Yamashita T, Suzuki S et al:Clinical outcomes according to dose re-duction criteria of apixaban in Japanese elderly patients with atrial fibrillation:J-ELD AF Registry subanalysis. Heart Ves-sels 36:1035-1046, 2021
27) An Y, Ogawa H, Yamashita Y et al:Causes of death in Japanese patients with atrial fibrillation:The Fushimi Atrial Fi-brillation Registry. Eur Heart J Qual Care Clin Outcomes 5:35-42, 2019
28) Kodani E, Inoue H, Atarashi H et al:Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation:A subanalysis of the J-RHYTHM Registry. Int J Cardiol 302:81-87, 2020
29) An Y, Ogawa H, Esato M et al:Cardio-vascular events and mortality in patients with atrial fibrillation and anemia(from the Fushimi AF Registry). Am J Cardiol 134:74-82, 2020
30) Kodani E, Inoue H, Atarashi H et al:Impact of digitalis use on mortality in Japa-nese patients with non-valvular atrial fibril-lation-A subanalysis of the J-RHYTHM Registry. Circ J 83:1644-1652, 2019
P.71 掲載の参考文献
1) Katsumata Y, Kimura T, Kohsaka S et al:Discrepancy in recognition of symp-tom burden among patients with atrial fi-brillation. Am Heart J 226:240-249, 2020
2) Katsumata Y, Kohsaka S, Ikemura N et al:Symptom underrecognition of atrial fibrillation patients in consideration for catheter ablation:A report from the Kics-AF Registry. JACC Clin Electrophysiol 7:565-574, 2020
3) Steinberg BA, Turner J, Lyons A et al:Systematic collection of patient-reported outcomes in atrial fibrillation:feasibility and initial results of the Utah mEVAL AF programme. Europace 22:368-374, 2020
4) Mark DB, Anstrom KJ, Sheng S et al:Effect of catheter ablation vs medical ther-apy on quality of life among patients with atrial fibrillation:The CABANA random-ized clinical trial. JAMA 321:1275-1285, 2019
5) Sohns C, Zintl K, Zhao Y et al:Impact of left ventricular function and heart failure symptoms on outcomes post abla-tion of atrial fibrillation in heart failure:CASTLE-AF trial. Circ Arrhtyhm Electro-physiol 13:e008461, 2020
6) Marrouche NF, Brachmann J, Andresen D et al:Catheter ablation for atrial fibril-lation with heart failure. N Engl J Med 378:417-427, 2018
7) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2021年JCS/JHRSガイドライン フォーカスアップデート版 不整脈非薬物治療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Kurita_No-gami.pdf
8) Sugumar H, Prabhu S, Costello B et al:Catheter ablation versus medication in atrial fibrillation and systolic dysfunction:Late outcomes of CAMERA-MRI study. JACC Clin Electrophysiol 6:1721-1731, 2020
9) Hindricks G, Potpara T, Dagres N et al:2020 ESC Guidelines for the diagnosis and management of atrial fibrillation devel-oped in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS). Eur Heart J 42:373-498, 2021
P.72 掲載の参考文献
10) Kirchhof P, Camm AJ, Goette A et al:Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383:1305-1316, 2020
11) Haissaguerre M, Jais P, Shah DC et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmo-nary veins. N Engl J Med 339:659-666, 1998
12) Wazni OM, Dandamudi G, Sood N et al:Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 384:316-324, 2021
13) Verma A, Jiang CY, Betts TR et al:Ap-proaches to catheter ablation for persis-tent atrial fibrillation. N Engl J Med 372:1812-1822, 2015
14) Valderrabano M, Peterson LE, Swarup V et al:Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrilla-tion:the VENUS randomized clinical trial. JAMA 324:1620-1628, 2020
15) Derval N, Duchateau J, Denis A et al:Marshall bundle elimination, Pulmonary vein isolation, and Line completion for ANatomical ablation of persistent atrial fi-brillation(Marshall-PLAN):Prospective, single-center study. Heart Rhythm 18:529-537, 2021
16) Lee SH, Tai CT, Hsieh MH et al:Predic-tors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation:Implication for catheter ablation. J Am Coll Cardiol 46:1054-1059, 2005
17) Kamanu S, Tan AY, Peter CT et al:Vein of Marshall activity during sustained atrial fibrillation. J Cardiovasc Electrophysiol 17:839-846, 2006
P.73 掲載の参考文献
18) Kashimura S, Fujisawa T, Nakajima K et al:Electrical isolation of the Marshall bundle by radiofrequency catheter abla-tion:in patients with atrial fibrillation. JACC Clin Electrophysiol 6:1647-1657, 2020
19) Su WW, Reddy VY, Bhasin K et al:Cryo-balloon ablation of pulmonary veins for persistent atrial fibrillation:results from the multicenter STOP Persistent AF trial. Heart Rhythm 17:1841-1847, 2020
20) Shigeta T, Okishige K, Nishimura T et al:Clinical investigation of the durability of the lesions created by left atrial linear ablation with a cryoballoon. J Cardiovasc Electrophysiol 31:875-884, 2020
21) Aryana A, Allen SL, Pujara DK et al:Concomitant pulmonary vein and poste-rior wall isolation using cryoballoon with adjunct radiofrequency in persistent atrial fibrillation. JACC Clin Electrophysiol 7:187-196, 2021
22) Hussein A, Das M, Riva S et al:Use of ablation index-guided ablation results in high rates of durable pulmonary vein isolation and freedom from arrhythmia in persistent atrial fibrillation patients:The PRAISE Study Results. Circ Arrhtyhm Electrophysiol 11:e006576, 2018
P.74 掲載の参考文献
23) Kottmaier M, Popa M, Bourier F et al:Safety and outcome of very high-power short-duration ablation using 70 W for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. Europace 22:388-393, 2020
24) Pambrun T, Durand C, Constantin M et al:High-power(40-50W)radiofrequency ablation guided by unipolar signal modifi-cation for pulmonary vein isolation:exper-imental findings and clinical results. Circ Arrhtyhm Electrophysiol 12:e007304, 2019
25) Chen S, Chun KRJ, Tohoku S et al:Esophageal endoscopy after catheter ab-lation of atrial fibrillation using ablation-index guided high-power:Frankfurt AI-HP ESO-I. JACC Clin Electrophysiol 6:1253-1261, 2020
26) Reddy VY, Neuzil P, Koruth JS et al:Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol 74:315-326, 2019
27) Reddy VY, Anic A, Koruth J et al:Pulsed field ablation in patients with persistent atrial fibrillation. J Am Coll Cardiol 76(9):1068-1080, 2020
P.75 掲載の参考文献
28) Providencia R, Adragao P, de Asmundis C et al:Impact of body mass index on the out-comes of catheter ablation of atrial fibrilla-tion:A European observational multicenter study. J Am Heart Assoc 8:e012253, 2019
29) Glover BM, Hong KL, Dagres N et al:Im-pact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart 105:244-250, 2019
30) Voskoboinik A, Kalman JM, De Silva A et al:Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 382:20-28, 2020
31) Donnellan E, Wazni OM, Harb S et al:Higher baseline cardiorespiratory fitness is associated with lower arrhythmia recur-rence and death after atrial fibrillation ab-lation. Heart Rhythm 17:1687-1693, 2020
32) Congrete S, Bintvihok M, Thongprayoon C et al:Effect of obstructive sleep apnea and its treatment of atrial fibrillation recur-rence after radiofrequency catheter abla-tion:a meta-analysis. J Evid Based Med 11:145-151, 2018
P.77 掲載の参考文献
1) Frankel DS, Tung R, Santangeli P et al:Sex and catheter ablation for ventricular tachycardia:An International Ventricular Tachycardia Ablation Center Collabora-tive Group Study. JAMA Cardiol 1:938-944, 2016
2) Kuo L, Shirai Y, Muser D et al:Compari-son of the arrhythmogenic substrate be-tween men and women with nonischemic cardiomyopathy. Heart Rhythm 16:1414-1420, 2019
3) Soto-Iglesias D, Penela D, Jauregui B et al:Cardiac magnetic resonance-guided ventricular tachycardia substrate abla-tion. JACC Clin Electrophysiol 6:436-447, 2020
4) Aronis KN, Ali RL, Prakosa A et al:Accurate conduction velocity maps and their association with scar distribution on magnetic resonance imaging in patients with postinfarction ventricular tachycar-dias. Circ Arrhythm Electrophysiol 13:e007792, 2020
5) Sepehri Shamloo A, Schoene K, Stauber A et al:Epicardial adipose tissue thickness as an independent predictor of ventricular tachycardia recurrence following ablation. Heart Rhythm 16:1492-1498, 2019
P.78 掲載の参考文献
6) Ghannam M, Siontis KC, Kim MH et al:Risk stratification in patients with fre-quent premature ventricular complexes in the absence of known heart disease. Heart Rhythm 17:423-430, 2020
7) Sung E, Prakosa A, Aronis KN et al:Personalized digital-heart technology for ventricular tachycardia ablation targeting in hearts with infiltrating adiposity. Circ Arrhythm Electrophysiol 13:e008912, 2020
8) de Riva M, Naruse Y, Ebert M et al:Myocardial calcification is associated with endocardial ablation failure of post-myo-cardial infarction ventricular tachycardia. Europace, 2021[online ahead of print]
9) Guandalini GS, Liang JJ, Marchlinski FE:Ventricular tachycardia ablation:past, present, and future perspectives. JACC Clin Electrophysiol 5:1363-1383, 2019
10) Fernandez-Armenta J, Soto-Iglesias D, Silva E et al:Safety and outcomes of ventricular tachycardia substrate ablation during sinus rhythm:A prospective mul-ticenter registry. JACC Clin Electrophysiol 6:1435-1448, 2020
P.79 掲載の参考文献
11) Okubo K, Gigli L, Trevisi N et al:Long-term outcome after ventricular tachy-cardia ablation in nonischemic cardiomy-opathy:Late potential abolition and VT noninducibility. Circ Arrhythm Electro-physiol 13:e008307, 2020
12) Quinto L, Sanchez-Somonte P, Alarcon F et al:Ventricular tachycardia burden reduction after substrate ablation:Pre-dictors of recurrence. Heart Rhythm 18:896-904, 2021
13) Okubo K, Frontera A, Bisceglia C et al:Grid mapping catheter for ventricular tachycardia ablation. Circ Arrhythm Elec-trophysiol 12:e007500, 2019
14) Frontera A, Melillo F, Baldetti L et al:High-density characterization of the ven-tricular electrical substrate during sinus rhythm in post-myocardial infarction pa-tients. JACC Clin Electrophysiol 6:799-811, 2020
15) Martin CA, Takigawa M, Martin R et al:Use of novel electrogram "Lumipoint" al-gorithm to detect critical isthmus and ab-normal potentials for ablation in ventricu-lar tachycardia. JACC Clin Electrophysiol 5:470-479, 2019
16) Aziz Z, Shatz D, Raiman M et al:Tar-geted ablation of ventricular tachycardia guided by wavefront discontinuities dur-ing sinus rhythm:A new functional sub-strate mapping strategy. Circulation 140:1383-1397, 2019
P.80 掲載の参考文献
17) Tung R, Raiman M, Liao H et al:Simulta-neous endocardial and epicardial delinea-tion of 3D reentrant ventricular tachycar-dia. J Am Coll Cardiol 75:884-897, 2020
18) Bhaskaran A, Nayyar S, Porta-Sanchez A et al:Direct and indirect mapping of in-tramural space in ventricular tachycardia. Heart Rhythm 17:439-446, 2020
19) Ghannam M, Siontis KC, Kim HM et al:Stepwise approach for ventricular tachy-cardia ablation in patients with predomi-nantly intramural scar. JACC Clin Electro-physiol 6:448-460, 2020
20) Zhou G, Lu X, Nie Z et al:QRS complex axis deviation changing in catheter abla-tion of left fascicular ventricular tachycar-dia. Europace 22:1688-1696, 2020
21) Phanthawimol W, Nogami A, Haruna T et al:Reverse-type left posterior fascicular ventricular tachycardia:A new electro-cardiographic entity. JACC Clin Electro-physiol, 7:843-854, 2021
P.81 掲載の参考文献
22) Ghannam M, Siontis KC, Cochet H et al:Value of mapping and ablation of ventricu-lar tachycardia targets within the coro-nary venous system in patients with non-ischemic cardiomyopathy. Heart Rhythm 17:520-526, 2020
23) Anderson RD, Lee G, Trivic I et al:Fo-cal ventricular tachycardias in structural heart disease:Prevalence, characteristics, and clinical outcomes after catheter abla-tion. JACC Clin Electrophysiol 6:56-69, 2020
24) Shirai Y, Liang JJ, Hirao K et al:Non-scar-related and Purkinje-related ventricu-lar tachycardia in patients with structural heart disease:Prevalence, mapping features, and clinical outcomes. JACC Clin Electrophysiol 6:231-240, 2020
25) Daimee UA, Assis FR, Murray B et al:Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardio-myopathy:Insights from the Johns Hop-kins ARVC Program. Heart Rhythm, 2021[online ahead of print]
26) Liang E, Wu L, Fan S et al:Catheter abla-tion of arrhythmogenic right ventricular cardiomyopathy ventricular tachycardia:18-year experience in 284 patients. Euro-pace 22:806-812, 2020
27) Pappone C, Mecarocci V, Manguso F et al:New electromechanical substrate ab-normalities in high-risk patients with Bru-gada syndrome. Heart Rhythm 17:637-645, 2020
28) Kamakura T, Cochet H, Juhoor M et al:Role of endocardial ablation in eliminating an epicardial arrhythmogenic substrate in patients with Brugada syndrome. Heart Rhythm, 2021[online ahead of print]
29) Anderson RD, Lee G, Virk S et al:Cath-eter Ablation of Ventricular Tachycardia in Patients With a Ventricular Assist De-vice:A Systematic Review of Procedural Characteristics and Outcomes. JACC Clin Electrophysiol 5:39-51, 2019
P.82 掲載の参考文献
30) Ballout JA, Wazni OM, Tarakji KG et al:Catheter ablation in patients with cardio-genic shock and refractory ventricular tachycardia. Circ Arrhythm Electrophysi-ol 13:e007669, 2020
31) Lloyd MS, Wight J, Schneider F et al:Clinical experience of stereotactic body radiation for refractory ventricular tachy-cardia in advanced heart failure patients. Heart Rhythm 17:415-422, 2020
P.83 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン:不整脈非薬物治療ガイドライン(2018年改訂版). 2019 https://www.j-circ.or.jp/old/guideline/pdf/JCS2018_kurita_nogami.pdf
2) McMurray JJV, Packer M, Desai AS et al;PARADIGM-HF investigators and committees:Angiotensin-neprilysin inhi-bition versus enalapril in heart failure. N Engl J Med 371:993-1004, 2014
3) Moss AJ, Zareba W, Hall WJ et al;Multi-center Automatic Defibrillator Implanta-tion Trial II Investigators:Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002
P.84 掲載の参考文献
4) Bardy GH, Lee KL, Mark DB et al;Sud-den Cardiac Death in Heart Failure Trial (SCD-HeFT)Investigators:Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237, 2005
5) Buxton AE, Lee KL, DiCarlo L et al;Mul-ticenter Unsustained Tachycardia Trial Investigators:Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342:1937-1945, 2000
6) Shen L, Jhund PS, McMurray JJV:De-clining risk of sudden death in heart fail-ure. N Engl J Med 377(18):1794-1795, 2017
7) Desai AS, Fang JC, Maisel WH et al:Im-plantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy:A meta-analysis of ran-domized controlled trials. JAMA 292:2874-2879, 2004
8) Kober L, Thune JJ, Nielsen JC et al;DANISH Investigators:Defibrillator im-plantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221-1230, 2016
9) Golwala H, Bajaj NS, Arora G et al:Implantable cardioverter-defibrillator for nonischemic cardiomyopathy:An updated meta-analysis. Circulation 135:201-203, 2017
10) Barakat AF, Saad M, Elgendy AY et al:Primary prevention implantable cardio-verter defibrillator in patients with non-ischaemic cardiomyopathy:A meta-analysis of randomised controlled trials. BMJ Open 7:e016352, 2017
11) Elming MB, Nielsen JC, Haarbo J et al:Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 136:1772-1780, 2017
12) Satake H, Fukuda K, Sakata Y et al;CHART-2 Investigators:Current status of primary prevention of sudden cardiac death with implantable cardioverter defi-brillator in patients with chronic heart fail-ure-a report from the CHART-2 Study. Circ J 79:381-390, 2015
P.85 掲載の参考文献
13) Noda T, Kurita T, Nitta T et al:Signifi-cant impact of electrical storm on mortali-ty in patients with structural heart disease and an implantable cardiac defibrillator. Int J Cardiol 255:85-91, 2018
14) Kondo Y, Noda T, Sato Y et al:Compari-son of 2-year outcomes between primary and secondary prophylactic use of defibril-lators in patients with coronary artery disease:A prospective propensity score-matched analysis from the Nippon Storm Study. Heart Rhythm O2 2:5-11, 2021
P.86 掲載の参考文献
15) Kotake Y, Yasuoka R, Tanaka M et al:Comparison of second appropriate defi-brillator therapy occurrence in patients implanted for primary prevention and secondary prevention-Sub-analysis of the Nippon Storm Study -. Int J Cardiol Heart Vasc 32:100704, 2020
16) Chinushi M, Furushima H, Saitoh O et al:Patient-by-patient basis anti-tachycardia pacing for fast ventricular tachycardia with structural heart diseases. Pacing Clin Electrophysiol 43:983-991, 2020
17) Hayashi H, Shimizu W, Iwasaki Y et al:Efficacy of antitachycardia pacing for elec-trical storms in patients with implantable defibrillators. J Cardiovasc Electrophysiol 32:823-831, 2021
18) Maruyama M, Yasuoka R, Nagano T et al:Impact of atrial fibrillation/flutter on outcomes of patients with implantable cardioverter defibrillators:A sub-analysis of the Nippon Storm study. J Cardiol, 2021[online ahead of print]
P.87 掲載の参考文献
19) Desai AS, McMurray JJV, Packer M et al:Effect of the angiotensin-receptor-ne-prilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36:1990-1997, 2015
20) Rohde LE, Chatterjee NA, Vaduganathan M et al:Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause:a PARADIGM-HF analysis. JACC Heart Fail 8:844-855, 2020
P.88 掲載の参考文献
21) Chia YMF, Teng THK, Tang ESJ et al:Disparity between indications for and utilization of implantable cardioverter defibrillators in Asian patients with heart failure. Circ Cardiovasc Qual Outcomes 10:e003651, 2017
P.89 掲載の参考文献
1) Adler A, Novelli V, Amin AS et al:An in-ternational, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation 141:418-428, 2020
P.90 掲載の参考文献
2) Lahrouchi N, Tadros R, Crotti L et al:Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome. Circulation 142:324-338, 2020
3) Sugrue A, van Zyl M, Enger N et al:Echo-cardiography-guided risk stratification for long QT syndrome. J Am Coll Cardiol 76:2834-2843, 2020
P.91 掲載の参考文献
4) Bos JM, Attia ZI, Albert DE et al:Use of artificial intelligence and deep neural networks in evaluation of patients with electrocardiographically concealed long QT syndrome from the surface 12-lead electrocardiogram. JAMA Cardiol 6:532-538, 2021
5) MacIntyre CJ, Rohatgi RK, Sugrue AM et al:Intentional nontherapy in long QT syn-drome. Heart Rhythm 17:1147-1150, 2020
6) Bos JM, Crotti L, Rohatgi RK et al:Mexi-letine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Elec-trophysiol 12:e007280, 2019
P.92 掲載の参考文献
7) Dagradi F, Spazzolini C, Castelletti S et al:Exercise training-induced repolarization abnormalities masquerading as congenital long QT syndrome. Circulation 142:2405-2015, 2020
8) Rubin GA, Desai AD, Chai Z et al:Cardiac corrected QT interval changes among patients treated for COVID-19 infection during the early phase of the pandemic. JAMA Netw Open 4:e216842, 2021
9) Man JCK, Bosada FM, Scholman KT et al:Variant intronic enhancer controls SCN10A-short expression and heart con-duction. Circulation, 2021[online ahead of print]
P.93 掲載の参考文献
10) Glazer AM, Wada Y, Li B et al:High-throughput reclassification of SCN5A vari-ants. Am J Hum Genet 107:111-123, 2020
11) Chatterjee D, Pieroni M, Fatah M et al:An autoantibody profile detects Brugada syndrome and identifies abnormally ex-pressed myocardial proteins. Eur Heart J 41:2878-2890, 2020
12) Wakamiya A, Kamakura T, Shinohara T et al:Improved risk stratification of Pa-tients With Brugada syndrome by the New Japanese Circulation Society Guideline- A multicenter validation study. Circ J 84:2158-2165, 2020
P.94 掲載の参考文献
13) Ciconte G, Monasky MM, Santinelli V et al:Brugada syndrome genetics is associ-ated with phenotype severity. Eur Heart J 42:1082-1090, 2021
14) Yamagata K, Horie M, Aiba T et al:Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardio-graphic characteristics of probands with Brugada syndrome:A Japanese multi-center registry. Circulation 135(23):2255-2270, 2017
15) Ishikawa T, Kimoto H, Mishima H et al:Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syn-drome. Eur Heart J, 2021[online ahead of print]
16) Honarbakhsh S, Providencia R, Garcia-Hernandez J et al:A primary prevention clinical risk score model for patients with Brugada syndrome(BRUGADA-RISK). JACC Clin Electrophysiol 7:210-222, 2021
P.95 掲載の参考文献
1) Hannun AY, Rajpurkar P, Haghpanahi M et al:Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med 25(1):65-69, 2019. Erratum in:Nat Med 25(3):530, 2019
P.96 掲載の参考文献
2) Ribeiro AH, Ribeiro MH, Paixao GMM et al:Automatic diagnosis of the 12-lead ECG using a deep neural network. Nat Commun 11(1):1760, 2020. Erratum in:Nat Com-mun 11(1):2227, 2020
3) Zhu H, Cheng C, Yin H et al:Automatic multilabel electrocardiogram diagnosis of heart rhythm or conduction abnormalities with deep learning:A cohort study. Lan-cet Digit Health 2(7):e348-e357, 2020. Erratum in:Lancet Digit Health 2(9):e455, 2020
4) Attia ZI, Noseworthy PA, Lopez-Jimenez F et al:An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during si-nus rhythm:A retrospective analysis of outcome prediction. Lancet 394(10201):861-867, 2019
5) Christopoulos G, Graff-Radford J, Lopez CL et al:Artificial intelligence-electrocar-diography to predict incident atrial fibril-lation:A population-based study. Circ Ar-rhythm Electrophysiol 13(12):e009355, 2020
6) Raghunath S, Pfeifer JM, Ulloa-Cerna AE et al:Deep neural networks can predict new-onset atrial fibrillation from the 12-lead ecg and help identify those at risk of atrial fibrillation-related stroke. Circulation 143(13):1287-1298, 2021
P.97 掲載の参考文献
7) Tiwari P, Colborn KL, Smith DE et al:Assessment of a machine learning model applied to harmonized electronic health record data for the prediction of incident atrial fibrillation. JAMA Netw Open 3(1):e1919396, 2020
8) Mittal S, Oliveros S, Li J et al:AI filter improves positive predictive value of atrial fibrillation detection by an implantable loop recorder. JACC Clin Electrophysiol, 2021[online ahead of print]
9) Wasserlauf J, You C, Patel R et al:Smart-watch performance for the detection and quantification of atrial fibrillation. Circ Ar-rhythm Electrophysiol 12(6):e006834, 2019
10) Luongo G, Azzolin L, Schuler S et al:Machine learning enables noninvasive pre-diction of atrial fibrillation driver location and acute pulmonary vein ablation success using the 12-lead ECG. Cardiovasc Digit Health J 2(2):126-136, 2021
11) Shade JK, Ali RL, Basile D et al:Prepro-cedure application of machine learning and mechanistic simulations predicts likelihood of paroxysmal atrial fibrillation recur-rence following pulmonary vein isolation. Circ Arrhythm Electrophysiol 13(7):e008213, 2020
12) Roney CH, Beach ML, Mehta AM et al:In silico comparison of left atrial ablation techniques that target the anatomical, structural, and electrical substrates of atrial fibrillation. Front Physiol 11:1145, 2020
P.98 掲載の参考文献
13) Alhusseini MI, Abuzaid F, Rogers AJ et al:Machine learning to classify intra-cardiac electrical patterns during atrial fibrillation:machine learning of atrial fibrillation. Circ Arrhythm Electrophysiol 13(8):e008160, 2020
14) Vinter N, Frederiksen AS, Albertsen AE et al:Role for machine learning in sex-specific prediction of successful electrical cardioversion in atrial fibrillation? Open Heart 7(1):e001297, 2020
15) Bos JM, Attia ZI, Albert DE et al:Use of artificial intelligence and deep neural networks in evaluation of patients with electrocardiographically concealed long QT syndrome from the surface 12-lead electrocardiogram. JAMA Cardiol 6(5):532-538, 2021
16) Giudicessi JR, Schram M, Bos JM et al:Artificial intelligence-enabled assessment of the heart rate corrected QT interval using a mobile electrocardiogram device. Circulation 143(13):1274-1286, 2021
P.99 掲載の参考文献
17) Okada DR, Miller J, Chrispin J et al:Substrate spatial complexity analysis for the prediction of ventricular arrhythmias in patients with ischemic cardiomyopathy. Circ Arrhythm Electrophysiol 13(4):e007975, 2020
18) Bhattacharya M, Lu DY, Kudchadkar SM et al:Identifying ventricular arrhythmias and their predictors by applying machine learning methods to electronic health records in patients with hypertrophic cardiomyopathy(HCM-VAr-Risk Model). Am J Cardiol 123(10):1681-1689, 2019
19) Rogers AJ, Selvalingam A, Alhusseini MI et al:Machine learned cellular pheno-types in cardiomyopathy predict sudden death. Circ Res 128(2):172-184, 2021
20) Shakibfar S, Krause O, Lund-Andersen C et al:Predicting electrical storms by remote monitoring of implantable cardio-verter-defibrillator patients using machine learning. Europace 21(2):268-274, 2019
21) Gyawali PK, Horacek BM, Sapp JL et al:Sequential factorized autoencoder for lo-calizing the origin of ventricular activation from 12-lead electrocardiograms. IEEE Trans Biomed Eng 67(5):1505-1516, 2020
P.100 掲載の参考文献
22) Nakamura T, Nagata Y, Nitta G et al:Pre-diction of premature ventricular complex origins using artificial intelligence-enabled algorithms. Cardiovasc Digit Health J 2 (1):76-83, 2021
23) Feeny AK, Rickard J, Patel D et al:Machine learning prediction of response to cardiac resynchronization therapy:improvement versus current guidelines. Circ Arrhythm Electrophysiol 12(7):e007316, 2019
24) Tokodi M, Schwertner WR, Kovacs A et al:Machine learning-based mortality pre-diction of patients undergoing cardiac re-synchronization therapy:The SEMMEL-WEIS-CRT score. Eur Heart J 41(18):1747-1756, 2020
25) Varma N, Cygankiewicz I, Turakhia M et al:2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Ar-rhythmia Management:Digital Medical Tools for Heart Rhythm Professionals:From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. J Arrhythm 37(2):271-319, 2021
P.101 掲載の参考文献
26) 厚生労働省医薬・生活衛生局医療機器審査管理課長:医療機器の変更計画の確認申請の取扱いについて. 薬生機審発0831第14号. 2020年8月31日
27) U.S. Food and Drug Administration:Arti-ficial Intelligence/Machine Learning Based Software as a Medical Device(SaMD) Action Plan. 2021 Jan https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-in-telligence-and-machine-learning-software-medical-device
P.103 掲載の参考文献
1) Hindricks G, Potpara T, Dagres N et al:2020 ESC Guidelines for the diagnosis and management of atrial fibrillation devel-oped in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):The Task Force for the diag-nosis and management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contri-bution of the European Heart Rhythm As-sociation(EHRA)of the ESC. Eur Heart J 42(5):373-498, 2021
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2020年改訂版 不整脈薬物治療ガイドライン.
3) Khurshid S, Chang Y, Guan W et al:Abstract 15336:Real-world diagnostic performance of single-lead handheld electrocardiograms for atrial fibrillation screening:The Vital-af Trial. Circulation 142:A15336, 2020
4) Reed MJ, Grubb NR, Lang CC et al:Multi-centre randomised controlled trial of a smartphone-based event recorder along-side standard care versus standard care for patients presenting to the emergency department with palpitations and pre-syn-cope:The IPED(Investigation of Palpita-tions in the ED)study. EClinicalMedicine 8:37-46, 2019
P.104 掲載の参考文献
5) Burke J, Haigney MCP, Borne R et al:Smartwatch detection of ventricular tachycardia:Case series. HeartRhythm Case Rep 6(10):800-804, 2020
6) Hochstadt A, Chorin E, Viskin S et al:Continuous heart rate monitoring for au-tomatic detection of atrial fibrillation with novel bio-sensing technology. J Electrocar-diol 52:23-27, 2019
P.105 掲載の参考文献
7) Choi W, Kim SH, Lee W et al:Comparison of continuous ECG monitoring by wear-able patch device and conventional tele-monitoring device. J Korean Med Sci 35(44):e363, 2020
P.106 掲載の参考文献
8) Perez MV, Mahaffey KW, Hedlin H et al:Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 381(20):1909-1917, 2019
9) Campion EW, Jarcho JA:Watched by Apple. N Engl J Med 381(20):1964-1965, 2019
10) Chen E, Jiang J, Su R et al:A new smart wristband equipped with an artificial intel-ligence algorithm to detect atrial fibrilla-tion. Heart Rhythm 17(5 Pt B):847-853, 2020
11) Guo Y, Wang H, Zhang H et al:Mobile photoplethysmographic technology to de-tect atrial fibrillation. J Am Coll Cardiol 74(19):2365-2375, 2019
12) Wasserlauf J, You C, Patel R et al:Smart-watch performance for the detection and quantification of atrial fibrillation. Circ Ar-rhythm Electrophysiol 12(6):e006834, 2019
P.107 掲載の参考文献
13) Sequeira N, D'Souza D, Angaran P et al:Common wearable devices demonstrate variable accuracy in measuring heart rate during supraventricular tachycardia. Heart Rhythm 17(5 Pt B):854-859, 2020
14) Goldenthal IL, Sciacca RR, Riga T et al:Recurrent atrial fibrillation/flutter detec-tion after ablation or cardioversion us-ing the AliveCor KardiaMobile device:iHEART results. J Cardiovasc Electro-physiol 30(11):2220-2228, 2019
15) Karunadas CP, Mathew C:Comparison of arrhythmia detection by conventional Holter and a novel ambulatory ECG sys-tem using patch and Android App, over 24 h period. Indian Pacing Electrophysiol J 20(2):49-53, 2020
16) Kaura A, Sztriha L, Chan FK et al:Early prolonged ambulatory cardiac monitoring in stroke(EPACS):An open-label ran-domised controlled trial. Eur J Med Res 24(1):25, 2019
17) Biersteker TE, Schalij MJ, Treskes RW:Impact of mobile health devices for the detection of atrial fibrillation:Systematic review. JMIR Mhealth Uhealth 9(4):e26161, 2021
P.108 掲載の参考文献
18) Heidbuchel H, Arbelo E, D'Ascenzi F et al:Recommendations for participation in leisure-time physical activity and competi-tive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2:Ventricular arrhythmias, chan-nelopathies, and implantable defibrillators. Europace 23(1):147-148, 2021
19) Szep J, Hariri S, Khalpey Z:Predictive diagnosis of fatal heart rhythms using wearables. 2019 Spring Simulation Confer-ence(SpringSim):1-10, 2019
20) Spaccarotella CAM, Polimeni A, Migliarino S et al:Multichannel electrocardiograms obtained by a smartwatch for the diagno-sis of ST-segment changes. JAMA Cardiol 5(10):1176-1180, 2020
21) Havakuk O, Sadeh B, Merdler I et al:Validation of a novel contact-free heart and respiratory rate monitor. J Med Eng Technol 45(5):344-350, 2021
P.109 掲載の参考文献
22) Nelson BW, Low CA, Jacobson N et al:Guidelines for wrist-worn consumer wear-able assessment of heart rate in biobehav-ioral research. NPJ Digit Med 3:90, 202
P.110 掲載の参考文献
1) Tawara S:Das Reitzleitungssystem des Saugetierherzens:Eine anatomisch-histol-ogische Studie uber das Atrioventrikular-bundel und die Purkinjeschen Faden. Jena, Germany:Gustav Fischer, 1906
2) Moe GK, Preston JB, Burlington H:Physi-ologic evidence for a dual A-V transmis-sion system. Circ Res 4:357-375, 1956
3) Denes P, Wu D, Dhingra RC et al:Dem-onstration of dual AV nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation 48:549-555, 1973
P.111 掲載の参考文献
4) Katritsis DG, Ellenbogen KA, Becker AE:Atrial activation during atrioventricular nodal reentrant tachycardia:Studies on retrograde fast pathway conduction. Heart Rhythm 3:993-1000, 2006
5) Anderson RH, Becker AE, Brechenmacher C et al:The human atrioventricular junc-tional area. A morphological study of the A-V node and bundle. Eur J Cardiol 3:11-25, 1975
6) Anderson RH, Sanchez-Quintana D, Mori S et al:Re-evaluation of the structure of the atrioventricular node and its connections with the atrium. Europace 22:821-830, 2020
7) Otomo K, Suyama K, Okamura H et al:Participation of a concealed atriohisian tract in the reentrant circuit of the slow-fast type of atrioventricular nodal reen-trant tachycardia. Heart Rhythm 4(6):703-710, 2007
8) Lockwood D, Nakagawa H, Jackman W:Electrophysiologic characteristics of atrio-ventricular nodal reentrant tachycardia:implications for the reentrant circuit. Car-diac electrophysiology:From cell to bed-side(Zipes DP, Jalife J), 6th ed. Elsevier, Philadelphia, pp767-787, 2014
9) Kaneko Y, Naito S, Okishige K et al:Atypical fast-slow atrioventricular nodal reentrant tachycardia incorporating a "su-perior" slow pathway:A distinct supra-ventricular tachyarrhythmia. Circulation 133(2):114-123, 2016
10) Kaneko Y, Nakajima T, Iizuka T et al:Atypical fast-slow atrioventricular nodal reentrant tachycardia using a slow path-way extending to the superoanterior right atrium. Int Heart J 60(3):756-760, 2019
P.112 掲載の参考文献
11) Kaneko Y, Nakajima T, Nogami A et al:Atypical fast-slow atrioventricular nodal reentrant tachycardia utilizing a slow pathway extending to the inferolateral right atrium. Circ Rep 1(2):46-54, 2019
12) Hucker WJ, McCain ML, Laughner JI et al:Connexin 43 expression delineates two discrete pathways in the human atrioven-tricular junction. Anat Rec 291:204-215, 2008
13) Mahaim I, Benatt A:Nouvelles recher-ches sur les connexionssuperieures de la branche gauche du faisceau de His-Tawara avec cloison interventriculaire. Cardiologia 1:61, 1937
14) Mahaim I:Kent's fibers and the A-V paraspecific conduction through the upper connections of the bundle of His-Tawara. Am Heart J 33:651-653, 1947
P.113 掲載の参考文献
15) Tchou P, Lehmann MH, Jazayeri M et al:Atriofascicular connection or a nodoven-tricular Mahaim fiber? Electrophysiologi-cal elucidation of the pathway and associ-ated reentrant circuit. Circulation 77:837-848, 1988
16) Gmeiner R, Ng CK, Hammer I et al:Tachycardia caused by an accessory nodo-ventricular tract:A clinico-pathologic cor-relation. Eur Heart J 5:233-242, 1984
17) Nazer B, Walters TE, Dewland TA et al:Variable presentations and ablation sites for manifest nodoventricular/nodofascicu-lar fibers. Circ Arrhythm Electrophysiol 12(9):e007337, 2019
18) Cardona-Guarache R, Han FT, Nguyen DT et al:Ablation of supraventricular tachy-cardias from concealed left-sided nodo-ventricular and nodofascicular accessory pathways. Circ Arrhythm Electrophysiol 13(5):e007853, 2020
19) Ho RT, Ortman M, Levi SA:The various manifestations of concealed nodofascicu-lar/nodoventricular bypass tracts. Heart Rhythm 17(8):1280-1290, 2020
20) Nagashima K, Kaneko Y, Maruyama M et al:Novel diagnostic observations of nodoventricular/nodofascicular pathway-related orthodromic reciprocating tachy-cardia differentiating from atrioventricular nodal re-entrant tachycardia. JACC Clin Electrophysiol 6(14):1797-1807, 2020
21) Otsuka N, Wakamatsu Y, Nagashima K et al:Old yet new form of permanent junc-tional reciprocating tachycardia:What is the mechanism? J Cardiovasc Electro-physiol, 2021(in press)
22) Wakamatsu Y, Nagashima K, Watanabe R et al:Novel V-V-A response after right ventricular entrainment pacing for narrow QRS tachycardia:What is the mechanism? J Cardiovasc Electrophysiol 30(11):2528-2530, 2019
P.115 掲載の参考文献
1) 「脳卒中レジストリを用いた我が国の脳卒中診療実態の把握(日本脳卒中データバンク)」報告書. 2019 http://strokedatabank.ncvc.go.jp/f12kQnRl/wp-content/uploads/27f9c9e8df9c5853644f84616ace7775.pdf
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン:不整脈非薬物治療ガイドライン(2018年改訂版). 2019 https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf
3) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2020年改訂版不整脈薬物治療ガイドライン. 2020 https://www.j-circ.or.jp/old/guideline/pdf/JCS2020_Ono.pdf
P.116 掲載の参考文献
4) 山崎 浩:左心耳閉鎖デバイス. 医学と薬学 78:567-573, 2021
5) 近藤祐介:いよいよ経皮的左心耳閉鎖術が本邦に導入!!. 心臓 52:1071-1073, 2020
6) Reddy VY, Doshi SK, Kar S et al:5-year outcomes after left atrial appendage clo-sure:From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 70:2964-2975, 2017
P.117 掲載の参考文献
7) Aonuma K, Yamasaki H, Nakamura M et al:Efficacy percutaneous WATCHMAN left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism-First results from the SALUTE Trial. Circ J 82:2946-2953, 2018
8) Aonuma K, Yamasaki H, Nakamura M et al:Efficacy and safety of left atrial ap-pendage closure With WATCHMAN in Japanese nonvalvular atrial fibrillation pa-tients-Final 2-year follow-up outcome data from the SALUTE Trial. Circ J 84:1237-1243, 2020
9) 日本循環器学会:左心耳閉鎖システムに関する適正使用指針. http://www.j-circ.or.jp/WatchMan/wm_tekisei_shishin.pdf
10) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2021年JCS/JHRSガイドラインフォーカスアップデート版 不整脈非薬物治療. 2021 https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Kurita_Nogami.pdf
P.118 掲載の参考文献
11) Osmancik P, Herman D, Neuzil P et al:Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 75:3122-3135, 2020
12) 近藤祐介, 井上耕一, 大久保健史 他:座談会「いよいよ経皮的左心耳閉鎖術が本邦に導入!!～不整脈医が考える良い適応と問題点～」. 心臓 52:1074-1091, 2020
13) Sondergaard L, Wong YH, Reddy VY et al:Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv 12:1055-1063, 2019
14) Osman M, Busu T, Osman K, Khan SU, Daniels M et al:Short-term antiplatelet versus anticoagulant therapy after left atrial appendage occlusion:A systematic review and meta-analysis. JACC Clin Elec-trophysiol 6:494-506, 2020
15) Chen M, Wang Q, Sun J et al:Double-blind, placebo-controlled randomised clini-cal trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation:protocol of the ASPIRIN LAAO trial. BMJ Open 11:e044695, 2021
16) Sivasambu B, Arbab-Zadeh A, Hays A et al:Delayed endothelialization of watchman device identified with cardiac CT. J Cardio-vasc Electrophysiol 30:1319-1324, 2019
P.119 掲載の参考文献
17) Kar S, Doshi SK, Sadhu A et al:Primary outcome evaluation of a next-generation left atrial appendage closure device:Results from the PINNACLE FLX Trial. Circulation 143:1754-1762, 2021
18) Ellis CR, Jackson GG, Kanagasundram AN et al:Left atrial appendage closure in pa-tients with prohibitive anatomy:Insights from PINNACLE FLX. Heart Rhythm 18:1153-1161, 2021
19) 原 英彦:WATCHMAN デバイスを用いた経皮的左心耳閉鎖術. 循環器内科 89:592-596, 2021
20) 日本透析医学会血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44:337-425, 2011
21) Genovesi S, Porcu L, Slaviero G et al:Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. J Nephrol 34:63-73, 2021
22) Tanaka K, Koga M, Lee KJ et al:Atrial fibrillation-associated ischemic stroke patients with prior anticoagulation have higher risk for recurrent stroke. Stroke 51:1150-1157, 2020
23) Seiffge DJ, De Marchis GM, Koga et al:Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 87:677-687, 2020
24) Glikson M, Wolff R, Hindricks G et al:EHRA/EAPCI expert consensus state-ment on catheter-based left atrial append-age occlusion-an update. Europace 22:184, 2020
P.120 掲載の参考文献
25) Ohtsuka T, Nonaka T, Hisagi M et al:Thoracoscopic stapler-and-loop technique for left atrial appendage closure in non-valvular atrial fibrillation:Mid-term out-comes in 201 patients. Heart Rhythm 15:1314-1320, 2018
26) Mohanty S, Gianni C, Trivedi C et al:Risk of thromboembolic events after per-cutaneous left atrial appendage ligation in patients with atrial fibrillation:Long-term results of a multicenter study. Heart Rhythm 17:175-181, 2020
27) CHAMPION-AF Clinical Trial(CHAMPI-ON-AF) https://www.clinicaltrials.gov/ct2/show/NCT04394546
P.121 掲載の参考文献
28) Velagapudi P, Turagam MK, Kolte D et al:Intracardiac vs transesophageal echo-cardiography for percutaneous left atrial appendage occlusion:A meta-analysis. J Cardiovasc Electrophysiol 30:461-467, 2019
29) Nielsen-Kudsk JE, Berti S, De Backer O et al:Use of intracardiac compared with transesophageal echocardiography for left atrial appendage occlusion in the Amulet Observational Study. JACC Cardiovasc Interv 12:1030-1039, 2019
30) Lakkireddy D, Thaler D, Ellis CR et al:AMPLATZER(TM) AMULET(TM) LEFT ATRIAL APPENDAGE OCCLUDER VERSUS WATCHMAN(TM) DEVICE FOR STROKE PROPHYLAXIS(AMULET IDE):A RANDOMIZED CONTROLLED TRIAL. Circulation, 2021[online ahead of print]
III章 心不全
P.124 掲載の参考文献
1) Komuro I, Kaneko H, Morita H et al:Na-tionwide actions against heart failure pan-demic in Japan- What should we do from academia? Circ J 83:1819-1821, 2019
P.125 掲載の参考文献
2) Masip J, Peacock WF, Price S et al;Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology:Indications and practical approach to non-invasive venti-lation in acute heart failure. Eur Heart J 39:17-25, 2018
3) Matsue Y, Kinugasa Y, Kitai T et al:Ef-fect of the COVID-19 pandemic on acute respiratory care of hypoxemic patients with acute heart failure in Japan- A cross-sectional study. Circ Rep 2:499-506, 2020
4) Tsutsui H, Isobe M, Ito H et al;Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group:JCS 2017/JHFS 2017 Guideline on Diagno-sis and Treatment of Acute and Chronic Heart Failure- Digest Version. Circ J 83:2084-2184, 2019
5) Caspi O, Naami R, Halfin E et al:Ad-verse dose-dependent effects of morphine therapy in acute heart failure. Int J Cardiol 293:131-136, 2019
P.126 掲載の参考文献
6) Caspi O, Aronson D:Morphine in the set-ting of acute heart failure:Do the risks outweigh the benefits? Card Fail Rev 6:e20, 2020
7) Shirakabe A, Hata N, Kobayashi N et al:Worsening renal failure in patients with acute heart failure:the importance of car-diac biomarkers. ESC Heart Fail 6:416-427, 2019
8) Fudim M, Brooksbank J, Giczewska A et al:Ultrafiltration in acute heart failure:Implications of ejection fraction and early response to treatment from CARRESS-HF. J Am Heart Assoc 9:e015752, 2020
P.127 掲載の参考文献
9) Matsue Y, Damman K, Voors AA et al:Time-to-furosemide treatment and mortal-ity in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:3042-3051, 2017
10) Wettersten N, Horiuchi Y, van Veldhuisen DJ et al:Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart fail-ure. Eur J Heart Fail 23:1122-1130, 2021
11) He X, Dong B, Xue R et al:Effect of ag-gressive diuresis in acute heart failure with reduced and preserved ejection fraction. ESC Heart Failure 8:3248-3256, 2021
12) Oguri M, Ishii H, Takahara K et al:Effi-cacy of rapid decongestion strategy in pa-tients hospitalized for acute heart failure. Circ J 84:958-964, 2020
13) Shirakabe A, Hata N, Yamamoto M et al:Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prog-nosis of patients with severely decompen-sated acute heart failure. Circ J 78:911-921, 2014
14) Shirakabe A, Asai K, Otsuka T et al:linical approach to shortening length of hospital stay in elderly patients with acute heart failure requiring intensive care. Circ Rep 2:95-103, 2020
15) Tamaki S, Yamada T, Morita T et al:Impact of adjunctive tolvaptan on sympa-thetic activity in acute heart failure with preserved ejection fraction. ESC Heart Failure 7:933-937, 2020
P.128 掲載の参考文献
16) Freund Y, Gorlicki J:High-dose intrave-nous nitrates in acute heart failure:Level of evidence and adherence. Am J Emerg Med 38:1272-1273, 2020
17) Matsushita M, Shirakabe A, Kobayashi N et al:Mechanisms of urgently presenting acute heart failure. Int Heart J 61:316-324, 2020
18) Kozhuharov N, Goudev A, Flores D et al;GALACTIC Investigators:Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart fail-ure rehospitalization among patients with acute heart failure:The GALACTIC Ran-domized Clinical Trial. JAMA 322:2292-2302, 2019
19) Nagai T, Iwakami N, Nakai M et al;JROAD-DPC investigators:Effect of intra-venous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure:Insight from a nationwide claim-based database. Int J Cardiol 280:104-109, 2019
20) Harada K, Yamamoto T, Okumura T et al:Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes:A randomized, controlled trial. Eur Heart J Acute Cardiovasc Care 6:329-338, 2017
P.130 掲載の参考文献
21) Sharma K, Vaishnav J, Kalathiya R et al:Randomized evaluation of heart failure with preserved ejection fraction patients with acute heart failure and dopamine:The ROPA-DOP Trial. JACC Heart Fail 6:859-870, 2018
22) Schafer A, Werner N, Westenfeld R et al:Clinical scenarios for use of transvalvular microaxial pumps in acute heart failure and cardiogenic shock-A European expe-rienced users working group opinion. Int J Cardiol 291:96-104, 2019
23) Jiritano F, Lo Coco V, Matteucci M et al:Temporary mechanical circulatory sup-port in acute heart failure. Card Fail Rev 6:e01, 2020
P.131 掲載の参考文献
24) Sacks CA, Jarcho JA, Curfman GD:Para-digm shifts in heart-failure therapy-a timeline. N Engl J Med 371:989-991, 2014
25) Wanner C, Inzucchi SE, Lachin JM et al;EMPA-REG OUTCOME Investigators:Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323-334, 2016
26) Heerspink HJL, Stefansson BV, Correa-Rotter R et al;DAPA-CKD Trial Com-mittees and Investigators:Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436-1446, 2020
27) McMurray JJV, Packer M:How should we sequence the treatments for heart failure and a reduced ejection fraction?:A redefi-nition of evidence-based medicine. Circula-tion 143:875-877, 2021
28) McDonald M, Virani S, Chan M et al:CCS/CHFS Heart Failure Guidelines Up-date:Defining a new pharmacologic stan-dard of care for heart failure with reduced ejection fraction. Can J Cardiol 37:531-546, 2021
P.133 掲載の参考文献
1) Maggioni AP, Dahlstrom U, Filippatos G et al:EURObservational Research Pro-gramme:regional differences and 1-year follow-up results of the Heart Failure Pilot Survey(ESC-HF Pilot). Eur J Heart Fail 15(7):808-817, 2013
2) Murphy SP, Ibrahim NE, Januzzi JL Jr:Heart failure with reduced ejection frac-tion:A review. JAMA 324(5):488-504, 2020
P.134 掲載の参考文献
3) Greene SJ, Butler J, Albert NM et al:Medical therapy for heart failure with re-duced ejection fraction:The CHAMP-HF Registry. J Am Coll Cardiol 72(4):351-366, 2018
4) Swedberg K, Komajda M, Bohm M et al:Ivabradine and outcomes in chronic heart failure(SHIFT):A randomised placebo-controlled study. Lancet 376(9744):875-885, 2010. Erratum in:Lancet 376(9757):1988, 2010
5) McMurray JJV, Solomon SD, Inzucchi SE et al:Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995-2008, 2019
6) Pieske B, Patel MJ, Westerhout CM et al:Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Frac-tion)trial. Eur J Heart Fail 21(12):1596-1604, 2019
7) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II):A randomised trial. Lancet 353(9146):9-13, 1999
8) Flather MD, Shibata MC, Coats AJ et al:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure(SENIORS). Eur Heart J 26(3):215-225, 2005
9) Hjalmarson A, Goldstein S, Fagerberg B et al:Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure:The Metoprolol CR/XL Randomized Inter-vention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283(10):1295-1302, 2000
10) Packer M, Bristow MR, Cohn JN et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349-1355, 1996
11) Talajic M, Khairy P, Levesque S et al:Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 55(17):1796-1802, 2010. Erratum in:J Am Coll Cardiol 55(24):2788, 2010
12) Cadrin-Tourigny J, Shohoudi A, Roy D et al:Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation:An AF-CHF substudy. JACC Heart Fail 5(2):99-106, 2017
P.135 掲載の参考文献
13) Chatterjee S, Biondi-Zoccai G, Abbate A et al:Benefits of β blockers in patients with heart failure and reduced ejection frac-tion:Network meta-analysis. BMJ 346:f55, 2013. Erratum in:BMJ 346:f596, 2013.
14) Yancy CW, Jessup M, Bozkurt B et al:2013 ACCF/AHA guideline for the man-agement of heart failure:A report of the American College of Cardiology Founda-tion/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147-e239, 2013
15) Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 14(1):30-38, 2017
16) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular en-largement trial. The SAVE Investigators. N Engl J Med 327(10):669-677, 1992
17) The Acute Infarction Ramipril Efficacy (AIRE)Study Investigators:Effect of ramipril on mortality and morbidity of sur-vivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342(8875):821-828, 1993
18) SOLVD Investigators, Yusuf S, Pitt B, Da-vis CE et al:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart fail-ure. N Engl J Med 325(5):293-302, 1991
19) McMurray JJ, Ostergren J, Swedberg K et al:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angio-tensin-converting-enzyme inhibitors:The CHARM-Added trial. Lancet 362(9386):767-771, 2003
20) Cohn JN, Tognoni G;Valsartan Heart Failure Trial Investigators:A random-ized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667-1675, 2001
21) Heran BS, Musini VM, Bassett K et al:Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012(4):CD003040, 2012
22) McMurray JJ, Packer M, Desai AS et al:Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993-1004, 2014
P.136 掲載の参考文献
23) Wachter R, Senni M, Belohlavek J et al:Initiation of sacubitril/valsartan in hae-modynamically stabilised heart failure patients in hospital or early after dis-charge:Primary results of the randomised TRANSITION study. Eur J Heart Fail 21(8):998-1007, 2019
24) Morrow DA, Velazquez EJ, DeVore AD et al:Clinical outcomes in patients with acute decompensated heart failure ran-domly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circu-lation 139(19):2285-2288, 2019
25) Solomon SD, Rizkala AR, Gong J et al:Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction:Rationale and design of the PARAGON-HF trial. JACC Heart Fail 5(7):471-482, 2017
26) Tsutsui H, Momomura S, Saito Y et al:Efficacy and safety of sacubitril/valsar-tan(LCZ696)in Japanese patients with chronic heart failure and reduced ejection fraction:Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 70(3):225-231, 2017
27) Pitt B, Zannad F, Remme WJ et al;Ran-domized Aldactone Evaluation Study In-vestigators:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341(10):709-717, 1999
P.137 掲載の参考文献
28) Zannad F, McMurray JJ, Krum H et al:Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11-21, 2011
29) Ponikowski P, Voors AA, Anker SD et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiol-ogy(ESC)Developed with the special contribution of the Heart Failure Associa-tion(HFA)of the ESC. Eur Heart J 37(27):2129-2200, 2016. Erratum in:Eur Heart J 39(10):860, 2018
30) WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al:2016 ACC/AHA/HFSA focused update on new phar-macological therapy for heart failure:An update of the 2013 ACCF/AHA guideline for the management of heart failure:A report of the American College of Cardiol-ogy/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Cir-culation 134(13):e282-e293, 2016. Erra-tum in:Circulation 134(13):e298, 2016
31) Lahnwong S, Chattipakorn SC, Chattipak-orn N:Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardio-vasc Diabetol 17(1):101, 2018
32) Tsutsui H, Momomura SI, Yamashina A et al:Efficacy and safety of ivabradine in Japanese patients with chronic heart fail-ure-J-SHIFT study. Circ J 83(10):2049-2060, 2019
P.139 掲載の参考文献
33) Matsue Y, Damman K, Voors AA et al:Time-to-furosemide treatment and mor-tality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69(25):3042-3051, 2017
34) Felker GM, O'Connor CM, Braunwald E;Heart Failure Clinical Research Network Investigators:Loop diuretics in acute decompensated heart failure:Necessary? Evil? A necessary evil?. Circ Heart Fail 2(1):56-62, 2009
35) Bauersachs J:Heart failure drug treat-ment:the fantastic four. Eur Heart J 42(6):681-683, 2021
36) McMurray JJV, Packer M:How should we sequence the treatments for heart failure and a reduced ejection fraction?:A redefinition of evidence-based medicine. Circulation 143(9):875-877, 2021
P.140 掲載の参考文献
1) Bozkurt B, Coats AJ, Tsutsui H et al:Uni-versal definition and classification of heart failure:A report of the Heart Failure Society of America, Heart Failure Associa-tion of the European Society of Cardiology, Japanese Heart Failure Society and Writ-ing Committee of the Universal Definition of Heart Failure. J Card Fail, 2021[online ahead of print]
P.141 掲載の参考文献
2) Belyavskiy E, Morris DA, Url-Michitsch M et al:Diastolic stress test echocardiogra-phy in patients with suspected heart failure with preserved ejection fraction:a pilot study. ESC Heart Fail 6(1):146-153, 2019
3) Obokata M, Kane GC, Reddy YN et al:Role of diastolic stress testing in the evalu-ation for heart failure with preserved ejec-tion fraction:A simultaneous invasive-echocardiographic study. Circulation 135(9):825-838, 2017
4) Pieske B, Tschope C, de Boer RA et al:How to diagnose heart failure with pre-served ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recom-mendation from the Heart Failure Asso-ciation(HFA)of the European Society of Cardiology(ESC). Eur Heart J 40(40):3297-3317, 2019
5) Reddy YNV, Carter RE, Obokata M et al:A simple, evidence-based approach to help guide diagnosis of heart failure with pre-served ejection fraction. Circulation 138(9):861-870, 2018
6) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021
7) Yancy CW, Jessup M, Bozkurt B et al:2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circula-tion 136(6):e137-e161, 2017
8) Ponikowski P, Voors AA, Anker SD et al;Authors/Task Force Members;Docu-ment Reviewers:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur J Heart Fail 18(8):891-975, 2016
P.142 掲載の参考文献
9) Halliday BP, Wassall R, Lota AS et al:Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy(TRED-HF):an open-label, pilot, randomised trial. Lancet 393(10166):61-73, 2019
10) Lund LH, Claggett B, Liu J et al:Heart failure with mid-range ejection fraction in CHARM:characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20(8):1230-1239, 2018
11) Del Buono MG, Iannaccone G, Scacciavil-lani R et al:Heart failure with preserved ejection fraction diagnosis and treatment:An updated review of the evidence. Prog Cardiovasc Dis 63(5):570-584, 2020
12) Kuno T, Ueyama H, Fujisaki T et al:Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction. Am J Cardiol 125(8):1187-1193, 2020
P.143 掲載の参考文献
13) Vaduganathan M, Jhund PS, Claggett BL et al:A putative placebo analysis of the effects of sacubitril/valsartan in heart fail-ure across the full range of ejection frac-tion. Eur Heart J 41(25):2356-2362, 2020
14) Vaduganathan M, Claggett BL, Desai AS et al:Prior heart failure hospitalization, clinical outcomes, and response to sacubi-tril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol 75(3):245-254, 2020
15) Mc Causland FR, Lefkowitz MP, Claggett B et al:Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142(13):1236-1245, 2020
16) Wachter R, Shah SJ, Cowie MR et al:Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade:design and rationale of the PARALLAX trial. ESC Heart Fail 7(3):856-864, 2020
17) Cleland JGF, Bunting KV, Flather MD et al:Beta-blockers for heart failure with reduced, mid-range, and preserved ejec-tion fraction:an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26-35, 2018
P.144 掲載の参考文献
18) Suzuki S, Motoki H, Kanzaki Y et al:Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction. ESC Heart Fail 7(5):2752-2761, 2020
19) Yaku H, Kato T, Morimoto T et al:As-sociation of mineralocorticoid receptor antagonist use with all-cause mortality and hospital readmission in older adults with acute decompensated heart failure. JAMA Netw Open 2(6):e195892, 2019
20) Packer M, Anker SD, Butler J et al:Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413-1424, 2020
21) McMurray JJV, Solomon SD, Inzucchi SE et al:Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995-2008, 2019
22) Bhatt DL, Szarek M, Steg PG et al;SOLOIST-WHF Trial Investigators:Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117-128, 2021
23) Komajda M, Isnard R, Cohen-Solal A et al:Effect of ivabradine in patients with heart failure with preserved ejection fraction:the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19(11):1495-1503, 2017
P.145 掲載の参考文献
24) Armstrong PW, Pieske B, Anstrom KJ et al:Vericiguat in patients with heart fail-ure and reduced ejection fraction. N Engl J Med 382(20):1883-1893, 2020
25) Armstrong PW, Lam CSP, Anstrom KJ et al;VITALITY-HFpEF Study Group:Effect of vericiguat vs placebo on quality of life in patients with heart failure and pre-served ejection fraction:The VITALITY-HFpEF Randomized Clinical Trial. JAMA 324(15):1512-1521, 2020
26) Marrouche NF, Brachmann J, Andresen D et al:Catheter ablation for atrial fibrilla-tion with heart failure. N Engl J Med 378(5):417-427, 2018
27) Packer DL, Mark DB, Robb RA et al:Ef-fect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleed-ing, and cardiac arrest among patients with atrial fibrillation:The CABANA Randomized Clinical Trial. JAMA 321(13):1261-1274, 2019
P.146 掲載の参考文献
28) Packer DL, Piccini JP, Monahan KH et al;CABANA Investigators:Ablation versus drug therapy for atrial fibrillation in heart failure:Results from the CABANA Trial. Circulation 143(14):1377-1390, 2021
29) Shah SJ, Feldman T, Ricciardi MJ et al:One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure(REDUCE LAP-HF I)Trial:A randomized clinical trial. JAMA Cardiol 3(10):968-977, 2018
30) Obokata M, Reddy YNV, Shah SJ et al:Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 74(21):2539-2550, 2019
31) Paitazoglou C, Bergmann MW, Ozdemir R et al;AFR-PRELIEVE Investigators:One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients:the PRELIEVE study. Eur J Heart Fail, 2021
32) Abraham WT, Adamson PB, Bourge RC et al:Wireless pulmonary artery haemo-dynamic monitoring in chronic heart fail-ure:a randomised controlled trial. Lancet 377(9766):658-666, 2011
P.147 掲載の参考文献
33) Shavelle DM, Desai AS, Abraham WT et al:Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambu-latory heart failure:One-year outcomes from the CardioMEMS Post-Approval Study. Circ Heart Fail 13(8):e006863, 2020
34) Kitzman DW, Whellan DJ, Duncan P et al:Physical Rehabilitation for Older Pa-tients Hospitalized for Heart Failure. N Engl J Med, 2021
35) Kamiya K, Sato Y, Takahashi T et al:Multidisciplinary cardiac rehabilitation and long-term prognosis in patients with heart failure. Circ Heart Fail 13(10):e006798, 2020
P.148 掲載の参考文献
1) 日本臓器移植ネットワーク website https://www.jotnw.or.jp/data/offer.php?year=2020
2) 厚生労働省 臓器移植の実施状況等に関する報告書 https://www.mhlw.go.jp/content/10900000/000789058.pdf
P.149 掲載の参考文献
3) 日本心臓移植研究会レジストリ報告 http://www.jsht.jp/2021/04/17/registry/japan/20201231%E3%83%AC%E3%82%B8%E3%82%B9%E3%83%88%E3%83%AA2.pdf
P.150 掲載の参考文献
4) Buchan TA, Moayedi Y, Truby LK et al:Incidence and impact of primary graft dysfunction in adult heart transplant re-cipients:A systematic review and meta-analysis. J Heart Lung Transplant 40:642-651, 2021
5) Kransdorf EP, Kittleson MM, Benck LR et al:Predicted heart mass is the optimal metric for size match in heart transplanta-tion. J Heart Lung Transplant 38:156-165, 2019
6) Shiraishi Y, Amiya E, Hatano M et al:Impact of tacrolimus versus cyclosporin A on renal function during the first year after heart transplant. ESC Heart Fail 7:1842-1849, 2020
7) Seferovic PM, Tsutsui H, McNamara DM et al:Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 23(6):854-871, 2021
8) Agbor-Enoh S, Shah P, Tunc I et al:Cell-Free DNA to detect heart allograft acute rejection. Circulation 143:1184-1197, 2021
P.151 掲載の参考文献
9) Nelson LM, Rossing K, Ihlemann N et al:Intravascular ultrasound-guided selection for early noninvasive cardiac allograft vas-culopathy screening in heart transplant re-cipients. Clin Transplant 34:e14124, 2020
10) Gustafsson F, Andreassen AK, Andersson B et al:Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients:long-term fol-low-up from the randomized SCHEDULE Study. Transplantation 104:154-164, 2020
11) Nguyen LS, Suc G, Kheav VD et al:Quadritherapy vs standard tritherapy immunosuppressant regimen after heart transplantation:A propensity score-matched cohort analysis. Am J Transplant 20:2791-2801, 2020
12) Asleh R, Briasoulis A, Smith B et al:As-sociation of aspirin treatment with cardiac allograft vasculopathy progression and adverse outcomes after heart transplanta-tion. J Card Fail 27:542-551, 2021
P.152 掲載の参考文献
13) Kimura Y, Yanase M, Mochizuki H et al:De novo malignancy in heart transplant recipients:A single center experience in Japan. J Cardiol 73:255-261, 2019
14) Bujo C, Amiya E, Hatano M et al:As-sociation between infectious event and de novo malignancy after heart transplanta-tion. Heart Vessels 36:499-508, 2021
15) Kinugawa K, Nishimura T, Toda K et al:The second official report from Japanese registry for mechanical assisted circula-tory support(J-MACS):first results of bridge to bridge strategy. Gen Thorac Cardiovasc Surg 68:102-111, 2020
16) Kirklin JK, Pagani FD, Kormos RL et al:Eighth annual INTERMACS report:Spe-cial focus on framing the impact of adverse events. J Heart Lung Transplant 36:1080-1086, 2017
17) Mehra MR, Goldstein DJ, Uriel N et al:Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 378:1386-1395, 2018
18) Mehra MR, Cleveland JC, Jr., Uriel N et al:Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase:a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail 23(8):1392-1400, 2021
P.153 掲載の参考文献
19) Yanase M, Iwasaki K, Watanabe T et al:Effect of therapeutic modification on out-comes in heart transplantation over the past two decades-A single-center experi-ence in Japan. Circ J 84:965-974, 2020
20) Dridi NP, Vishram-Nielsen JKK, Gustafsson F:Exercise tolerance in patients treated with a durable left ventricular assist de-vice:Importance of myocardial recovery. J Card Fail 27:486-493, 2021
21) Nytroen K, Rolid K, Andreassen AK et al:Effect of high-intensity interval training in de novo heart transplant recipients in scan-dinavia. Circulation 139:2198-2211, 2019
22) Khush KK, Potena L, Cherikh WS et al:The International Thoracic Organ Trans-plant Registry of the International Society for Heart and Lung Transplantation:37th adult heart transplantation report-2020;focus on deceased donor characteristics. J Heart Lung Transplant 39:1003-1015, 2020
23) Sibona A, Khush KK, Oyoyo UE et al:Long-term transplant outcomes of donor hearts with left ventricular dysfunction. J Thorac Cardiovasc Surg 157:1865-1875, 2019
24) Poptsov V, Khatutskiy V, Skokova A et al:Heart transplantation from donors with left ventricular ejection fraction un-der forty percent. Clin Transplant 35:e14341, 2021
P.154 掲載の参考文献
25) Chew HC, Iyer A, Connellan M et al:Out-comes of donation after circulatory death heart transplantation in Australia. J Am Coll Cardiol 73:1447-1459, 2019
26) Messer S, Cernic S, Page A et al:A 5-year single-center early experience of heart transplantation from donation after circu-latory-determined death donors. J Heart Lung Transplant 39:1463-1475, 2020
27) Shudo Y, Benjamin-Addy R, Koyano TK et al:Donors after circulatory death heart trial. Future cardiology 17:11-17, 2021
28) Teuteberg JJ, Cleveland JC, Jr., Cowger J et al:The Society of Thoracic Surgeons In-termacs 2019 Annual Report:The Chang-ing Landscape of Devices and Indications. Ann Thorac Surg 109:649-660, 2020
29) Kilic A, Hickey G, Mathier MA et al:Outcomes of the first 1300 adult heart transplants in the United States after the allocation policy change. Circulation 141:1662-1664, 2020
30) 松田 暉:心臓移植登録患者の待機中死亡に関する全国調査-臓器配分システム改定への考察-. 移植 54(6):291-298, 2020
P.155 掲載の参考文献
1) Tsutsui H, Isobe M, Ito H et al:JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83(10):2084-2184, 2019
2) Anzai T, Sato T, Fukumoto Y et al:JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases. Circ J 85(5):695-757, 2021
P.156 掲載の参考文献
3) Hill L, Prager Geller T, Baruah R et al:Integration of a palliative approach into heart failure care:a European Society of Cardiology Heart Failure Association position paper. Eur J Heart Fail 22(12):2327-2339, 2020
4) Crimmins RM, Elliott L, Absher DT:Pal-liative care in a death-denying culture:Exploring barriers to timely palliative efforts for heart failure patients in the pri-mary care setting. Am J Hosp Palliat Care 38(1):77-83, 2021
5) Diop MS, Bowen GS, Jiang L et al:Pallia-tive care consultation reduces heart failure transitions:A matched analysis. J Am Heart Association 9(11):e013989, 2020
6) Sobanski PZ, Alt-Epping B, Currow DC et al:Palliative care for people living with heart failure:European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 116(1):12-27, 2019
P.157 掲載の参考文献
7) Ament SM, Couwenberg IM, Boyne JJ et al:Tools to help healthcare professionals recognize palliative care needs in patients with advanced heart failure:A systematic review. Palliat Med 35(1):45-58, 2021
8) Ament SMC, van den Beuken-Everdingen M, Maessen JMC et al:Professionals guid-ance about palliative medicine in chronic heart failure:A mixed-method study. BMJ Support Palliat Care, 2020[online ahead of print]
9) Aaronson EL, George N, Ouchi K et al:The surprise question can be used to identify heart failure patients in the emer-gency department who would benefit from palliative care. J Pain Symptom Manage 57(5):944-951, 2019
P.158 掲載の参考文献
10) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021 https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
11) Chang YK, Kaplan H, Geng Y et al:Refer-ral criteria to palliative care for patients with heart failure:A systematic review. Circ Heart Fail 13(9):e006881, 2020
12) Hamatani Y, Takada Y, Miyamoto Y et al:Development and practical test of quality indicators for palliative care in pa-tients with chronic heart failure. Circ J 84(4):584-591, 2020
P.159 掲載の参考文献
13) Schichtel M, Wee B, Perera R et al:The effect of advance care planning on heart failure:A systematic review and meta-analysis. J Gen Intern Med 35(3):874-884, 2020
14) Nakazawa M, Suzuki T, Shiga T et al:Deactivation of implantable cardioverter defibrillator in Japanese patients with end-stage heart failure. J Arrhythm 37(1):196-202, 2021
15) Goldstein NE, Mather H, McKendrick K et al:Improving communication in heart failure patient care. J Am Coll Cardiol 74(13):1682-1692, 2019
16) Kawaguchi J, Hamatani Y, Hirayama A et al:Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients. J Cardiol 75(6):682-688, 2020
P.160 掲載の参考文献
17) Rogers JG, Patel CB, Mentz RJ et al:Pal-liative care in heart failure:The PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol 70(3):331-341, 2017
18) Truby LK, O'Connor C, Fiuzat M et al:Sex differences in quality of life and clini-cal outcomes in patients with advanced heart failure:Insights from the PAL-HF trial. Circ Heart Fail 13(4):e006134, 2020
P.161 掲載の参考文献
1) Seferovic PM, Petrie MC, Filippatos GS et al:Type 2 diabetes mellitus and heart failure:A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:853-872, 2018
2) Dunlay SM, Givertz MM, Aguilar D et al:Type 2 diabetes mellitus and heart failure:a scientific statement from the American Heart Association and the Heart Failure Society of America:This state-ment does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 140:e294-e324, 2019
3) Echouffo-Tcheugui JB, Xu H, DeVore AD et al:Temporal trends and factors associ-ated with diabetes mellitus among patients hospitalized with heart failure:Findings from Get With The Guidelines-Heart Fail-ure registry. Am Heart J 182:9-20, 2016
P.162 掲載の参考文献
4) Gilbert RE, Krum H:Heart failure in dia-betes:Effects of anti-hyperglycaemic drug therapy. Lancet(London, England) 385:2107-2117, 2015
5) Atherton JJ, Hayward CS, Wan Ahmad WA et al:Patient characteristics from a regional multicenter database of acute de-compensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 18:82-88, 2012
6) Lam CS, Anand I, Zhang S et al:Asian sudden cardiac death in heart failure (ASIAN-HF)registry. Eur J Heart Fail 15:928-936, 2013
7) Lam CS, Teng TK, Tay WT et al:Region-al and ethnic differences among patients with heart failure in Asia:The Asian sud-den cardiac death in heart failure registry. Eur Heart Journal 37:3141-3153, 2016
P.163 掲載の参考文献
8) Zinman B, Wanner C, Lachin JM et al:Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117-2128, 2015
9) Neal B, Perkovic V, Mahaffey KW et al:Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644-657, 2017
10) Wiviott SD, Raz I, Bonaca MP et al:Dapa-gliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347-357, 2019
11) Perkovic V, Jardine MJ, Neal B et al:Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295-2306, 2019
12) McMurray JJV, Solomon SD, Inzucchi SE et al:Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995-2008, 2019
13) Packer M, Anker SD, Butler J et al:Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413-1424, 2020
14) Bhatt DL, Szarek M, Steg PG et al:So-tagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117-128, 2021
15) Lee MMY, Ghouri N, McGuire DK et al:Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes. Diabetes Care, 2021
16) Butler J, Usman MS, Khan MS et al:Efficacy and safety of SGLT2 inhibitors in heart failure:systematic review and meta-analysis. ESC Heart Fail 7:3298-3309, 2020
P.164 掲載の参考文献
17) Seong JM, Kim JJ, Kim HJ et al:Com-parison of heart failure risk and medical costs between patients with type 2 dia-betes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors:A nationwide population-based cohort study. Cardiovasc Diabetol 19:95, 2020
18) Kohsaka S, Takeda M, Bodegard J et al:Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan:Subanalyses of the CVD-REAL 2 Study. J Diabetes Investig 12:67-73, 2021
19) Palmer SC, Tendal B, Mustafa RA et al:Sodium-glucose cotransporter protein-2(SGLT-2)inhibitors and glucagon-like peptide-1(GLP-1)receptor agonists for type 2 diabetes:Systematic review and network meta-analysis of randomised con-trolled trials. BMJ(Clinical research ed) 372:m4573, 2021
20) Inagaki N, Harashima S, Maruyama N et al:Efficacy and safety of canagliflozin in combination with insulin:A double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol 15:89, 2016
21) Handelsman Y, Henry RR, Bloomgarden ZT et al:American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Dia-betic Ketoacidosis. Endocr Pract 22:753-762, 2016
22) Hallow KM, Helmlinger G, Greasley PJ et al:Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479-487, 2018
23) Weber MA, Mansfield TA, Cain VA et al:Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination an-tihypertensive therapy:A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4:211-220, 2016
24) Chilton R, Tikkanen I, Cannon CP et al:Effects of empagliflozin on blood pressure and markers of arterial stiffness and vas-cular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180-1193, 2015
P.165 掲載の参考文献
25) Cai X, Yang W, Gao X et al:The associa-tion between the dosage of SGLT2 inhibi-tor and weight reduction in Type 2 dia-betes patients:A meta-analysis. Obesity (Silver Spring, Md)26:70-80, 2018
26) Ferrannini E, Baldi S, Frascerra S et al:Shift to fatty substrate utilization in re-sponse to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190-1195, 2016
27) Arima Y, Izumiya Y, Ishida T et al:Myo-cardial ischemia suppresses ketone body utilization. J Am Coll Cardiol 73:246-247, 2019
28) Oshima H, Miki T, Kuno A et al:Em-pagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther 368:524-534, 2019
29) Sano M, Takei M, Shiraishi Y et al:In-creased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J clin medicine research 8:844-847, 2016
30) Shimizu W, Kubota Y, Hoshika Y et al:Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus:the EMBODY trial. Cardiovasc Diabetol 19:148, 2020
IV章 弁膜症
P.169 掲載の参考文献
1) Smith CR, Leon MB, Mack MJ et al:Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187-2198, 2011
2) Leon MB, Smith CR, Mack M et al:Trans-catheter aortic-valve implantation for aor-tic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597-1607, 2010
3) Reardon MJ, Adams DH, Kleiman NS et al:2-year outcomes in patients undergo-ing surgical or self-expanding transcath-eter aortic valve replacement. J Am Coll Cardiol 66:113-121, 2015
P.170 掲載の参考文献
4) Leon MB, Smith CR, Mack MJ et al:Transcatheter or surgical aortic-valve re-placement in intermediate-risk patients. N Engl J Med 374:1609-1620, 2016
5) Thourani VH, Kodali S, Makkar RR et al:Transcatheter aortic valve replacement versus surgical valve replacement in inter-mediate-risk patients:a propensity score analysis. Lancet 387:2218-2225, 2016
6) Reardon MJ, Van Mieghem NM, Popma JJ et al:Surgical or transcatheter aortic-valve replacement in intermediate-risk pa-tients. N Engl J Med 376:1321-1331, 2017
7) Mack MJ, Leon MB, Thourani VH et al:Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695-1705, 2019
P.171 掲載の参考文献
8) Popma JJ, Deeb GM, Yakubov SJ et al;Evolut Low Risk Trial I:Transcatheter aortic-valve replacement with a self-ex-panding valve in low-risk patients. N Engl J Med 380:1706-1715, 2019
P.173 掲載の参考文献
9) Jorgensen TH, Thyregod HGH, Ihlemann N et al:Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgi-cal aortic valve replacement. Eur Heart J, 2021[online ahead of print]
10) Jilaihawi H, Zhao Z, Du R et al:Minimiz-ing permanent pacemaker following re-positionable self-expanding transcatheter aortic valve replacement. JACC Cardio-vasc Interv 12:1796-1807, 2019
11) Szerlip M, Zajarias A, Vemalapalli S et al:Transcatheter aortic valve replacement in patients with end-stage renal disease. J Am Coll Cardiol 73:2806-2815, 2019
P.175 掲載の参考文献
1) Stone GW, Vahanian AS, Adams DH et al;Mitral Valve Academic Research C:Clinical trial design principles and end-point definitions for transcatheter mitral valve repair and replacement:Part 1:Clinical trial design principles:A con-sensus document from the mitral valve academic research consortium. J Am Coll Cardiol 66:278-307, 2015
2) 弁膜症治療のガイドライン合同研究班:2020年改訂版 弁膜症治療のガイドライン. 2020 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf
P.176 掲載の参考文献
3) Feldman T, Foster E, Glower DD et al:Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364:1395-1406, 2011
4) Boekstegers P, Hausleiter J, Baldus S et al:Percutaneous interventional mitral re-gurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103:85-96, 2014
5) Feldman T, Kar S, Elmariah S et al:Randomized comparison of percutaneous repair and surgery for mitral regurgita-tion:5-year results of EVEREST II. J Am Coll Cardiol 66:2844-2854, 2015
6) Piriou N, Al Habash O, Donal E et al:The MITRA-HR study:design and rationale of a randomised study of MitraClip trans-catheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery. EuroInter-vention 15:e329-e335, 2019
P.177 掲載の参考文献
7) Stone GW, Lindenfeld J, Abraham WT et al:Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307-2318, 2018
8) Izumo M, Kuwata S, Ishibashi Y et al:Prognostic impact of transcatheter mitral valve repair in patients with exercise-induced secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging 22:530-538, 2021
9) Deferm S, Bertrand PB, Verbrugge FH et al:Atrial functional mitral regurgita-tion:JACC review topic of the week. J Am Coll Cardiol 73:2465-2476, 2019
10) Yoshida J, Ikenaga H, Nagaura T et al:Impact of percutaneous edge-to-edge re-pair in patients with atrial functional mitral regurgitation. Circ J, 2021
11) Asch FM, Grayburn PA, Siegel RJ et al:Echocardiographic outcomes after trans-catheter leaflet approximation in patients with secondary mitral regurgitation:the COAPT trial. J Am Coll Cardiol 74:2969-2979, 2019
12) Obadia JF, Messika-Zeitoun D, Leurent G et al:Percutaneous repair or medical treatment for secondary mitral regurgita-tion. N Engl J Med 379:2297-2306, 2018
P.178 掲載の参考文献
13) Grayburn PA, Sannino A and Packer M:Proportionate and disproportionate functional mitral regurgitation:A new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 12:353-362, 2019
14) Hahn RT:Disproportionate emphasis on proportionate mitral regurgitation-are there better measures of regurgitant se-verity? JAMA cardiology 5:377-379, 2020
15) Messika-Zeitoun D, Iung B, Armoiry X et al:Impact of mitral regurgitation sever-ity and left ventricular remodeling on outcome after MitraClip implantation:Results from the Mitra-FR trial. JACC Cardiovasc Imaging 14:742-752, 2021
16) Lindenfeld J, Abraham WT, Grayburn PA et al;Cardiovascular Outcomes As-sessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation I:As-sociation of effective regurgitation orifice area to left ventricular end-diastolic vol-ume ratio with transcatheter mitral valve repair outcomes:a secondary analysis of the COAPT trial. JAMA cardiology 6:427-436, 2021
17) Packer M, Grayburn PA:New evidence supporting a novel conceptual framework for distinguishing proportionate and dis-proportionate functional mitral regurgita-tion. JAMA cardiology 5:469-475, 2020
18) Debonnaire P, Heyning CMV, Haddad ME et al:Left ventricular end-systolic dimen-sion and outcome in patients with heart failure undergoing percutaneous MitraClip valve repair for secondary mitral regurgi-tation. Am J Cardiol 126:56-65, 2020
P.179 掲載の参考文献
19) Hubert A, Galli E, Leurent G et al:Left ventricular function after correction of mi-tral regurgitation:Impact of the clipping approach. Echocardiography 36:2010-2018, 2019
20) Papadopoulos K, Ikonomidis I, Chrissoheris M et al:MitraClip and left ventricular re-verse remodelling:a strain imaging study. ESC heart failure 7:1409-1418, 2020
21) Utsunomiya H, Itabashi Y, Kobayashi S et al:Comparison of mitral valve geo-metrical effect of percutaneous edge-to-edge repair between central and eccentric functional mitral regurgitation:clinical implications. Eur Heart J Cardiovasc Im-aging 20:455-466, 2019
22) Agricola E, Oppizzi M, Maisano F et al:Echocardiographic classification of chronic ischemic mitral regurgitation caused by restricted motion according to tethering pattern. Eur J Echocardiogr 5:326-334, 2004
23) Raghunathan D, Garcia-Sayan E, Schechter M et al:First-in-human report of Mitra-Clip G4 implantation for torrential tricuspid regurgitation and severe secondary mitral regurgitation. JACC Cardiovasc Interv 13:1599-1602, 2020
24) Chakravarty T, Makar M, Patel D et al:Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 system. JACC Cardiovasc Interv 13:5217, 2020
P.181 掲載の参考文献
1) Otto CM, Nishimura RA, Bonow RO et al:2020 ACC/AHA Guideline for the man-agement of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guide-lines. Circulation 143(5):e72-e227, 2021
2) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会合同ガイドライン:2020年改訂版 弁膜症治療のガイドライン. 2020 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf
P.182 掲載の参考文献
3) Baumgartner H, Lung B, Otto CM:Timing of intervention in asymptomatic patients with valvular heart disease. Eur Heart J 41(45):4349-4356, 2020
4) Zoghbi WA, Adams D, Bonow RO et al:Recommendations for non- invasive evalu-ation of native valvular regurgitation:A report from the American Society of Echo-cardiography Developed in Collaboration with the Society for Cardiovascular Mag-netic Resonance. J Am Soc Echocardiogr 30:303-371, 2017
5) Gao SA, Polte CL, Lagerstrand KM et al:Evaluation of the integrative algorithm for grading chronic aortic and mitral regurgitation severity using the Current American Society of Echocardiography Recommendations:To discriminate severe from moderate regurgitation. J Am Soc Echocardiogr 31(9):1002-1012, 2018
6) Kammerlander AA, Wiesinger M, Duca F et al:Diagnostic and prognostic utility of cardiac magnetic resonance imaging in aortic regurgitation. JACC Cardiovasc Imaging 12(8):1474-1483, 2019
7) Mentias A, Feng K, Alashi A et al:Long-term outcomes in patients with aortic re-gurgitation and preserved left ventricular ejection fraction. J Am Coll Cardiol 68:2144-2153, 2016
8) Yang LT, Michelena HI, Scott CG et al:Outcomes in chronic hemodynamically significant aortic regurgitation and limi-tations of current guidelines. J Am Coll Cardiol 73:1741-1752, 2019
9) De Meester C, Gerber BL, Vancraeynest D et al:Do guideline-based indications result in an outcome penalty for patients with severe aortic regurgitation? JACC Cardio-vasc Imaging 12(11):2126-2138, 2019
P.183 掲載の参考文献
10) Alashi A, Khullar T, Mentias A et al:Long-term outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF:impact of baseline and follow-up global longitudinal strain. JACC Cardio-vasc Imaging 13:12-21, 2020
11) Amano M, Izumi C, Imamura S et al:Pre-and postoperative predictors of long-term prognosis after aortic valve replacement for severe chronic aortic regurgitation. Circ J 80:2460-2467, 2016
12) David TE, David CM, Feindel CM et al:Reimplantation of the aortic valve at 20 years. J Thorac Cardiovasc Surg 153:232-238, 2017
13) Baumgartner H, Falk V, Bax JJ et al:2017 ESC/EACTS Guidelines for the manage-ment of valvular heart disease:The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS). Euro Heart 38:2739-2786, 2017
P.184 掲載の参考文献
14) David TE, David CM, Tsang W et al:Long-term results of mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 74(8):1044-1053, 2019
15) Dejgaard LA, Skjolsvik ET, Lie OH et al:The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol 72(14):1600-1609, 2018
16) Essayagh B, Sabbag A, Antoine et al:The mitral annular disjunction of mitral valve prolapse:Presentation and outcome. JACC Cardiovasc Imagin, 2021[online ahead of print]
P.185 掲載の参考文献
17) Nishi H, Myata H, Motomura N et al:Which patients are candidates for mini-mally invasive mitral valve surgery? Establishment of risk calculators using national clinical database. Circ J 83:1674-1681, 2019
18) Nishimura RA, O'Gara PT, Bavaria JE et al:2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document:a proposal to optimize care for patients with valvular heart disease:A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocar-diography, Society for Cardiovascular An-giography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 73:2609-2635, 2019
19) Chung H, Amaki M, Takashio S et al:Effect of mitral valve surgery in patients with dilated cardiomyopathy and severe functional mitral regurgitation. Circ J 82:131-140, 2017
P.186 掲載の参考文献
20) Stone GW, Lindenfeld J, Abraham WT et al:COAPT Investigators:Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307-2318, 2018
21) Deferm S, Bertrand PB, Verbrugge FH et al:Atrial functional mitral regurgitation. J Am Coll Cardiol 73(19):2465-2476, 2019
22) Kagiyama N, Mondillo S, Yoshida K et al:Subtypes of atrial functional mitral regur-gitation. J Am Coll Cardiol Img 13(3):820-835, 2020
23) Mesi O, Gad MM, Crane AD et al:Severe atrial functional mitral regurgitation. Clini-cal and echocardiographic characteristics, management and outcomes. J Am Coll Cardiol Img 14(4):797-808, 2021
24) Gertz ZM, Raina A, Saghy L et al:Evi-dence of atrial functional mitral regurgita-tion due to atrial fibrillation. Reversal with arrhythmia control. J Am Coll Cardiol 58:1474-1481, 2011
25) Carino D, Lapenna E, Ascione G et al:Is mitral annuloplasty an effective treatment for severe atrial functional mitral regurgi-tation? J Card Surg 36(2):596-602, 2021
26) Takahashi Y, Abe Y, Takashi M et al:Mid-term results of valve repairs for atrial functional mitral and tricuspid regurgita-tions. Gen Thorac Cardiovasc Surg 68(5):467-476, 2020
P.187 掲載の参考文献
1) Kato N, Padang R, Scott CG et al:The natural history of severe calcific mitral ste-nosis. J Am Coll Cardiol 75:3048-3057, 2020
2) Abramowitz Y, Jilaihawi H, Chakravarty T et al:Mitral annulus calcification. J Am Coll Cardiol 66:1934-1941, 2015
3) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会合同ガイドライン:2020年改訂版 弁膜症治療のガイドライン. 2020
4) Otto CM, Nishimura RA, Bonow RO et al:2020 ACC/AHA Guideline for the Manage-ment of Patients With Valvular Heart Dis-ease:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guide-lines. J Am Coll Cardiol 77:450-500, 2020
P.188 掲載の参考文献
5) Chandrashekhar Y, Westaby S, Narula J:Mitral stenosis. Lancet 374(9697):1271-1283, 2009
P.189 掲載の参考文献
6) Kato N, Pislaru SV, Padang R et al:A novel assessment using projected transmi-tral gradient improves diagnostic yield of Doppler hemodynamics in rheumatic and calcific mitral stenosis. JACC Cardiovasc Imaging 14:559-570, 2021
P.190 掲載の参考文献
7) Asami M, Windecker S, Praz F et al:Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. Eur Heart J 40:1342-1351, 2018
8) Joseph L, Bashir M, Xiang Q et al:Preva-lence and outcomes of mitral stenosis in patients undergoing transcatheter aortic valve replacement:Findings from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. JACC Cardiovasc In-terv 11:693-702, 2018
9) Kato N, Padang R, Pislaru C et al:He-modynamics and prognostic impact of concomitant mitral stenosis in patients undergoing surgical or transcatheter aor-tic valve replacement for aortic stenosis. Circulation 140:1251-1260, 2019
P.191 掲載の参考文献
10) Eleid MF, Foley TA, Said SM et al:Severe mitral annular calcification:Mul-timodality imaging for therapeutic strate-gies and interventions. JACC Cardiovasc Imaging 9:1318-1337, 2016
11) Sannino A, Potluri S, Pollock B et al:Impact of mitral stenosis on survival in patients undergoing isolated transcatheter aortic valve implantation. Am J Cardiol, 2019
P.192 掲載の参考文献
12) Bertrand PB, Churchill TW, Yucel E et al:Prognostic importance of the transmi-tral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J 41:4321-4328, 2020
13) Guerrero M, Urena M, Himbert D et al:1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Car-diol 71:1841-1853, 2018
14) Guerrero M, Vemulapalli S, Xiang Q et al:Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses(valve-in-valve), failed surgical rings(valve-in-ring), and native valve with severe mitral annular calcification(valve-in-mitral annular calci-fication)in the United States:Data from the Society of Thoracic Surgeons/Ameri-can College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv 13:e008425, 2020
15) Yoon SH, Bleiziffer S, Latib A et al:Pre-dictors of left ventricular outflow tract ob-struction after transcatheter mitral valve replacement. JACC Cardiovasc Interv 12:182-193, 2019
16) Praz F, Khalique OK, Lee R et al:Imag-ing in patients with severe mitral annular calcification:insights from a multicentre experience using transatrial balloon-expandable valve replacement. Eur Heart J Cardiovasc Imaging 20:1395-1406, 2019
17) Russell HM, Guerrero ME, Salinger MH et al:Open atrial transcatheter mitral valve replacement in patients with mitral an-nular calcification. J Am Coll Cardiol 72:1437-1448, 2018
P.194 掲載の参考文献
1) Nath J, Foster E, Heidenreich PA:Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43(3):405-409, 2004
2) Rodes-Cabau J, Taramasso M, O'Gara PT:Diagnosis and treatment of tricuspid valve disease:current and future perspec-tives. Lancet 388(10058):2431-2442, 2016
3) Axtell AL, Bhambhani V, Moonsamy P et al:Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol 74(6):715-725, 2019
4) Writing Committee Members;Otto CM, Nishimura RA, Bonow RO et al:2020 ACC/AHA Guideline for the management of patients with valvular heart disease:A report of the American College of Car-diology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 77(4):e25-e197, 2021
5) Nickenig G, Weber M, Schueler R et al:6-month outcomes of tricuspid valve recon-struction for patients with severe tricuspid regurgitation. J Am Coll Cardiol 73(15):1905-1915, 2019
P.195 掲載の参考文献
6) Vismara R, Gelpi G, Prabhu S et al:Transcatheter edge-to-edge treatment of functional tricuspid regurgitation in an ex vivo pulsatile heart model. J Am Coll Car-diol 68(10):1024-1033, 2016
7) Nickenig G, Weber M, Lurz P et al:Trans-catheter edge-to-edge repair for reduction of tricuspid regurgitation:6-month out-comes of the TRILUMINATE single-arm study. Lancet 394(10213):2002-2011, 2019
8) Fam NP, Braun D, von Bardeleben RS et al:Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation:A multi-center, observational, first-in-human expe-rience. JACC Cardiovasc Interv 12(24):2488-2495, 2019
9) Sugiura A, Vogelhuber J, Ozturk C et al:PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation:A propensity-matched analysis. Clin Res Cardiol 110(3):451-459, 2021
10) Boudjemline Y, Agnoletti G, Bonnet D et al:Steps toward the percutaneous replace-ment of atrioventricular valves an experi-mental study. J Am Coll Cardiol 46(2):360-365, 2005
11) Fam NP, von Bardeleben RS, Hensey M et al:Transfemoral transcatheter tricuspid valve replacement with the EVOQUE Sys-tem:A multicenter, observational, first-in-human experience. JACC Cardiovasc Interv 14(5):501-511, 2021
P.196 掲載の参考文献
12) Ansari MM, Cardoso R, Garcia D et al:Percutaneous pulmonary valve implanta-tion:present status and evolving future. J Am Coll Cardiol 66(20):2246-2255, 2015
13) Hirata Y, Hirahara N, Murakami A et al:Current status of cardiovascular surgery in Japan, 2015 and 2016:A report based on the Japan Cardiovascular Surgery Database. 1-congenital heart surgery. Gen Thorac Car-diovasc Surg 67(9):731-735, 2019
14) Verheugt CL, Uiterwaal CS, van der Velde ET et al:Mortality in adult congenital heart disease. Eur Heart J 31(10)1220-1229, 2010
15) Holst KA, Dearani JA, Burkhart HM et al:Risk factors and early outcomes of multiple reoperations in adults with con-genital heart disease. Ann Thorac Surg 92 (1):122-128;discussion 129-130, 2011
16) Somerville J:Grown-up congenital heart disease--medical demands look back, look forward 2000. Thorac Cardiovasc Surg 49 (1):21-26, 2001
P.197 掲載の参考文献
17) Oosterhof T, van Straten A, Vliegen HW et al:Preoperative thresholds for pulmo-nary valve replacement in patients with corrected tetralogy of Fallot using cardio-vascular magnetic resonance. Circulation 1165:545-551, 2000
18) Tretter JT, Friedberg MK, Wald RM et al:Defining and refining indications for transcatheter pulmonary valve replace-ment in patients with repaired tetralogy of Fallot:Contributions from anatomical and functional imaging. Int J Cardiol 221:916-925, 2016
19) Shahanavaz S, Zahn EM, Levi DS et al:Transcatheter pulmonary valve replace-ment with the Sapien Prosthesis. J Am Coll Cardiol 76(24):2847-2858, 2020
20) Kenny D, Rhodes JF, Fleming GA et al:3-year outcomes of the Edwards SAPIEN Transcatheter Heart Valve for conduit failure in the pulmonary position from the COMPASSION Multicenter Clinical Trial. JACC Cardiovasc Interv 11(19):1920-1929, 2018
P.198 掲載の参考文献
21) Shahanavaz S, Balzer D, Babaliaros V et al:Alterra adaptive prestent and SAPI-EN 3 THV for congenital pulmonic valve dysfunction:An early feasibility study. JACC Cardiovasc Interv 13(21):2510-2524, 2020
22) Nordmeyer J, Ewert P, Gewillig M et al:Acute and midterm outcomes of the post-approval MELODY Registry:a multicen-tre registry of transcatheter pulmonary valve implantation. Eur Heart J 40(27):2255-2264, 2019
23) Cheatham JP, Hellenbrand WE, Zahn EM et al:Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmo-nary valve replacement in the US melody valve investigational device exemption trial. Circulation 131(22):1960-1970, 2015
P.199 掲載の参考文献
24) Bergersen L, Benson LN, Gillespie MJ et al:Harmony Feasibility Trial:Acute and short-term outcomes with a self-expanding transcatheter pulmonary valve. JACC Car-diovasc Interv 10(17):1763-1773, 2017
25) Benson LN, Gillespie MJ, Bergersen L et al:Three-year outcomes from the Harmo-ny Native Outflow Tract Early Feasibility Study. Circ Cardiovasc Interv, 2020
P.200 掲載の参考文献
26) Georgiev S, Ewert P, Eicken A et al:Mu-nich Comparative Study:Prospective long-term outcome of the transcatheter Melody valve versus surgical pulmonary biopros-thesis with up to 12 years of follow-up. Circ Cardiovasc Interv 13(7):e008963, 2020
27) Caughron H, Kim D, Kamioka N et al:Re-peat pulmonary valve replacement:Similar intermediate-term outcomes with surgical and transcatheter procedures. JACC Cardio-vasc Interv 11(24):2495-2503, 2018
28) Sharma V, Griffiths ER, Eckhauser AW et al:Pulmonary valve replacement:A single-institution comparison of surgical and transcatheter valves. Ann Thorac Surg 106(3):807-813, 2018
29) Steinberg ZL, Jones TK, Verrier E et al:Early outcomes in patients undergoing transcatheter versus surgical pulmonary valve replacement. Heart 103(18):1455-1460, 2017
30) Egbe AC, Pislaru SV, Pellikka PA et al:Bioprosthetic valve thrombosis versus structural failure:Clinical and echocar-diographic predictors. J Am Coll Cardiol 66(21):2285-2294, 2015
31) Stewart WJ:Thrombosis of bioprosthetic valves:Can we afford to ignore it? J Am Coll Cardiol 66(21):2295-2297, 2015
32) Hammadah M, Han BK, de Oliveira Nunes M et al:Hypoattenuated leaflet thicken-ing after transcatheter pulmonary valve replacement with the SAPIEN 3 valve. JACC Cardiovasc Imaging, 2021
V章 原発性心筋症・心筋炎・心膜疾患・心臓腫瘍
P.202 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. 2021
2) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2021年JCS/JHRSガイドラインフォーカスアップデート版 不整脈非薬物治療. 2021
P.203 掲載の参考文献
3) 日本循環器学会/日本心不全学会合同ガイドライン:心筋症診療ガイドライン(2018年改訂版). 2019
4) Fatkin D, Huttner IG, Kovacic JC et al:Precision medicine in the management of dilated cardiomyopathy:JACC State-of-the-Art Review. J Am Coll Cardiol 74(23):2921-2938, 2019
5) Verdonschot JAJ, Wang P, Van Bilsen M et al:Metabolic profiling associates with disease severity in nonischemic dilated cardiomyopathy. J Card Fail 26(3):212-222, 2020
6) Jordan E, Peterson L, Ai T et al:Evidence-based assessment of genes in dilated car-diomyopathy. Circulation 144(1):7-19, 2021
7) Fullenkamp DE, Puckelwartz MJ, McNally EM:Genome-wide association for heart failure:From discovery to clinical use. Eur Heart J 42(20):2012-2014, 2021
8) Garnier S, Harakalova M, Weiss S et al:Genome-wide association analysis in di-lated cardiomyopathy reveals two new players in systolic heart failure on chromo-somes 3p25.1 and 22q11.23. Eur Heart J 42(20):2000-2011, 2021
9) Verdonschot JAJ, Merlo M, Dominguez F et al:Phenotypic clustering of dilated cardiomyopathy patients highlights impor-tant pathophysiological differences. Eur Heart J 42(2):162-174, 2021
P.204 掲載の参考文献
10) Calderon-Dominguez M, Belmonte T, Quezada-Feijoo M et al:Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy. Sci Rep 11(1):7517, 2021
11) Sammani A, Baas AF, Asselbergs FW et al:Diagnosis and risk prediction of dilated cardiomyopathy in the era of big data and genomics. J Clin Med 10(5):921, 2021
12) Millar LM, Fanton Z, Finocchiaro G et al:Differentiation between athlete's heart and dilated cardiomyopathy in athletic indi-viduals. Heart 106(14):1059-1065, 2020
13) Kimura Y, Okumura T, Morimoto R et al:A clinical score for predicting left ven-tricular reverse remodelling in patients with dilated cardiomyopathy. ESC Heart Fail 8(2):1359-1368, 2021
P.205 掲載の参考文献
14) Xu Y, Li W, Wan K et al:Myocardial tis-sue reverse remodeling after guideline-directed medical therapy in idiopathic dilated cardiomyopathy. Circ Heart Fail 14(1):e007944, 2021
15) Mandawat A, Chattranukulchai P, Man-dawat A et al:Progression of myocardial fibrosis in nonischemic DCM and asso-ciation with mortality and heart failure outcomes. JACC Cardiovasc Imaging 14(7):1338-1350, 2021
P.206 掲載の参考文献
16) Halliday BP, Wassall R, Lota AS et al:Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy(TRED-HF):an open-label, pilot, randomised trial. Lancet 393(10166):61-73, 2019
17) Enzan N, Matsushima S, Ide T et al:Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. J Am Heart As-soc 10(12):e019240, 2021
18) Di Marco A, Brown PF, Bradley J et al:Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 77(23):2890-2905, 2021
19) Anagnostopoulos I, Kousta M, Kossyvakis C et al:The prognostic role of late gado-linium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter de-fibrillators for primary prevention. A sys-tematic review and meta-analysis. J Interv Card Electrophysiol, 2021
P.207 掲載の参考文献
20) Dziewiecka E, Gliniak M, Winiarczyk M et al:Mortality risk in dilated cardiomy-opathy:the accuracy of heart failure prog-nostic models and dilate cardiomyopathy-tailored prognostic model. ESC Heart Fail 7(5):2455-2467, 2020
21) Marrow BA, Cook SA, Prasad SK et al:Emerging techniques for risk stratification in nonischemic dilated cardiomyopathy:JACC review topic of the week. J Am Coll Cardiol 75(10):1196-1207, 2020
P.208 掲載の参考文献
22) 小室一成 編:Cutting Edge of Molecular Cardiology 新しい臨床を開拓するための分子循環器病学. 南山堂, 2019
23) 朝野仁裕 企画:特集 心臓病に挑むゲノム医療. 心臓 51(12), 2019
24) 大石醒悟, 野村征太郎, 山口徹雄 企画:特集 U40世代が描く心不全診療の現状と未来-基礎研究を識り, 臨床を素心深考する. 循環器ジャーナル 68(1),2020
25) 野村征太郎 編, YIBC(Young investiga-tor Initiative for Basic Cardiovascular sci-ence)著:実験医学別冊 もっとよくわかる!シリーズ もっとよくわかる!循環器学と精密医療. 羊土社, 2020
26) 島田和典 企画:特集 スポーツと循環器疾患:Sports Cardiologyのすゝめ. 心臓 52(4), 2020
27) 北岡裕章 編:循環器診療コンプリートシリーズ 心筋症 心・腎・脳の視点でとらえる循環器疾患. 学研メディカル秀潤社, 2021
28) 福田哲也 企画協力:特集:Precision Medi-cine 時代のCardiac Imaging 2021-技術革新が切り開く循環器画像診断の未来【後編:MRI/超音波診断装置/IT】. 月刊インナービジョン 36(5), 2021
P.209 掲載の参考文献
1) Ommen SR, Mital S, Burke MA et al:2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:Executive summary:A report of the American College of Car-diology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142(25):e533-e557, 2020
P.210 掲載の参考文献
2) Ahmad F, McNally EM, Ackerman MJ et al:Establishment of specialized clinical cardiovascular genetics programs:Recog-nizing the need and meeting standards:A scientific statement from the American Heart Association. Circ Genom Precis Med 12(6):e000054, 2019
3) Lafreniere-Roula M, Bolkier Y, Zahavich L et al:Family screening for hypertrophic cardiomyopathy:Is it time to change prac-tice guidelines? Eur Heart J 40(45):3672-3681, 2019
4) Norrish G, Ding T, Field E et al:A vali-dation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hy-pertrophic cardiomyopathy. Europace 21(10):1559-1565, 2019
5) Balaji S, DiLorenzo MP, Fish FA et al:Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibril-lator:An international multicenter study. Heart Rhythm 16(10):1462-1467, 2019
6) Maron MS, Rowin EJ, Wessler BS et al:Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomy-opathy. JAMA Cardiol 4(7):644-657, 2019
7) Miron A, Lafreniere-Roula M, Steve Fan CP et al:A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 142(3):217-229, 2020
8) Kimmelstiel C, Zisa DC, Kuttab JS et al:Guideline-based referral for septal reduc-tion therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes. Circ Cardiovasc Interv 12(7):e007673, 2019
9) Hodges K, Rivas CG, Aguilera J et al:Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg 157(6):2289-2299, 2019
10) Cui H, Schaff HV, Nishimura RA et al:Conduction abnormalities and long-term mortality following septal myectomy in pa-tients with obstructive hypertrophic car-diomyopathy. J Am Coll Cardiol 74(5):645-655, 2019
P.211 掲載の参考文献
11) Guttmann OP, Rahman MS, O'Mahony C et al:Atrial fibrillation and thromboembo-lism in patients with hypertrophic cardio-myopathy:Systematic review. Heart 100(6):465-472, 2014
12) Jung H, Yang PS, Jang E et al:Effective-ness and safety of non-vitamin K antago-nist oral anticoagulants in patients with atrial fibrillation with hypertrophic car-diomyopathy:A nationwide cohort study. Chest 155(2):354-363, 2019
13) Saijo Y, Van Iterson E, Vega Brizneda M et al:Impact of left atrial strain mechan-ics on exercise intolerance and need for septal reduction therapy in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging, 2021
14) Arnett DK, Blumenthal RS, Albert MA et al:2019 ACC/AHA Guideline on the primary prevention of cardiovascular dis-ease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140(11):e596-e646, 2019
15) Pelliccia A, Solberg EE, Papadakis M et al:Recommendations for participation in competitive and leisure time sport in ath-letes with cardiomyopathies, myocarditis, and pericarditis:Position statement of the Sport Cardiology Section of the Euro-pean Association of Preventive Cardiology(EAPC). Eur Heart J 40(1):19-33, 2019
16) Marstrand P, Han L, Day SM et al:Hypertrophic cardiomyopathy with left ventricular systolic dysfunction:Insights from the SHaRe Registry. Circulation 141(17):1371-1383, 2020
P.212 掲載の参考文献
17) Weissler-Snir A, Allan K, Cunningham K et al:Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario. Circulation 140(21):1706-1716, 2019
18) Ogura S, Nakamura K, Morita H et al:New appearance of fragmented QRS as a predictor of ventricular arrhythmic events in patients with hypertrophic cardiomy-opathy. Circ J 84(3):487-494, 2020
P.213 掲載の参考文献
19) Nakashima Y, Kubo T, Sugiura K et al:Lifelong clinical impact of the presence of sarcomere gene mutation in Japanese pa-tients with hypertrophic cardiomyopathy. Circ J 84(10):1846-1853, 2020
P.214 掲載の参考文献
20) Hirota T, Kubo T, Baba Y et al:Clinical profile of thromboembolic events in pa-tients with hypertrophic cardiomyopathy in a regional Japanese cohort- results from Kochi RYOMA Study. Circ J 83(8):1747-1754, 2019
21) Hohneck A, Overhoff D, Doesch C et al:Extent of late gadolinium enhancement predicts thromboembolic events in pa-tients with hypertrophic cardiomyopathy. Circ J 84(5):754-762, 2020
P.215 掲載の参考文献
22) Xu J, Zhuang B, Sirajuddin A et al:MRI T1 mapping in hypertrophic cardiomy-opathy:Evaluation in patients without late gadolinium enhancement and hemo-dynamic obstruction. Radiology 294(2):275-286, 2020
23) Xu H, Wang J, Yuan J et al:Implication of apnea-hypopnea index, a measure of obstructive sleep apnea severity, for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Heart Assoc 9(8):e015013, 2020
P.216 掲載の参考文献
24) Wang S, Cui H, Song C et al:Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 16(5):694-701, 2019
25) Olivotto I, Oreziak A, Barriales-Villa R et al:Mavacamten for treatment of symp-tomatic obstructive hypertrophic cardio-myopathy(EXPLORER-HCM):a ran-domised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759-769, 2020
P.217 掲載の参考文献
26) Saberi S, Cardim N, Yamani M et al:Mavacamten favorably impacts cardiac structure in obstructive hypertrophic car-diomyopathy:EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 143(6):606-608, 2021
P.218 掲載の参考文献
27) Ho CY, Mealiffe ME, Bach RG et al:Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649-2660, 2020
28) Veselka J, Faber L, Liebregts M et al:Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstruc-tive cardiomyopathy in patients with mild left ventricular hypertrophy:a propen-sity score matching analysis. Eur Heart J 40(21):1681-1687, 2019
P.219 掲載の参考文献
29) Matsuda J, Takano H, Morooka M et al:Relationship between procedural right bun-dle branch block and 1-year outcome after alcohol septal ablation for hypertrophic ob-structive cardiomyopathy-A retrospective study. Circ J 85(9):1481-1491, 2021
30) Imori Y, Takano H, Mase H et al:Biso-prolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy. BMC Cardiovasc Disord 19(1):316, 2019
P.221 掲載の参考文献
1) Marcus FI, McKenna WJ, Sherrill D et al:Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia:Proposed modification of the task force criteria. Circulation 121:1533-1541, 2010
P.222 掲載の参考文献
2) Towbin JA, McKenna WJ, Abrams DJ et al:2019 HRS expert consensus statement on evaluation, risk stratification, and man-agement of arrhythmogenic cardiomyopa-thy. Heart Rhythm 16:e301-e372, 2019
3) Corrado D, Perazzolo Marra M, Zorzi A et al:Diagnosis of arrhythmogenic car-diomyopathy:The Padua criteria. Int J Cardiol 319:106-114, 2020
4) James CA, Jongbloed JDH, Hershberger RE et al:International evidence based reappraisal of genes associated with arrhythmogenic right ventricular car-diomyopathy using the Clinical Genome Resource Framework. Circ Genom Precis Med 14:e003273, 2021
P.223 掲載の参考文献
5) Hoogendoorn JC, Venlet J, Out YNJ et al:The precordial R' wave:A novel discriminator between cardiac sarcoidosis and arrhythmogenic right ventricular car-diomyopathy in patients presenting with ventricular tachycardia. Heart Rhythm, 2021[online ahead of print]
6) Kataoka N, Nagase S, Kamakura T et al:Clinical differences in Japanese patients between Brugada syndrome and arrhyth-mogenic right ventricular cardiomyopathy with long-term follow-up. Am J Cardiol 124:715-722, 2019
7) Corrado D, van Tintelen PJ, McKenna WJ et al:Arrhythmogenic right ventricular cardiomyopathy:evaluation of the cur-rent diagnostic criteria and differential di-agnosis. Eur Heart J 41:1414-1429, 2020
8) Cappelletto C, Gregorio C, Barbati G et al:Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmogenic right ventricle cardiomy-opathy. Int J Cardiol 334:58-64, 2021
P.224 掲載の参考文献
9) Daimee UA, Assis FR, Murray B et al:Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardio-myopathy:Insights from the Johns Hop-kins ARVC Program. Heart Rhythm, 2021[online ahead of print]
10) Kalantarian S, Vittinghoff E, Klein L et al:Effect of preload reducing therapy on right ventricular size and function in patients with arrhythmogenic right ven-tricular cardiomyopathy. Heart Rhythm 18:1186-1191, 2021
11) Cadrin-Tourigny J, Bosman LP, Nozza A et al:A new prediction model for ventric-ular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 40:1850-1858, 2019
P.225 掲載の参考文献
12) Corrado D, Wichter T, Link MS et al:Treatment of arrhythmogenic right ven-tricular cardiomyopathy/dysplasia:An international task force consensus state-ment. Circulation 132:441-453, 2015
13) Cadrin-Tourigny J, Bosman LP, Wang W et al:Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Car-diomyopathy:A Multinational Collabora-tion. Circ Arrhythm Electrophysiol 14:e008509, 2021
14) Aquaro GD, De Luca A, Cappelletto C et al:Prognostic value of magnetic reso-nance phenotype in patients with arrhyth-mogenic right ventricular cardiomyopathy. J Am Coll Cardiol 75:2753-2765, 2020
15) Platonov PG, Castrini AI, Svensson A et al:Pregnancies, ventricular arrhythmias, and substrate progression in women with arrhythmogenic right ventricular cardio-myopathy in the Nordic ARVC Registry. Europace 22:1873-1879, 2020
P.227 掲載の参考文献
1) Templin C, Ghadri JR, Diekmann J et al:Clinical features and outcomes of takot-subo(stress)cardiomyopathy. N Engl J Med 373(10):929-938, 2015
2) Uribarri A, Nunez-Gil IJ, Conty DA et al:Short- and long-term prognosis of patients with takotsubo syndrome based on dif-ferent triggers:Importance of the physi-cal nature. J Am Heart Assoc 8(24):e013701, 2019
3) Ghadri JR, Kato K, Cammann VL et al:Long-term prognosis of patients with ta-kotsubo syndrome. J Am Coll Cardiol 72(8):874-882, 2018
4) Kato K, Cammann VL, Napp LC et al:Prognostic impact of acute pulmonary triggers in patients with takotsubo syn-drome:new insights from the International Takotsubo Registry. ESC Heart Fail 8(3):1924-1932, 2021
P.228 掲載の参考文献
5) Arcari L, Musumeci MB, Stiermaier T et al:Incidence, determinants and prognostic relevance of dyspnea at admission in pa-tients with Takotsubo syndrome:Results from the international multicenter GEIST registry. Sci Rep 10(1):13603, 2020
6) Jurisic S, Gili S, Cammann VL et al:Clinical predictors and prognostic impact of recovery of wall motion abnormalities in takotsubo syndrome:Results from the International Takotsubo Registry. J Am Heart Assoc 8(21):2019
7) El-Battrawy I, Santoro F, Stiermaier T et al:Incidence and clinical impact of right ventricular involvement(biventricular ballooning)in takotsubo syndrome:Re-sults from the GEIST Registry. Chest, 2021
8) Santoro F, Nunez Gil IJ, Stiermaier T et al:Assessment of the German and Italian stress cardiomyopathy score for risk strati-fication for in-hospital complications in patients with takotsubo syndrome. JAMA Cardiol, 2019
9) Wischnewsky MB, Candreva A, Bacchi B et al:Prediction of short-and long-term mortality in takotsubo syndrome:the InterTAK Prognostic Score. Euro J Heart Fail, 2019
P.229 掲載の参考文献
10) Cammann VL, Sarcon A, Ding KJ et al:Clinical features and outcomes of patients with malignancy and takotsubo syn-drome:Observations from the International Takotsubo Registry. J Am Heart Assoc 8(15):e010881, 2019
11) Nguyen TH, Stansborough J, Ong GJ et al:Antecedent cancer in Takotsubo syn-drome predicts both cardiovascular and long-term mortality. Cardiooncology 5:20, 2019
12) Desai R, Desai A, Abbas SA et al:Na-tional prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal/intratho-racic cancer and radiation therapy. Int J Cardiol 309:14-18, 2020
13) Imori Y, Kato K, Cammann VL et al:Eth-nic comparison in takotsubo syndrome:Novel insights from the International Ta-kotsubo Registry. Clin Res Cardiol, 2021
14) Zaghlol R, Dey AK, Desale et al:Racial differences in takotsubo cardiomyopathy outcomes in a large nationwide sample. ESC Heart Fail 7(3):1056-1063, 2020
P.230 掲載の参考文献
15) Napp LC, Cammann VL, Jaguszewski M et al:Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Eur Heart J 41(34):3255-3268, 2020
16) Montone RA, Galiuto L, Meucci MC et al:Coronary slow flow is associated with a worse clinical outcome in patients with Takotsubo syndrome. Heart 106(12):923-930, 2020
17) Ding KJ, Cammann VL, Szawan KA et al:Intraventricular thrombus formation and embolism in takotsubo syndrome:Insights from the International Takotsubo Registry. Arterioscler Thromb Vasc Biol 40(1):279-287, 2020
P.231 掲載の参考文献
18) Cammann VL, Szawan KA, Stahli BE et al:Age-related variations in takotsubo syndrome. J Am Coll Cardiol 75(16):1869-1877, 2020
19) Mariani S, Richter J, Pappalardo F et al:Mechanical circulatory support for takot-subo syndrome:A systematic review and meta-analysis. Int J Cardiol 316:31-39, 2020
20) Ghadri JR, Wittstein IS, Prasad A et al:In-ternational expert consensus document on takotsubo syndrome(Part II):Diagnostic workup, outcome, and management. Eur Heart J, 2018
21) D'Ascenzo F, Gili S, Bertaina M et al:Im-pact of aspirin on takotsubo syndrome:a propensity score-based analysis of the InterTAK Registry. Eur J Heart Fail 22(2):330-337, 2020
P.232 掲載の参考文献
19) Sanchez JB, Alcalde JDC, Isidro RR et al:Acute limb ischemia in a peruvian cohort infected by COVID-19. Ann Vasc Surg 72:106-204, 2021
20) Perini P, Nabulsi B, Massoni CB et al:Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet 395:1546, 2020
21) Bjorck M, Earnshaw JJ, Acosta S et al:Editor's Choice-European Society for Vascular Surgery(ESVS)2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endo-vasc Surg 59:173-218, 2020
22) Templin C, Manka R, Cammann VL et al:Takotsubo syndrome in coronavirus dis-ease 2019. Am J Cardiol 138:118-120, 2021
23) Jabri A, Kalra A, Kumar A et al:Incidence of stress cardiomyopathy during the coro-navirus disease 2019 pandemic. JAMA Netw Open 3(7):e2014780, 2020
24) Imori Y, Yoshikawa T, Murakami T et al:Impact of trigger on outcome of takot-subo syndrome- multi-center registry from Tokyo Cardiovascular Care Unit Network. Circ Rep 1(11):493-501, 2019
25) Kimura A, Yoshikawa T, Isogai T et al:Impact of body temperature at admission on inhospital outcomes in patients with takotsubo syndrome:Insights from the Tokyo Cardiovascular Care Unit Network Registry. Eur Heart J Acute Cardiovasc Care 9(7):703-710, 2020
26) Kanaoka K, Okayama S, Terasaki S et al:Role of climatic factors in the incidence of Takotsubo syndrome:A nationwide study from 2012 to 2016. ESC Heart Fail 7(5):2629-2636, 2020
27) Itoh T, Toda N, Yoshizawa M et al:Im-pact of the Great East Japan Earthquake and Tsunami on the Incidence of Takot-subo Syndrome Using a Multicenter, Long-Term Regional Registry. Circ J, 2021
P.233 掲載の参考文献
1) 日本循環器学会 他:急性および慢性心筋炎の診断・治療に関するガイドライン(2009年改訂版). 2009
P.234 掲載の参考文献
2) Blanco-Dominguez R, Sanchez-Diaz R, de la Fuente H et al:A novel circulating Mi-croRNA for the detection of acute myocar-ditis. N Engl J Med 384:2014-2027, 2021
P.235 掲載の参考文献
3) Wang Z, Wang Y, Lin H et al:Early char-acteristics of fulminant myocarditis vs non-fulminant myocarditis:A meta-analysis. Medicine 98:e14697, 2019
4) Butta C, Zappia L, Laterra G et al:Diagnostic and prognostic role of elec-trocardiogram in acute myocarditis:A comprehensive review. Ann Noninvasive Electrocardiol 25:125-134, 2020
5) Oka E, Iwasaki YK, Maru Y et al:Preva-lence and significance of an early repolar-ization electrocardiographic pattern and its mechanistic insight based on cardiac magnetic resonance imaging in patients with acute myocarditis. Circ Arrhythmia Electrophysiol 12:e006969, 2019
P.236 掲載の参考文献
6) Ogunbayo GO, Elayi SC, Ha LD et al:Outcomes of heart block in myocarditis:A review of 31,760 patients. Hear Lung Circ 28:272-276, 2019
7) Peretto G, Sala S, Rizzo S et al:Ventricu-lar arrhythmias in myocarditis:Charac-terization and relationships with myocar-dial inflammation. J Am Coll Cardiol 75:1046-1057, 2020
P.237 掲載の参考文献
8) Peretto G, Sala S, Basso C et al:Inflamma-tion as a predictor of recurrent ventricular tachycardia after ablation in patients with myocarditis. J Am Coll Cardiol 76:1644-1656, 2020
P.238 掲載の参考文献
9) Li S, Xu S, Li C et al:A life support-based comprehensive treatment regimen dra-matically lowers the in-hospital mortality of patients with fulminant myocarditis:a multiple center study. Sci China Life Sci 62:369-380, 2019
10) Schrage B, Becher PM, Bernhardt A et al:Left ventricular unloading is associated with lower mortality in patients with car-diogenic shock treated with venoarterial extracorporeal membrane oxygenation:Results from an international, multicenter Cohort Study. Circulation 2095-2106, 2020
11) Baran DA, Grines CL, Bailey S et al:SCAI clinical expert consensus statement on the classification of cardiogenic shock:This document was endorsed by the American College of Cardiology(ACC), the Ameri-can Heart Association(AHA), the Society of Critical Care Medicine(SCCM), and the Society of Thoracic Surgeons(STS)in April 2019. Catheter Cardiovasc Interv 94:29-37, 2019
P.239 掲載の参考文献
12) 田尻和子, 関根郁夫, 家田真樹:免疫チェックポイント阻害薬と心臓有害事象. 循環器医 28:3-9, 2019
13) Hu JR, Florido R, Lipson EJ et al:Cardio-vascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115:854-868, 2019
14) Mahmood SS, Fradley MG, Cohen JV et al:Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755-1764, 2018
15) Ho JS, Sia CH, Chan MY et al:Coronavi-rus-induced myocarditis:A meta-summa-ry of cases. Hear Lung 49:681-685, 2020
16) Halushka MK, Vander Heide RS. Myo-carditis is rare in COVID-19 autopsies:cardiovascular findings across 277 post-mortem examinations. Cardiovasc Pathol 50:107300, 2021
17) Daniels CJ, Rajpal S, Greenshields JT et al:Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection. JAMA Car-diol, 2021[Epub ahead of print]
P.240 掲載の参考文献
18) Imazio M, Brucato A, Cemin R et al:A Randomized trial of colchicine for acute pericarditis. N Engl J Med 369:1522-1528, 2013
19) Imazio M, Belli R, Brucato A et al:Effi-cacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2):A multicentre, double-blind, placebo-controlled, randomised trial. Lan-cet 383:2232-2237, 2014
20) Klein AL, Imazio M, Cremer P et al:Phase 3 trial of interleukin-1 trap rilona-cept in recurrent pericarditis. N Engl J Med 384:31-41, 2021
21) Shenthar J:Clinical presentations, diag-nosis, and management of arrhythmias associated with cardiac tumors. J Arrhyth-mia 34:384-393, 2018
22) Stefanou MI, Rath D, Stadler V et al:Cardiac myxoma and cerebrovascular events:A retrospective cohort study. Front Neurol 9:1-10, 2018
VI章 二次性心筋症 ( アミロイドーシス, サルコイドーシス, ファブリーなど )
P.245 掲載の参考文献
1) Di Stefano C, Bruno G, Arciniegas Calle MC et al:Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis. BMC Cardiovasc Dis-ord 20:21, 2020
2) Kusunose K, Fujiwara M, Yamada H et al:Deterioration of biventricular strain is an early marker of cardiac involvement in confirmed sarcoidosis. Eur Heart J Cardio-vasc Imaging 21:796-804, 2020
3) Omote K, Naya M, Koyanagawa K et al:18F-FDG uptake of the right ventricle is an important predictor of histopathologic diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis. J Nucl Cardiol 27:2135-2143, 2020
4) Komoriyama H, Omote K, Nagai T et al:Lower left ventricular ejection fraction and higher serum angiotensin-converting enzyme activity are associated with histo-pathological diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis. Int J Cardiol 321:113-117, 2020
P.246 掲載の参考文献
5) Subramanian M, Swapna N, Ali AZ et al:Pre-treatment myocardial 18FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging, 2021[online ahead of print]
6) Ballul T, Borie R, Crestani B et al:Treat-ment of cardiac sarcoidosis:A compara-tive study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol 276:208-211, 2019
7) Gilotra NA, Wand AL, Pillarisetty A et al:Clinical and imaging response to tumor necrosis factor alpha inhibitors in treat-ment of cardiac sarcoidosis:A multicenter experience. J Card Fail 27:83-91, 2021
P.247 掲載の参考文献
8) Birnie D, Beanlands RSB, Nery P et al:Cardiac Sarcoidosis multi-center random-ized controlled trial(CHASM CS-RCT). Am Heart J 220:246-252, 2020
9) Kaur D, Roukoz H, Shah M et al:Impact of the inflammation on the outcomes of catheter ablation of drug-refractory ven-tricular tachycardia in cardiac sarcoidosis. J Cardiovasc Electrophysiol 31:612-620, 2020
10) Flamee L, Symons R, Degtiarova G et al:Prognostic value of cardiovascular mag-netic resonance in patients with biopsy-proven systemic sarcoidosis. Eur Radiol 30(7):3702-3710, 2020
P.248 掲載の参考文献
11) Velangi PS, Chen KA, Kazmirczak F et al:Right ventricular abnormalities on car-diovascular magnetic resonance imaging in patients with sarcoidosis. JACC Cardio-vasc Imaging 13:1395-1405, 2020
12) Yodogawa K, Fukushima Y, Ando T et al:Prevalence of atrial FDG uptake and association with atrial arrhythmias in patients with cardiac sarcoidosis. Int J Cardiol 313:55-59, 2020
13) Tuominen H, Haarala A, Tikkakoski A et al:FDG-PET in possible cardiac sarcoid-osis:Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events. J Nucl Cardiol 28:199-205, 2021
P.249 掲載の参考文献
14) Gowani Z, Habibi M, Okada DR et al:Util-ity of cardiac magnetic resonance imaging versus cardiac positron emission tomogra-phy for risk stratification for ventricular arrhythmias in patients with cardiac sar-coidosis. Am J Cardiol 134:123-129, 2020
15) Koyanagawa K, Naya M, Aikawa T et al:The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. J Nucl Cardiol, 2019[online ahead of print]
16) Yamamoto A, Nagao M, Watanabe E et al:Prognosis and recurrence in cardiac sarcoidosis:Serial assessment of BMIPP SPECT and FDG-PET. J Nucl Cardiol, 2021[online ahead of print]
17) Zipse MM, Tzou WS, Schuller JL et al:Electrophysiologic testing for diagnostic evaluation and risk stratification in pa-tients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. J Cardiovasc Electro-physiol 30:1939-1948, 2019
P.250 掲載の参考文献
18) Hoogendoorn JC, Ninaber MK, Piers SRD et al:The harm of delayed diagnosis of arrhythmogenic cardiac sarcoidosis:A case series. Europace 22:1376-1383, 2020
19) Al-Khatib SM, Stevenson WG, Ackerman MJ et al:2017 AHA/ACC/HRS guideline for management of patients with ven-tricular arrhythmias and the prevention of sudden cardiac death:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72:e91-e220, 2018
20) Takenaka S, Kobayashi Y, Nagai T et al:Applicability of the AHA/ACC/HRS guideline for implantable cardioverter defi-brillator implantation in Japanese patients with cardiac sarcoidosis. JACC Clin Elec-trophysiol, 2021[online ahead of print]
P.251 掲載の参考文献
1) Benson MD, Buxbaum JN, Eisenberg DS et al:Amyloid nomenclature 2018:recommendations by the International So-ciety of Amyloidosis(ISA)nomenclature committee. Amyloid 25:215-219, 2018
P.252 掲載の参考文献
2) 日本循環器学会, 日本心不全学会:心筋症診療ガイドライン(2018年改訂版).
3) 日本循環器学会, 日本アミロイドーシス学会, 日本血液学会 他:2020年版 心アミロイドーシス診療ガイドライン.
4) Kitaoka H, Izumi C, Izumiya Y et al:JCS 2020 Guideline on Diagnosis and Treat-ment of Cardiac Amyloidosis. Circ J 84:1610-1671, 2020
5) Garcia-Pavia P, Rapezzi C, Adler Y et al:Diagnosis and treatment of cardiac amy-loidosis:a position statement of the ESC Working Group on Myocardial and Peri-cardial Diseases. Eur Heart J 42:1554-1568, 2021
6) Devesa A, Camblor Blasco A, Pello Lazaro AM et al:Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail 8:2856-2865, 2021
7) Ternacle J, Krapf L, Mohty D et al:Aortic stenosis and cardiac amyloidosis:JACC review topic of the week. J Am Coll Car-diol 74:2638-2651, 2019
8) Castano A, Narotsky DL, Hamid N et al:Unveiling transthyretin cardiac amyloi-dosis and its predictors among elderly patients with severe aortic stenosis under-going transcatheter aortic valve replace-ment. Euro Heart J 38:2879-2887, 2017
9) Scully PR, Treibel TA, Fontana M et al:Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol 71:463-464, 2018
10) Nitsche C, Scully PR, Patel KP et al:Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 77:128-139, 2021
P.253 掲載の参考文献
11) Oda S, Kidoh M, Nagayama Y et al:Trends in diagnostic imaging of cardiac amyloidosis:Emerging knowledge and concepts. Radiographics 40:961-981, 2020
12) Witteles RM, Bokhari S, Damy T et al:Screening for transthyretin amyloid car-diomyopathy in everyday practice. JACC Heart failure 7:709-716, 2019
13) Ruberg FL, Grogan M, Hanna M et al:Transthyretin amyloid cardiomyopathy:JACC State-of-the-Art Review. J Am Coll Cardiol 73:2872-2891, 2019
14) Marume K, Takashio S, Nishi M et al:Combination of commonly examined pa-rameters is a useful predictor of positive(99 m)Tc-Labeled Pyrophosphate Scin-tigraphy findings in elderly patients with suspected transthyretin cardiac amyloido-sis. Circ J 83:1698-1708, 2019
P.254 掲載の参考文献
15) Aus dem Siepen F, Hein S, Prestel S et al:Carpal tunnel syndrome and spinal ca-nal stenosis:harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 108:1324-1330, 2019
16) Dang D, Fournier P, Cariou E et al:Gate-way and journey of patients with cardiac amyloidosis. ESC Heart Fail 7:2418-2430, 2020
17) Donnellan E, Wazni OM, Hanna M et al:Atrial fibrillation in transthyretin cardiac amyloidosis:Predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 6:1118-1127, 2020
18) Takashio S, Yamamuro M, Izumiya Y et al:Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 5:27-35, 2018
P.255 掲載の参考文献
19) Stricagnoli M, Cameli M, Incampo E et al:Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev 24:701-707, 2019
20) Huntjens PR, Zhang KW, Soyama Y et al:Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging 14:1508-1519, 2021
21) Martinez-Naharro A, Treibel TA, Abdel-Gadir A et al:Magnetic resonance in transthyretin cardiac amyloidosis. J Am College Cardiol 70:466-477, 2017
22) Fontana M, Pica S, Reant P et al:Prog-nostic value of late gadolinium enhance-ment cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132:1570-1579, 2015
P.256 掲載の参考文献
23) Messroghli DR, Moon JC, Ferreira VM et al:Clinical recommendations for cardio-vascular magnetic resonance mapping of T1, T2, T2* and extracellular volume:A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR)endorsed by the European As-sociation for Cardiovascular Imaging(EACVI). J Cardiovasc Magn Reson 19:75, 2017
24) Martinez-Naharro A, Kotecha T, Nor-rington K et al:Native T1 and extracel-lular volume in transthyretin amyloidosis. JACC Cardiovascul Imaging 12:810-819, 2019
25) Fontana M, Martinez-Naharro A, Chacko L et al:Reduction in CMR derived extra-cellular volume with patisiran indicates cardiac amyloid regression. JACC Cardio-vasc Imaging 14:189-199, 2021
26) Singh V, Falk R, Di Carli MF et al:State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Cardiovasc Magn Reson 26:158-173, 2019
27) Gillmore JD, Maurer MS, Falk RH et al:Nonbiopsy diagnosis of cardiac transthyre-tin amyloidosis. Circulation 133:2404-2412, 2016
P.257 掲載の参考文献
28) Castano A, Haq M, Narotsky DL et al:Multicenter study of planar technetium 99m pyrophosphate cardiac imaging:Pre-dicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiology 1:880-889, 2016
29) Tsuda N, Shiraishi S, Oda S et al:Util-ity of single-photon emission computed tomography/computed tomography fusion imaging with(99 m)Tc-Pyrophosphate Scintigraphy in the assessment of cardiac transthyretin amyloidosis. Circ J 82:1970-1971, 2018
30) Oda S, Emoto T, Nakaura T et al:Myocardial late iodine enhancement and extracellular volume quantification with dual-layer spectral detector dual-energy cardiac CT. Radiol Cardiothorac Imaging 1:e180003, 2019
31) Ohta Y, Kitao S, Yunaga H et al:Myo-cardial delayed enhancement CT for the evaluation of heart failure:Comparison to MRI. Radiology 288:682-691, 2018
32) Oda S, Nakaura T, Utsunomiya D et al:Late iodine enhancement and myocardial extracellular volume quantification in cardiac amyloidosis by using dual-energy cardiac computed tomography performed on a dual-layer spectral detector scanner. Amyloid 25:137-138, 2018
33) Oda S, Kidoh M, Takashio S et al:Quanti-fication of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis. Circ Cardiovasc Imaging 13:e010358, 2020
34) Scully PR, Patel KP, Saberwal B et al:Identifying cardiac amyloid in aortic ste-nosis:ECV quantification by CT in TAVR patients. JACC Cardiovasc Imaging 13:2177-2189, 2020
35) Kastritis E, Palladini G, Minnema MC et al:Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Eng J Med 385:46-58, 2021
36) Maurer MS, Schwartz JH, Gundapaneni B et al:Tafamidis treatment for patients with transthyretin amyloid cardiomyopa-thy. N Engl J Med 379:1007-1016, 2018
P.258 掲載の参考文献
37) Adams D, Gonzalez-Duarte A, O'Riordan WD et al:Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11-21, 2018
38) Solomon SD, Adams D, Kristen A et al:Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139:431-443, 2019
39) Minamisawa M, Claggett B, Adams D et al:Association of patisiran, an RNA inter-ference therapeutic, with regional left ven-tricular myocardial strain in hereditary transthyretin amyloidosis:The APOLLO Study. JAMA Cardiol 4:466-472, 2019
P.259 掲載の参考文献
1) Sawada T, Kido J, Yoshida S et al:New-born screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep 22:100562, 2020
P.260 掲載の参考文献
2) Yoshida S, Kido J, Sawada T et al:Fabry disease screening in high-risk populations in Japan:A nationwide study. Orphanet J Rare Dis 15(1):220, 2020
3) Capuano I, Garofalo C, Buonanno P et al:Identifying Fabry patients in dialysis population:Prevalence of GLA mutations by renal clinic screening, 1995-2019. J Nephrol 33(3):569-581, 2020
4) Azevedo O, Marques N, Reis L et al:Pre-dictors of Fabry disease in patients with hypertrophic cardiomyopathy:How to guide the diagnostic strategy? Am Heart J 226:114-126, 2020
5) Hemelsoet D, De Keyser J, Van Heuver-swyn F et al:Screening for Fabry disease in male patients with arrhythmia requiring a pacemaker or an implantable cardiovert-er-defibrillator. Circulation 143(8):872-874, 2021
6) Morimoto S, Nojiri A, Fukuro E et al:Characteristics of the electrocardiogram in Japanese Fabry patients under long-term enzyme replacement therapy. Front Cardiovasc Med 7:614129, 2021
P.261 掲載の参考文献
7) Roller FC, Fuest S, Meyer M et al:As-sessment of cardiac involvement in Fabry disease(FD)with native T1 mapping. Rofo 191(10):932-939, 2019
8) Hanneman K, Karur GR, Wasim S et al:Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease. Radiology 294(1):42-49, 2020
9) Nordin S, Kozor R, Medina-Menacho K et al:Proposed stages of myocardial pheno-type development in Fabry disease. JACC Cardiovasc Imaging 12(8 Pt 2):1673-1683, 2019
P.262 掲載の参考文献
10) Augusto JB, Johner N, Shah D et al:The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable stor-age. Eur Heart J Cardiovasc Imaging 22:790-799, 2021
11) Chimenti C, Verardo R, Frustaci A:Hy-pertrophy of unaffected cardiomyocytes correlates with severity of cardiomyopa-thy in female patients with Fabry disease. Orphanet J Rare Dis 16(1):169, 2021
12) Baydakova GV, Ilyushkina AA, Moiseev S et al:alpha-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females. Clin Chim Acta 501:27-32, 2020
P.263 掲載の参考文献
13) Yamashita S, Saotome M, Satoh H et al:Plasma globotriaosylsphingosine level as a primary screening target for Fabry disease in patients with left ventricular hy-pertrophy. Circ J 83(9):1901-1907, 2019
14) Nowak A, Beuschlein F, Sivasubramaniam V et al:Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet, 2021
15) Yonishi H, Namba-Hamano T, Hamano T et al:Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement ther-apy in Fabry nephropathy. Nephrol Dial Transplant, 2020[online ahead of print]
P.264 掲載の参考文献
16) Limgala RP, Fikry J, Veligatla V et al:The interaction of innate and adaptive immunity and stabilization of mast cell ac-tivation in management of infusion related reactions in patients with Fabry disease. Int J Mol Sci 21(19):7213, 2020
17) Feriozzi S, Linhart A, Ramaswami U et al;Fabry Outcome Survey Study Group:Effects of baseline left ventricular hypertro-phy and decreased renal function on car-diovascular and renal outcomes in patients with Fabry disease treated with agalsidase alfa:A Fabry outcome survey study. Clin Ther 42(12):2321-2330, 2020
18) Wanner C, Feldt-Rasmussen U, Jovanovic A et al:Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients:a pre-treatment vs. post-treatment analysis. ESC Heart Fail 7(3):825-834, 2020
P.265 掲載の参考文献
19) Nordin S, Kozor R, Vijapurapu R et al:Myocardial storage, inflammation, and car-diac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging 12(12):e009430, 2019
20) Lenders M, Nordbeck P, Kurschat C et al:Treatment of Fabry's disease with migalastat:Outcome from a prospective observational multicenter study(FA-MOUS). Clin Pharmacol Ther 108(2):326-337, 2020
21) Lenders M, Nordbeck P, Kurschat C et al:Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Phar-macother, 2021
P.266 掲載の参考文献
22) Riccio E, Zanfardino M, Ferreri L et al:Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease:Real-life data. Eur J Hum Genet 28(12):1662-1668, 2020
23) Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G et al:Long-term efficacy and safety of migalastat treatment in Fabry disease:30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab 131:219-228, 2020
24) Narita I, Ohashi T, Sakai N et al:Efficacy and safety of migalastat in a Japanese population:A subgroup analysis of the ATTRACT study. Clin Exp Nephrol 24(2):157-166, 2020
P.267 掲載の参考文献
25) 日本先天代謝異常学会 編:ファブリー病診療ガイドライン 2020. 診断と治療社, 2020
P.268 掲載の参考文献
1) Sturgeon KM, Deng L, Bluethmann SM et al:A population-based study of cardiovas-cular disease mortality risk in US cancer patients. Eur Heart J 40:3889-3897, 2019
2) 日本心エコー図学会:抗がん剤治療関連心筋障害の診療における心エコー図検査の手引. 2020
P.269 掲載の参考文献
3) Zhang S, Liu X, Bawa-Khalfe T et al:Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642, 2012
4) Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA et al:Genetic variants associated with cancer therapy-induced cardiomy-opathy. Circulation 140:31-41, 2019
5) Sabater-Molina M, Navarro-Penalver M, Munoz-Esparza C et al:Genetic factors involved in cardiomyopathies and in can-cer. J Clin Med 9:1702, 2020
6) Zamorano JL, Lancellotti P, Rodriguez Munoz D et al;ESC Scientific Document Group:2016 ESC Position Paper on can-cer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC). Eur Heart J 37:2768-2801, 2016
7) Wood PW, Choy JB, Nanda NC et al:Left ventricular ejection fraction and vol-umes:It depends on the imaging method. Echocardiography 31:87-100, 2014
8) Lang RM, Badano LP, Mor-Avi V et al:Recommendations for cardiac chamber quantification by echocardiography in adults:an update from the American Society of Echocardiography and the Euro-pean Association of Cardiovascular Imag-ing. J Am Soc Echocardiogr 28:1-39, 2015
9) Thavendiranathan P, Poulin F, Lim KD et al:Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy:A systematic review. J Am Coll Cardiol 63:2751-2768, 2014
P.270 掲載の参考文献
10) Houbois CP, Nolan M, Somerset E et al:Serial cardiovascular magnetic resonance strain measurements to identify cardio-toxicity in breast cancer:Comparison with echocardiography. JACC Cardiovasc Imaging 14:962-974, 2021
11) Thavendiranathan P, Negishi T, Somerset E et al;SUCCOUR Investigators:Strain-guided management of potentially cardio-toxic cancer therapy. J Am Coll Cardiol 77:392-401, 2021
12) Upshaw JN, Finkelman B, Hubbard RA et al:Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging 13:198-210, 2020
13) Galan-Arriola C, Lobo M, Vilchez-Tsch-ischke JP et al:Serial magnetic resonance imaging to identify early stages of anthra-cycline-induced cardiotoxicity. J Am Coll Cardiol 73:779-791, 2019
14) Nakamori S, Jang J, Tschabrunn CM et al:Noncontrast CMR for detecting early myocardial tissue injury in a swine model of anthracycline-induced cardiotoxicity. JACC Cardiovasc Imaging 12:2085-2087, 2019
15) Altaha MA, Nolan M, Marwick TH et al:Can quantitative CMR tissue character-ization adequately identify cardiotoxicity during chemotherapy?:Impact of tempo-ral and observer variability. JACC Cardio-vasc Imaging 13:951-962, 2020
P.271 掲載の参考文献
16) Gulati G, Heck SL, Ree AH et al:Preven-tion of cardiac dysfunction during adju-vant breast cancer therapy(PRADA):a2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671-1680, 2016
17) Pituskin E, Mackey JR, Koshman S et al:Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast):A random-ized trial for the prevention of trastuzum-ab-associated cardiotoxicity. J Clin Oncol 35:870-877, 2017
18) Guglin M, Krischer J, Tamura R et al:Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardio-toxicity in patients with breast cancer. J Am Coll Cardiol 73:2859-2868, 2019
19) Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr et al:Carvedilol for prevention of chemotherapy-related car-diotoxicity:The CECCY Trial. J Am Coll Cardiol 71:2281-2290, 2018
20) Boekhout AH, Gietema JA, Milojkovic Kerklaan B et al:Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer:A randomized clinical trial. JAMA Oncol 2:1030-1037, 2016
21) Vaduganathan M, Hirji SA, Qamar A et al:Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 1:54-65, 2019
22) Boutagy NE, Feher A, Pfau D et al:Dual angiotensin receptor-neprilysin in-hibition with sacubitril/valsartan attenu-ates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity. JACC CardioOncol 2:774-787, 2020
P.272 掲載の参考文献
23) Awadalla M, Mahmood SS, Groarke JD et al:Global longitudinal strain and cardiac events in patients with immune check-point inhibitor-related myocarditis. J Am Coll Cardiol 75:467-478, 2020
24) Escudier M, Cautela J, Malissen N et al:Clinical features, management, and out-comes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085-2087, 2017
25) Zhang L, Awadalla M, Mahmood SS et al:Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41:1733-1743, 2020
P.273 掲載の参考文献
26) Brahmer JR, Lacchetti C, Schneider BJ et al;National Comprehensive Cancer Net-work:Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714-1768, 2018
27) Zhang L, Zlotoff DA, Awadalla M et al:Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 141:2031-2034,2020
28) Arbour KC, Mezquita L, Long N et al:Im-pact of baseline steroids on efficacy of pro-grammed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872-2878, 2018
29) Champion SN, Stone JR:Immune check-point inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol 33:99-108, 2020
30) Palaskas NL, Segura A, Lelenwa L et al:Immune checkpoint inhibitor myocardi-tis:elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail, 2021[online ahead of print]
P.275 掲載の参考文献
1) 厚生労働省科学研究難治性疾患政策研究事業「周産期心筋症ガイドライン作成」班・「特発性心筋症に関する調査研究」班 編:周産期心筋症診療の手引き. 中外医学社, 2019
2) Isogai T, Kamiya CA:Worldwide inci-dence of peripartum cardiomyopathy and overall maternal mortality. Int Heart J 60:503-511, 2019
3) Ricke-Hoch M, Pfeffer T, Hilfiker-Kleiner D:Peripartum cardiomyopathy:Basic mechanisms and hope for new therapies. Cardiovasc Res 116:520-531, 2020
4) Ricke-Hoch M, Hoes MF, Pfeffer T et al:In peripartum cardiomyopathy plasmino-gen activator inhibitor-1 is a potential new biomarker with controversial roles. Car-diovasc Res 116:1875-1886, 2020
P.276 掲載の参考文献
5) Ekizler FA, Cay S:A novel marker of persistent left ventricular systolic dys-function in patients with peripartum car-diomyopathy:Monocyte count- to- HDL cholesterol ratio. BMC Cardiovasc Disord 19:114, 2019
6) Otani K, Tokudome T, Kamiya CA et al:Deficiency of cardiac natriuretic peptide signaling promotes peripartum cardiomy-opathy-like remodeling in the mouse heart. Circulation 141:571-588, 2020
P.277 掲載の参考文献
7) Hoes MF, Bomer N, Ricke-Hoch M et al:Human iPSC-derived cardiomyocytes of peripartum patients with cardiomyopathy reveal aberrant regulation of lipid metabo-lism. Circulation 142:2288-2291, 2020
P.278 掲載の参考文献
8) Kamiya CA, Shioyama W, Nakagawa Y et al:Cardiovascular disease among preg-nant women after anticancer therapy. J Obstet Gynaecol Res 47:2278-2290, 2021
9) Pfeffer TJ, Schlothauer S, Pietzsch S et al:Increased cancer prevalence in peri-partum cardiomyopathy. JACC CardioOn-col 1:196-205, 2019
P.279 掲載の参考文献
10) Bauersachs J, Konig T, van der Meer P et al:Pathophysiology, diagnosis and man-agement of peripartum cardiomyopathy:A position statement from the Heart Fail-ure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Euro J Heart Fail 21:827-843, 2019
VII章 大動脈疾患
P.282 掲載の参考文献
1) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会合同ガイドライン:2020年改訂版 大動脈瘤・大動脈解離診療ガイドライン. 2020 https://www.j-circ.or.jp/cms/wp-content/uploads/2020/07/JCS2020_Ogino.pdf
2) Howard DP, Banerjee A, Fairhead JF et al:Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control:10-year results from the Oxford Vascular Study. Circulation 127(20):2031-2037, 2013
P.283 掲載の参考文献
3) Smedberg C, Steuer J, Leander K et al:Sex differences and temporal trends in aortic dissection:a population-based study of incidence, treatment strategies, and out-come in Swedish patients during 15 years. Eur Heart J 41(26):2430-2438, 2020
4) Chen SW, Kuo CF, Huang YT et al:As-sociation of family history with incidence and outcomes of aortic dissection. J Am Coll Cardiol 76(10):1181-1192, 2020
5) Zhu Y, Lingala B, Baiocchi M et al:Type A aortic dissection-experience over 5 de-cades:JACC historical breakthroughs in perspective. J Am Coll Cardiol 76(14):1703-1713, 2020
6) Committee for Scientific Affairs, The Japanese Association for Thoracic Sur-gery:Shimizu H, Okada M, Toh Y et al:Thoracic and cardiovascular surgeries in Japan during 2018:Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 69(1):179-212, 2021
7) Erbel R, Aboyans V, Boileau C et al:2014 ESC Guidelines on the diagnosis and treatment of aortic diseases:Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology(ESC). Eur Heart J 35(41):2873-2926, 2014
8) Hiratzka LF, Bakris GL, Beckman JA et al:2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Ameri-can Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardio-vascular Anesthesiologists, Society for Cardiovascular Angiography and Interven-tions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121(13):e266-e369, 2010
P.284 掲載の参考文献
9) Kaji S, Akasaka T, Horibata Y et al:Long-term prognosis of patients with type A aortic intramural hematoma. Circulation 106(12 Suppl 1):I248-I252, 2002
10) Kaji S, Akasaka T, Katayama M et al:Long-term prognosis of patients with type B aortic intramural hematoma. Circulation 108 Suppl 1:II307-II311, 2003
11) Ahn JM, Kim H, Kwon O et al:Differential clinical features and long-term prognosis of acute aortic syndrome according to dis-ease entity. Eur Heart J 40(32):2727-2736, 2019
12) Sueyoshi E, Matsuoka Y, Imada T et al:New development of an ulcerlike projection in aortic intramural hematoma:CT evalu-ation. Radiology 224(2):536-541, 2002
13) Kitai T, Kaji S, Yamamuro A et al:Impact of new development of ulcer-like projection on clinical outcomes in patients with type B aortic dissection with closed and thrombosed false lumen. Circulation 122(11 Suppl):S74-S80, 2010
14) Wu MT, Wang YC, Huang YL et al:In-tramural blood pools accompanying aortic intramural hematoma:CT appearance and natural course. Radiology 258(3):705-713, 2011
15) Moral S, Cuellar H, Avegliano G et al:Clinical implications of focal intimal disrup-tion in patients with type B intramural hematoma. J Am Coll Cardiol 69(1):28-39, 2017
P.285 掲載の参考文献
16) Nienaber CA, Kische S, Rousseau H et al:Endovascular repair of type B aortic dis-section:long-term results of the random-ized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 6(4):407-416, 2013
17) Matsushita A, Tabata M, Mihara W et al:Risk score system for late aortic events in patients with uncomplicated type B aortic dissection. J Thorac Cardiovasc Surg 159(6):2173-2183. e1, 2020
18) Xiang D, Kan X, Liang H et al:Compari-son of mid-term outcomes of endovascu-lar repair and medical management in patients with acute uncomplicated type B aortic dissection. J Thorac Cardiovasc Surg 162(1):26-36. e1, 2021
19) Tolenaar JL, van Keulen JW, Jonker FH et al:Morphologic predictors of aortic dila-tation in type B aortic dissection. J Vasc Surg 58(5):1220-1225, 2013
20) Kaji S:Update on the therapeutic strat-egy of type B aortic dissection. J Athero-scler Thromb 25(3):203-212, 2018
21) Tadros RO, Tang GHL, Barnes HJ et al:Optimal Treatment of Uncomplicated Type B Aortic Dissection:JACC Review Topic of the Week. J Am Coll Cardiol 74(11):1494-1504, 2019
22) Lombardi JV, Hughes GC, Appoo JJ et al:Society for Vascular Surgery(SVS) and Society of Thoracic Surgeons(STS) reporting standards for type B aortic dis-sections. Ann Thorac Surg 109(3):959-981, 2020
23) Hong JC, Le Huu A, Preventza O:Medi-cal or endovascular management of acute type B aortic dissection. J Thorac Cardio-vasc Surg, 2021[online ahead of print]
24) Kodama K, Nishigami K, Sakamoto T et al:Tight heart rate control reduces sec-ondary adverse events in patients with type B acute aortic dissection. Circulation 118(14 Suppl):S167-S170, 2008
P.286 掲載の参考文献
25) Chen SW, Lin YS, Wu VC et al:Effect of beta-blocker therapy on late outcomes af-ter surgical repair of type A aortic dissec-tion. J Thorac Cardiovasc Surg 159(5):1694-1703. e3, 2020
P.287 掲載の参考文献
26) Meyrignac O, Bal L, Zadro C et al:Com-bining volumetric and wall shear stress analysis from CT to assess risk of abdomi-nal aortic aneurysm progression. Radiol-ogy 295(3):722-729, 2020
27) Wang Z, Flores N, Lum M et al:Wall stress analyses in patients with >- 5 cm versus < 5 cm ascending thoracic aortic aneurysm. J Thorac Cardiovasc Surg, 2020[online ahead of print]
28) Kang YN, Chi SC, Wu MH et al:The ef-fects of losartan versus beta-blockers on cardiovascular protection in marfan syn-drome:A systematic review and meta-analysis. J Formos Med Assoc 119(1 Pt 1):182-190, 2020
29) Elbadawi A, Omer M, Ogunbayo G et al:Antiplatelet medications protect against aortic dissection and rupture in patients with abdominal aortic aneurysms. J Am Coll Cardiol 75(13):1609-1610, 2020
P.289 掲載の参考文献
1) Shimizu H, Okada M, Toh Y et al:Thoracic and cardiovascular surgeries in Japan during 2018. Annual report by the Japanese Association for Thoracic Sur-gery. Gen Thorac Cardiovasc Surg 69:179-212, 2021
P.290 掲載の参考文献
2) Rosinski BF, Idrees JJ, Roselli EE et al:Cannulation strategies in acute type A dis-section repair:A systematic axillary ar-tery approach. J Thorac Cardiovasc Surg 158:647-659, 2019
3) Kreibich M, Chen Z, Rylski B et al:Outcome after aortic, axillary, or femoral cannulation for acute type A aortic dissec-tion. J Thorac Cardiovasc Surg 158:27-34, 2019
4) Shimura S, Odagiri S, Furuya H et al:Echocardiography -guided aortic cannula-tion by the Seldinger technique for type A dissection with cerebral malperfusion. J Thorac Cardiovasc Surg 159:784-793, 2020
5) Angleitner P, Stelzmueller ME, Mahr S et al:Bilateral or unilateral antegrade cere-bral perfusion during surgery for acute type A dissection. J Thorac Cardiovasc Surg 159:2159-2167, 2020
6) Norton EL, Wu X, Kim KM et al:Unilat-eral is comparable to bilateral antegrade cerebral perfusion in acute type A aortic dissection repair. J Thorac Cardiovasc Surg 160:617-625, 2020
P.291 掲載の参考文献
7) Yang B, Norton EL, Hobbs R et al:Short- and long-term outcomes of aortic root repair and replacement in patients undergoing acute type A aortic dissection repair:Twenty-year experience. J Tho-rac Cardiovasc Surg 157:2125-2136, 2019
8) Rosenblum JM, Leshnower BG, Moon RC et al:Durability and safety of David V valve-sparing root replacement in acute type A aortic dissection. J Thorac Cardio-vasc Surg 157:14-23, 2019
9) Irimie V, Atieh A, Kucinoski G et al:Long-term outcomes after valve-sparing anatomical aortic root reconstruction in acute dissection involving the root. J Tho-rac Cardiovasc Surg 159:1176-1184, 2020
P.292 掲載の参考文献
10) Ikeno Y, Yokawa K, Koda Y et al:The fate of the downstream aorta after open aortic repair for acute DeBakey type I aortic dissection:total arch replacement with elephant trunk technique versus non-total arch replacement. Eur J Thorac Cardiovasc Surg 55:966-974, 2019
11) Leone A, Beckmann E, Aandreas M et al:Total aortic arch replacement with frozen elephant trunk technique:Results from two European institutes. J Thorac Cardiovasc Surg 159:1201-1211, 2020
12) Kreibich M, Berger T, Rylski B et al:Aor-tic reintervention after the frozen elephant trunk procedure. J Thorac Cardiovasc Surg 159:392-399, 2020
13) Preventza O, Liao JL, Olive JK et al:Neurologic complications after the frozen elephant trunk procedure:A meta-anal-ysis of more than 3000patients. J Thorac Cardiovasc Surg 160:20-33, 2020
14) Poon SS, Tian DH, Yan T et al:Frozen elephant trunk does not increase incidence of paraplegia in patients with acute type A aortic dissection. J Thorac Cardiovasc Surg 159:1189-1196, 2020
P.293 掲載の参考文献
15) Uchida K, Karube N, Kasama K et al:Early reperfusion strategy improves the outcomes of surgery for type A acute aor-tic dissection with malperfusion. J Thorac Cardiovasc Surg 156:483-489, 2018
16) Uchida K, Karube N, Minami T et al:Treatment of coronary malperfusion in type A acute aortic dissection. Gen Thorac Cardiovasc Surg 66:621-625, 2018
P.294 掲載の参考文献
1) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会合同ガイドライン:2020年改訂版 大動脈瘤・大動脈解離診療ガイドライン. 2020
2) OECD Data. Computed tomography(CT) scanners.(Last accessed July 10, 2021) https://data.oecd.org/healtheqt/comput-ed-tomography-ct-scanners.htm
3) Committee for Scientific Affairs, The Japa-nese Association for Thoracic Surgery;Shimizu H, Okada M, Toh Y et al:Tho-racic and cardiovascular surgeries in Japan during 2018:Annual report by the Japa-nese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 69:179-212, 2021
P.295 掲載の参考文献
4) Yamaguchi T, Nakai M, Yano T et al:Population-based incidence and outcomes of acute aortic dissection in Japan. Eur Heart J Acute Cardiovasc Care, 2021[on-line ahead of print]
5) Uehara K, Matsuda H, Matsuo J et al:Surgical outcomes of acute type A aortic dissection in patients undergoing cardio-pulmonary resuscitation. J Thorac Cardio-vasc Surg 161:1173-1180, 2021
6) VIRTUE Registry Investigators:Mid-termoutcomes and aortic remodelling after thoracic endovascular repair for acute, subacute, and chronic aortic dissection:The VIRTUE registry. Eur J Vasc Endo-vasc Surg 48:363-371, 2014
7) Tsai TT, Fattori R, Trimarchi S et al:Long-term survival in patients present-ing with type B acute aortic dissection:Insights from the International Registry of Acute Aortic Dissection. Circulation 114:2226-2231, 2006
8) Bavaria JE, Brinkman WT, Hughes GC et al:Outcomes of thoracic endovascular aortic repair in acute Type B aortic dissec-tion:Results from the Valiant United States investigational device exemption study. Ann Thorac Surg 100:802-808, 2015
P.296 掲載の参考文献
9) Bavaria JE, Brinkman WT, Hughes GC et al:Five-year outcomes of endovascular repair of complicated acute type B aortic dissections. J Thorac Cardiovasc Surg, 2020[online ahead of print]
10) Nienaber CA, Kische S, Zeller T et al:Provisional extension to induce complete attachment after stent-graft placement in type B aortic dissection:The PET-TICOAT concept. J Endovasc Ther 13:738-746, 2006
11) Lombardi JV, Cambria RP, Nienaber CA et al;STABLE I Investigators:Five-year results from the Study of Thoracic Aortic Type B Dissection Using Endoluminal Re-pair(STABLE I)study of endovascular treatment of complicated type B aortic dissection using a composite device design. J Vasc Surg 70:1072-1081. e2, 2019
12) Iwakoshi S, Dake MD, Irie Y et al:Man-agement of renal arteries in conjunction with thoracic endovascular aortic repair for complicated stanford type B aortic dis-section:The Japanese multicenter study(J-Predictive Study). Radiology 294:455-463, 2020
P.297 掲載の参考文献
13) Inoue Y, Matsuda H, Matsuo J et al:Ef-ficacy of entry exclusion strategy for De-Bakey type III retrograde Stanford type A acute aortic dissection. Eur J Cardiothorac Surg, 2020[online ahead of print]
14) Omura A, Matsuda H, Matsuo J et al:Thoracic endovascular repair for retro-grade acute type A aortic dissection as an alternative choice. Gen Thorac Cardiovasc Surg 68:1397-1404, 2020
15) DeBakey ME, Henly WS, Cooley DA et al:Surgical management of dissecting an-eurysms of the aorta. J Thorac Cardiovasc Surg 49:130-149, 1965
16) Daily PO, Trueblood HW, Stinson EB et al:Management of acute aortic dissec-tions. Ann Thorac Surg 10:237-247, 1970
17) Lombardi JV, Hughes GC, Appoo JJ et al:Society for Vascular Surgery(SVS) and Society of Thoracic Surgeons(STS) reporting standards for type B aortic dis-sections. J Vasc Surg 71:723-747, 2020. Ann Thorac Surg 109:959-981, 2020
18) Fillinger MF, Greenberg RK, McKinsey JF et al;Society for Vascular Surgery Ad Hoc Committee on TEVAR Report-ing Standards:Reporting standards for thoracic endovascular aortic repair(TE-VAR). J Vasc Surg 52:1022-1033, 2010
19) Nienaber CA, Kische S, Rousseau H et al;INSTEAD-XL trial:Endovascular repair of type B aortic dissection:Long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 6:407-416, 2013
P.298 掲載の参考文献
20) Tadros RO, Tang GHL, Barnes HJ et al:Optimal treatment of uncomplicated type B aortic dissection:JACC review topic of the week. J Am Coll Cardiol 74:1494-1504, 2019
21) Desai ND, Gottret JP, Szeto WY et al:Impact of timing on major complications after thoracic endovascular aortic repair for acute type B aortic dissection. J Thorac Cardiovasc Surg 149(2 Suppl):S151-S156, 2015
22) VIRTUE Registry Investigators:Mid-term outcomes and aortic remodelling af-ter thoracic endovascular repair for acute, subacute, and chronic aortic dissection:the VIRTUE Registry. Eur J Vasc Endo-vasc Surg 48:363-371, 2014
23) Xie E, Yang F, Liu Y et al:Timing and outcome of endovascular repair for un-complicated type B aortic dissection. Eur J Vasc Endovasc Surg 61:788-797, 2021
24) Rodriguez JA, Olsen DM, Lucas L et al:Aortic remodeling after endografting of thoracoabdominal aortic dissection. J Vasc Surg 47:1188-1194, 2008
25) Matsuda H:Treatment of uncomplicated type B aortic dissection. Gen Thorac Car-diovasc Surg 65:74-79, 2017
26) Puech-Leao P, Estenssoro AEV, Wakassa TB et al:Long-term results of endovas-cular treatment of chronic type B aortic dissection by closure of the primary tear. Ann Vasc Surg 66:179-182, 2020
27) Kuzniar MK, Wanhainen A, Tegler G et al:Endovascular treatment of chronic aortic dissection with fenestrated and branched stent grafts. J Vasc Surg 73:1573-1582. e1, 2021
28) Czerny M, Berger T, Kondov S et al:Results of endovascular aortic arch repair using the Relay Branch system. Eur J Car-diothorac Surg, 2021[online ahead of print]
29) Spear R, Hertault A, Van Calster K et al:Complex endovascular repair of postdis-section arch and thoracoabdominal aneu-rysms. J Vasc Surg 67:685-693, 2018
30) Oikonomou K, Kasprzak P, Katsargyris A et al:Mid-term results of fenestrated/branched stent grafting to treat post-dis-section thoraco-abdominal aneurysms. Eur J Vasc Endovasc Surg 57:102-109, 2019
P.299 掲載の参考文献
31) Tenorio ER, Oderich GS, Farber MA et al;U.S. Fenestrated and Branched Aortic Research Consortium Investigators:Out-comes of endovascular repair of chronic postdissection compared with degenera-tive thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. J Vasc Surg 72:822-836. e9, 2020
32) Kolbel T, Lohrenz C, Kieback A et al:Distal false lumen occlusion in aortic dis-section with a homemade extra-large vascular plug:the candy-plug technique. J Endovasc Ther 20:484-489, 2013
33) Kolbel T1, Carpenter SW, Lohrenz C et al:Addressing persistent false lumen flow in chronic aortic dissection:The knicker-bocker technique. J Endovasc Ther 21:117-122, 2014
34) Fukuhara S, Tchouta L, Pampati R et al:Laser aortic septotomy during thoracic endovascular aortic repair for chronic type B aortic dissection. J Thorac Cardiovasc Surg, 2021[online ahead of print]
VIII章 末梢血管疾患
P.302 掲載の参考文献
1) Song P, Rudan D, Zhu Y et al:Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015:An updated systematic review and analysis. Lancet Glob Health 7(8):e1020-e1030, 2019
2) Roth GA, Mensah GA, Johnson CO et al;GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group:Global burden of cardiovascular diseases and risk factors, 1990-2019:Update from the GBD 2019 study. J Am Coll Cardiol 76(25):2982-3021, 2020
3) Fowkes FG, Murray GD, Butcher I et al;Ankle Brachial Index Collaboration:Ankle brachial index combined with Framingham Risk Score to predict cardio-vascular events and mortality:A meta-analysis. JAMA 300(2):197-208, 2008
P.303 掲載の参考文献
4) Gerhard-Herman MD, Gornik HL, Barrett C et al:2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease:A report of the American College of Cardiol-ogy/American Heart Association Task Force on Clinical Practice Guidelines. Cir-culation 135(12):e726-e779, 2017
5) CAPRIE Steering Committee:A ran-domised, blinded, trial of clopidogrel ver-sus aspirin in patients at risk of ischaemic events(CAPRIE). Lancet 348(9038):1329-1339, 1996
6) Cacoub PP, Bhatt DL, Steg PG et al;CHARISMA Investigators:Patients with peripheral arterial disease in the CHA-RISMA trial. Eur Heart J 30(2):192-201, 2009
7) Hiatt WR, Fowkes FG, Heizer G et al;EUCLID Trial Steering Committee and In-vestigators:Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376(1):32-40, 2017
8) Hess CN, Hiatt WR:Antithrombotic ther-apy for peripheral artery disease in 2018. JAMA 319(22):2329-2330, 2018
9) Anand SS, Caron F, Eikelboom JW et al:Major adverse limb events and mortal-ity in patients with peripheral artery disease:the COMPASS trial. J Am Coll Cardiol 71(20):2306-2315, 2018
10) Bonaca MP, Bauersachs RM, Anand SS et al:Rivaroxaban in peripheral artery dis-ease after revascularization. N Engl J Med 382(21):1994-2004, 2020
11) Grundy SM, Stone NJ, Bailey AL et al:2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of the Ameri-can College of Cardiology/American Heart Association Task Force on Clinical Prac-tice Guidelines. Circulation 139(25):e1082-e1143, 2019
12) Mach F, Baigent C, Catapano AL et al;ESC Scientific Document Group:2019 ESC/EAS guidelines for the management of dyslipidaemias:Lipid modification to reduce cardiovascular risk. Eur Heart J 41 (1):111-188, 2020
P.304 掲載の参考文献
13) Whelton PK, Carey RM, Aronow WS et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detec-tion, evaluation, and management of high blood pressure in adults:Executive sum-mary:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6):1269-1324, 2018
14) Yusuf S, Sleight P, Pogue J et al;Heart Outcomes Prevention Evaluation Study Investigators:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342(3):145-153, 2000
15) Mahaffey KW, Neal B, Perkovic V et al;CANVAS Program Collaborative Group:Canagliflozin for primary and secondary prevention of cardiovascular events:results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137(4):323-334, 2018
16) Chang HY, Singh S, Mansour O et al:Association between sodium-glucose co-transporter 2 inhibitors and lower extrem-ity amputation among patients with type 2 diabetes. JAMA Intern Med 178(9):1190-1198, 2018
17) Dhatariya K, Bain SC, Buse JB et al;LEADER Publication Committee on behalf of the LEADER Trial Investigators:The impact of liraglutide on diabetes-related foot ulceration and associated complica-tions in patients with type 2 diabetes at high risk for cardiovascular events:Results from the LEADER trial. Diabetes Care 41(10):2229-2235, 2018
18) Iida O, Yokoi H, Soga Y et al:Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Pe-ripheral Intervention by Cilostazol study. Circulation 127:2307-2315, 2013
19) Dua A, Gologorsky R, Savage D et al:National assessment of availability, aware-ness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. J Vasc Surg 71:1702-1707, 2020
P.305 掲載の参考文献
20) Collins TC, Lu L, Ahluwalia JS et al:Efficacy of community-based exercise therapy among African American patients with peripheral artery disease:a random-ized clinical trial. JAMA Netw Open 2:e187959, 2019
21) McDermott MM, Spring B, Berger JS et al:Effect of a home-based exercise inter-vention of wearable technology and tele-phone coaching on walking performance in peripheral artery disease:The HONOR randomized clinical trial. JAMA 319(16):1665-1676, 2018
22) McDermott MM, Spring B, Tian L et al:Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease:The LITE randomized clinical trial. JAMA 325:1266-1276, 2021
P.306 掲載の参考文献
1) Yamauchi Y, Takahara M, Shintani Y et al:Three-year outcomes of endovascular therapy for aortoiliac lesions. Circ Cardio-vasc Interv 13:e009168, 2020
2) Motta F, Parodi FE, Knowles M et al:Performance of Viabahn balloon-expandable stent compared with self-expandable cov-ered stents for branched endovascular aor-tic repair. J Vasc Surg 73:410-416. e2, 2021
3) Mwipatayi BP, Ouriel K, Anwari T et al:A systematic review of covered balloon-expandable stents for treating aortoiliac occlusive disease. J Vasc Surg 72:1473-1486. e2, 2020
38) Tang TY, Yap C, Soon SXY et al:World's first experience treating TASC II C and D tibial occlusive disease using the selution SLR sirolimus-eluting balloon:Six-month results from the PRESTIGE Study. J En-dovasc Ther:15266028211007457, 2021
P.307 掲載の参考文献
4) Changal KH, Syed MA, Dar T et al:Sys-tematic Review and Proportional Meta-Analysis of Endarterectomy and Endovas-cular Therapy with Routine or Selective Stenting for Common Femoral Artery Atherosclerotic Disease. J Interv Cardiol 2019:1593401, 2019
5) Goueffic Y, Della Schiava N, Thaveau F et al:Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv 10:1344-1354, 2017
6) Soga Y, Iida O, Urasawa K et al:Three-year results of the IN.PACT SFA Japan Trial comparing drug-coated balloons with percutaneous transluminal angioplasty. J Endovasc Ther 27:946-955, 2020
7) Horie K, Tanaka A, Suzuki K et al:Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropop-liteal lesions. CVIR Endovasc 4:13, 2021
8) PMDA. http://www.pmda.go.jp/medical_devices/2017/M20170830001/780045000_22900BZX00252000_A100_1.pdf
9) Sachar R, Soga Y, Ansari M et al:One year results from the RANGER II SFA Randomized Trial of the ranger drug-coated balloon. JACC Cardiovasc Interv 14:1123-1133, 2021
10) Steiner S, Schmidt A, Zeller T et al:COMPARE:prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoro-popliteal interventions. Eur Heart J 41:2541-2552, 2020
P.308 掲載の参考文献
11) Hata Y, Iida O, Ito N et al:Roles of angio-plasty with drug-coated balloon for chronic ischemia in wound healing. J Endovasc Ther, 2021[online ahead of print]
12) Shimada T, Shima Y, Miura K et al:Im-pact of guidewire route on severe dissec-tion after balloon angioplasty for femoro-popliteal chronic total occlusion lesions:an intravascular ultrasound analysis. Eur J Vasc Endovasc Surg 61:830-836, 2021
13) Tokuda T, Mori S, Oba Y et al:Compari-son of ultrasound-guided versus angiog-raphy-guided endovascular treatment for femoropopliteal artery occlusive disease. Catheter Cardiovasc Interv 97:E518-E524, 2021
14) Kozuki A, Takahara M, Shimizu M et al:Outcomes of dissection angles as predic-tor of restenosis after drug-coated balloon treatment. J Atheroscler Thromb, 2020[online ahead of print]
15) Muller-Hulsbeck S, Benko A, Soga Y et al:Two-year efficacy and safety results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol 44:368-375, 2021
16) Soga Y, Fujihara M, Iida O et al:Japa-nese patients treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents. Cardiovasc Intervent Radiol 43:215-222, 2020
17) Soga Y, Fujihara M, Tomoi Y et al:One-year late lumen loss between a Polymer-Coated Paclitaxel-Eluting Stent(Eluvia) and a Polymer-Free Paclitaxel-Coated Stent(Zilver PTX) for femoropopliteal disease. J Atheroscler Thromb 27:164-171, 2020
18) Stavroulakis K, Torsello G, Bosiers M et al:2-year outcomes of the Eluvia Drug-Eluting Stent for the treatment of complex femoropopliteal lesions. JACC Cardiovasc Interv 14:692-701, 2021
19) Soga Y, Ando K:"Low Echoic Area" around stent after bare and drug-coated stenting or stent graft placement for super-ficial femoral artery disease. SAGE Open Med Case Rep 9:2050313X211014519, 2021
20) Ohki T, Kichikawa K, Yokoi H et al:Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovas-cular stent grafts for long and complex lesions in the superficial femoral artery. J Vasc Surg, 2021[online ahead of print]
P.309 掲載の参考文献
21) Iida O, Takahara M, Soga Y et al:One-year outcomes of heparin-bonded stent-graft therapy for real-world femoropopli-teal lesions and the association of patency with the prothrombotic state based on the prospective, observational, multicenter Viabahn Stent-Graft Placement for Femo-ropopliteal Diseases Requiring Endovas-cular Therapy(VANQUISH)Study. J Endovasc Ther 28:123-131, 2021
22) Tsujimura T, Takahara M, Iida O et al:Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions. J Vasc Surg 73:1998-2008. e1, 2021
23) Ichihashi S, Takahara M, Iida O et al:Clinical impact of stent graft thrombosis in femoropopliteal arterial lesions. JACC Cardiovasc Interv 14:1137-1147, 2021
24) Katsuki T, Yamaji K, Soga Y et al:New lesion after endovascular therapy of femo-ropopliteal lesions for intermittent claudi-cation. Catheter Cardiovasc Interv, 2021[online ahead of print]
25) Katsanos K, Spiliopoulos S, Kitrou P et al:Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg:A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 7:e011245, 2018
26) Rocha-Singh KJ, Duval S, Jaff MR et al:Mortality and paclitaxel-coated devices:An individual patient data meta-analysis. Circulation 141:1859-1869, 2020
27) Nordanstig J, James S, Andersson M et al:Mortality with paclitaxel-coated de-vices in peripheral artery disease. N Engl J Med 383:2538-2546, 2020
28) Secemsky EA, Barrette E, Bockstedt L et al:Long-term safety of drug-coated de-vices for peripheral revascularisation. Euro-Intervention, 2020[online ahead of print]
29) Gutierrez JA, Rao SV, Jones WS et al:Survival and Causes of death among Veter-ans with lower extremity revascularization with paclitaxel-coated devices:Insights from the Veterans Health Administration. J Am Heart Assoc 10:e018149, 2021
30) Behrendt CA, Sedrakyan A, Peters F et al:Long term survival after femoro-popliteal artery revascularisation with paclitaxel coated devices:A propensity score matched cohort analysis. Eur J Vasc Endovasc Surg 59:587-596, 2020
P.310 掲載の参考文献
31) Bohme T, Noory E, Beschorner U et al:Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femo-ropopliteal lesions in the real world. JACC Cardiovasc Interv 13:2052-2061, 2020
32) Katsuki T, Takahara M, Soga Y et al:Mortality risk following application of a paclitaxel-coated stent in femoropopliteal lesions. J Endovasc Ther 26:593-599, 2019
33) Nakamura M, Takata M, Yokoi H et al:An individual-level meta-analysis using real-world and pivotal studies on mortality from the use of paclitaxel-containing de-vices in Japanese femoropopliteal disease patients. Circ J, 2021(in press)
34) Zeller T, Brechtel K, Meyer DR et al:Six-month outcomes from the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions. J Endovasc Ther 27(5):683-690, 2020
35) Zeller T, Micari A, Scheinert D et al:The IN.PACT DEEP Clinical Drug-Coated Balloon Trial:5-year outcomes. JACC Cardiovasc Interv 13:431-443, 2020
36) Fujihara M, Yazu Y, Takahara M:Intra-vascular ultrasound-guided interventions for below-the-knee disease in patients with chronic limb-threatening ischemia. J Endo-vasc Ther 27:565-574, 2020
37) Soga Y, Takahara M, Ito N et al:Clinical impact of intravascular ultrasound-guided balloon angioplasty in patients with chron-ic limb threatening ischemia for isolated infrapopliteal lesion. Catheter Cardiovasc Interv 97:E376-E384, 2021
P.312 掲載の参考文献
1) Conte MS, Bradbury AW, Kolh P et al:Global vascular guidelines on the manage-ment of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58(1s):S1-S109. e33, 2019
2) Iida O, Takahara M, Soga Y et al:Three-year outcomes of surgical versus endovascular revascularization for criti-cal limb ischemia:The SPINACH Study(Surgical Reconstruction Versus Periph-eral Intervention in Patients With Critical Limb Ischemia). Circ Cardiovasc Interv 10(12):e005531, 2017
3) Nakama T, Watanabe N, Haraguchi T et al:Clinical outcomes of pedal artery angioplasty for patients with ischemic wounds:Results from the Multicenter RENDEZVOUS Registry. JACC Cardio-vasc Interv 10(1):79-90, 2017
P.313 掲載の参考文献
4) Goueffic Y, Della Schiava N, Thaveau F et al:Stenting or surgery for de novo com-mon femoral artery stenosis. JACC Cardio-vasc Interv 10(13):1344-1354, 2017
5) Edenfield L, Blazick E, Eldrup-Jorgensen J et al:Outcomes of carotid endarterec-tomy in the Vascular Quality Initiative based on patch type. J Vasc Surg 71(4):1260-1267, 2020
P.314 掲載の参考文献
6) Pereira CE, Albers M, Romiti M et al:Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insuffi-ciency. J Vasc Surg 44(3):510-517, 2006
7) Daenens K, Schepers S, Fourneau I et al:Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses:1- and 2-year re-sults. J Vasc Surg 49(5):1210-1216, 2009
8) Shibutani S, Obara H, Matsubara K et al:Midterm results of a Japanese prospective multicenter registry of heparin-bonded expanded polytetrafluoroethylene grafts for above-the-knee femoropopliteal bypass. Circ J 84(3):501-508, 2020
9) Ohki T, Kichikawa K, Yokoi H et al:Outcomes of the Japanese multicenter Viabahn trial of endovascular stent graft-ing for superficial femoral artery lesions. J Vasc Surg 66(1):130-142. e1, 2017
10) Conte MS, Pomposelli FB, Clair DG et al:Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities:manage-ment of asymptomatic disease and claudi-cation. J Vasc Surg 61(3 Suppl):2s-41s, 2015
P.315 掲載の参考文献
11) Azuma N, Uchida H, Kokubo T et al:Fac-tors influencing wound healing of critical ischaemic foot after bypass surgery:is the angiosome important in selecting by-pass target artery? Eur J Vasc Endovasc Surg 43(3):322-328, 2012
P.316 掲載の参考文献
12) Kikuchi S, Sasajima T, Inaba M et al:Evaluation of paramalleolar and inframal-leolar bypasses in dialysis- and nondialysis-dependent patients with critical limb isch-emia. J Vasc Surg 67(3):826-837, 2018
13) Kalra M, Gloviczki P, Bower TC et al:Limb salvage after successful pedal by-pass grafting is associated with improved long-term survival. J Vasc Surg 33(1):6-16, 2001
14) Adam DJ, Beard JD, Cleveland T et al:Bypass versus angioplasty in severe isch-aemia of the leg(BASIL):multicentre, randomised controlled trial. Lancet 366(9501):1925-1934, 2005
15) Meecham L, Patel S, Bate GR et al:Editor's choice-A comparison of clinical outcomes between primary bypass and secondary bypass after failed plain balloon angioplasty in the Bypass versus Angio-plasty for Severe Ischaemia of the Limb(BASIL) Trial. Eur J Vasc Endovasc Surg 55(5):666-671, 2018
P.317 掲載の参考文献
1) 急性下肢動脈閉塞. "末梢閉塞性動脈疾患の治療ガイドライン(2015年改訂版)"日本循環器学会, 日本インターベンショナルラジオロジー学会, 日本形成外科学会 他編. pp11-15, 2015
2) Norgren L, Hiatt WR, Dormandy JA et al;TASC II Working Group:Inter-society consensus for the management of periph-eral arterial disease(TASC II). J Vasc Surg 45(Suppl S):S5-S67, 2007
3) Creager MA, Kaufman JA, Conte MS:Acute limb ischemia. N Engl J Med 366:2198-2206, 2012
P.318 掲載の参考文献
4) 松原健太郎, 東谷迪昭:急性下肢虚血-総論. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp89-91, 南江堂, 2018
5) Higashitani M, Anzai H, Mizuno A et al:One-year limb outcome and mortality in patients undergoing revascularization therapy for acute limb ischemia:short-term results of the Edo registry. Cardio-vasc Interv Ther 36:226-236, 2021
6) Higashitani M, Uemura Y, Mizuno A et al:Cardiovascular outcome and mortality in patients undergoing endovascular treat-ment for symptomatic peripheral artery disease-Short-Term Results of the Toma-Code Registry. Circ J 82:1917-1925, 2018
P.319 掲載の参考文献
7) Lian WS, Das SK, Hu XX et al:Efficacy of intra-arterial catheter-directed thromboly-sis for popliteal and infrapopliteal acute limb ischemia. J Vasc Surg 71:141-148, 2020
8) 尾原秀明, 松原健太郎, 北川雄光:急性下肢虚血. 日血外会誌 27:109-114, 2018
9) Ge H, Song B, Wang X et al:Compari-son of digital subtraction angiography combined arterial thrombectomy versus simple arterial thrombectomy in the treat-ment of acute lower limb ischemia. BMC Surg 21:313-319, 2021
10) 森口 暁:急性下肢虚血-カテーテル治療:吸引, 破砕. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp101-102, 南江堂, 2018
P.320 掲載の参考文献
11) 高橋保裕:急性下肢虚血-カテーテル治療:経皮的Fogartyカテーテル血栓除去術. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp105-109, 南江堂, 2018
P.321 掲載の参考文献
12) 望月宏樹, 水野篤:急性下肢虚血-血栓溶解療法:全身性. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp95-96, 南江堂, 2018
13) 山内靖隆:急性下肢虚血-血栓溶解療法:CDT. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp97-100, 南江堂, 2018
14) 藤村直樹:急性下肢虚血-ハイブリッド治療. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp117-119, 南江堂, 2018
15) de Donato G, Setacci F, Sirignano P et al:The combination of surgical embolectomy and endovascular techniques may improve outcomes of patients with acute lower limb ischemia. J Vasc Surg 59:729-736, 2014
P.322 掲載の参考文献
16) 松野俊介:急性下肢虚血-カテーテル治療:血栓移動. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp103-104, 南江堂, 2018
17) 田中悌史, 東谷迪昭:急性下肢虚血-カテーテル治療:ステント. "末梢血管疾患診療マニュアル" 東谷迪昭, 尾原秀明, 金岡祐司 他編, pp110-111, 南江堂, 2018
18) Bonaca MP, Bauersachs RM, Anand SS et al:Rivaroxaban in peripheral artery dis-ease after revascularization. N Engl J Med 382:1994-2004, 2020
P.324 掲載の参考文献
1) Jujo K, Saito K, Ishida I et al:Efficacy of 24-hour blood pressure monitoring in evalu-ating response to percutaneous translumi-nal renal angioplasty. Circ J 80:1922-1930, 2016
2) Investigators A, Wheatley K, Ives N et al:Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361:1953-1962, 2009
3) Cooper CJ, Murphy TP, Cutlip DE et al:Stenting and medical therapy for athero-sclerotic renal-artery stenosis. N Engl J Med 370:13-22, 2014
P.325 掲載の参考文献
4) Zachrisson K, Krupic F, Svensson M et al:Results of renal artery revascularization in the post-ASTRAL era with 4 years mean follow-up. Blood Press 29:285-290, 2020
5) Mochida Y, Ohtake T, Miyashita Y et al:Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal an-gioplasty. Ren Replace Ther 4:5, 2018
6) Abboud J, Romer A, Kasper W et al:Per-cutaneous transluminal renal angioplasty of global kidney ischemia improves renal function and blood pressure. Int J Cardiol Heart Vasc 27:100475, 2020
P.326 掲載の参考文献
7) Bax L, Woittiez AJ, Kouwenberg HJ et al:Stent placement in patients with athero-sclerotic renal artery stenosis and impaired renal function:a randomized trial. Ann Intern Med 150:840-848, W150-1, 2009
8) Murphy TP, Cooper CJ, Matsumoto AH et al:Renal artery stent outcomes:Effect of baseline blood pressure, stenosis severity, and translesion pressure gradient. J Am Coll Cardiol 66:2487-2494, 2015
9) Piaggio D, Bracale U, Pecchia L et al:Endovascular treatment versus medical therapy for hypertensive patients with renal artery stenosis:An updated system-atic review. Ann Vasc Surg 61:445-454, 2019
10) Chen Y, Pan H, Luo G et al:Use of per-cutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis:a systematic review and meta-analysis. J Int Med Res 49:300060520983585, 2021
11) Yang M, Lin L, Niu G et al:Successful endovascular treatment of chronic renal artery occlusion:a preliminary retrospec-tive case series including 15 patients. Int Urol Nephrol 51:285-291, 2019
P.327 掲載の参考文献
12) Zachrisson K, Elverfors S, Jensen G et al:Long-term outcome of stenting for atherosclerotic renal artery stenosis and the effect of angiographic restenosis. Acta Radiol 59:1438-1445, 2018
13) Mannemuddhu SS, Ojeda JC, Yadav A:Renovascular hypertension. Prim Care 47:631-644, 2020
14) Siddiqui EU, Murphy TP, Naeem SS et al:Interaction between albuminuria and treat-ment group outcomes for patients with renal artery stenosis:The NITER Study. J Vasc Interv Radiol 29:966-970, 2018
15) Boutari C, Georgianou E, Sachinidis A et al:Renovascular hypertension:Novel insights. Curr Hypertens Rev 16:24-29, 2020
16) Fujihara M, Yokoi Y, Abe T et al:Clini-cal outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study-pro-spective, single-arm, multicenter clinical study. Circ J 79:351-359, 2015
P.328 掲載の参考文献
17) Ram CVS, Dani S, Oomman A et al:Corre-lation between ambulatory blood pressure monitoring and office blood pressure mea-surement in patients with hypertension:A community study. Am J Med Sci, 2021
18) Mangiacapra F, Trana C, Sarno G et al:Translesional pressure gradients to pre-dict blood pressure response after renal artery stenting in patients with renovas-cular hypertension. Circ Cardiovasc Interv 3:537-542, 2010
19) Iwashima Y, Ishimitsu T:How should we define appropriate patients for percutane-ous transluminal renal angioplasty treat-ment? Hypertens Res 43:1015-1027, 2020
20) Gornik HL, Persu A, Adlam D et al:First international consensus on the diagnosis and management of fibromuscular dyspla-sia. J Hypertens 37:229-252, 2019
21) Chen Y, Dong H, Jiang X et al:Percutane-ous transluminal angioplasty with selec-tive stenting for the treatment of renal artery stenosis caused by fibromuscular dysplasia:18 years' experience from the China Center for Cardiovascular Disease. Catheter Cardiovasc Interv 95(Suppl 1):641-647, 2020
22) Oribe S, Toyohara T, Mishima E et al:Fibromuscular dysplasia with recurrence after "long-term" following percutaneous transcatheter renal angioplasty:two case reports with a review of 26 patients. BMC Nephrol 22:187, 2021
P.329 掲載の参考文献
23) Iwashima Y, Fukuda T, Horio T et al:Im-pact of percutaneous revascularization on left ventricular mass and its relationship to outcome in hypertensive patients with re-nal artery stenosis. Am J Hypertens 33:570-580, 2020
24) Takamiya Y, Okamura K, Shirai K et al:Successful depressor effect concomitant with complete normalization of high renin and aldosterone profile by percutaneous transluminal renal angioplasty in a patient with acute exacerbated heart failure with preserved ejection fraction. Am J Case Rep 20:1684-1690, 2019
25) Toda H, Uchida HA, Nakamura K et al:Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease. Intern Med 58:1917-1922, 2019
26) Chen XJ, Eirin A, Kane GC et al:Impact of serum uric acid levels on outcomes fol-lowing renal artery revascularization in patients with renovascular disease. Int J Hypertens 2019:3872065, 2019
IX章 先天性心疾患
P.333 掲載の参考文献
1) Nakayama R, Takaya Y, Akagi T et al:Efficacy and safety of atrial septal defect closure using Occlutech Figulla Flex II compared with Amplatzer Septal Occlud-er. Heart Vessels 36(5):704-709, 2021
2) Sommer RJ, Love BA, Paolillo JA et al;ASSURED Investigators:ASSURED clin-ical study:New GORE(R) CARDIOFORM ASD occluder for transcatheter closure of atrial septal defect. Catheter Cardiovasc Interv 95(7):1285-1295, 2020
3) Batteux C, Azarine A, Karsenty C et al:Sinus Venosus ASDs:Imaging and per-cutaneous closure. Curr Cardiol Rep 23(10):138, 2021
4) Takaya Y, Akagi T, Sakamoto I et al:Effi-cacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. Heart, 2021[online ahead of print]
5) Guo Q, Sang C, Bai R et al:Transseptal puncture in patients with septal occluder devices during catheter ablation of atrial fibrillation. EuroIntervention, 2021[online ahead of print]
6) 日本循環器学会/日本心臓病学会/日本心臓血管外科学会/日本血管外科学会/日本胸部外科学会合同ガイドライン:2021年改訂版 先天性心疾患, 心臓大血管の構造的疾患(structural heart disease)に対するカテーテル治療のガイドライン. 2021 https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Sakamoto_Kawamura.pdf
P.334 掲載の参考文献
7) Saver JL, Carroll JD, Thaler DE et al;RESPECT Investigators:Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377:1022-1032, 2017
8) Kasner SE, Rhodes JF, Andersen G et al;Gore REDUCE Clinical Study Investiga-tors:Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 384(10):970-971, 2021
9) 井口保之, 岩間 亨, 大木宏一 他;日本脳卒中学会, 日本循環器学会, 日本心血管インターベンション治療学会 三学会合同手引き作成委員会:潜因性脳梗塞に対する経皮的卵円孔開存閉鎖術の手引き. 脳卒中41(5):417-441, 2019
P.335 掲載の参考文献
10) Nakayama R, Takaya Y, Akagi T et al:Identification of high-risk patent foramen ovale associated with cryptogenic stroke:Development of a scoring system. J Am Soc Echocardiogr 32(7):811-816, 2019
11) Yepes I, Ji S, Wu F et al:Platypnea-orthodeoxia syndrome:Rare or under-diagnosed syndrome? 3 case reports and a literature review. Cardiovasc Revasc Med 22:115-119, 2021
P.336 掲載の参考文献
12) Yoshimoto H, Yasuto M, Inoue T et al:Intracardiac echocardiography as a guide for transcatheter closure of patent ductus arteriosus. J Interv Cardiol 2020:5147193, 2020
13) Yamamoto H, Otake H, Akagi T et al:Acute aortic dissection as a rare compli-cation of percutaneous closure using the Amplatzer Vascular Plug II for a tubular and enlarged patent ductus arteriosus in an elderly patient. JACC Cardiovasc In-terv 12:e5-e7, 2019
P.337 掲載の参考文献
1) McCrindle BW, Rowley AH, Newburger JW et al:Diagnosis, treatment, and long-term management of Kawasaki disease:A scientific statement for health profes-sionals From the American Heart Associa-tion. Circulation 135:e927-e999, 2017
P.338 掲載の参考文献
2) 日本循環器学会学術委員会合同研究班:川崎病心臓血管後遺症の診断と治療に関するガイドライン(2020年改訂版). 2020 https://wwwj-circorjp/cms/wp-content/uploads/2020/02/JCS2020_Fukazawa_Kobayashipdf
3) Mitani Y, Tsuda E, Kato H et al:Emer-gence and characterization of acute coro-nary syndrome in adults after confirmed or missed history of Kawasaki disease in Japan:A Japanese nationwide survey. Front Pediatr 7:275, 2019
4) Suzuki A, Miyagawa-Tomita S, Komatsu K et al:Active remodeling of the coronary arterial lesions in the late phase of Kawa-saki disease:immunohistochemical study. Circulation 101:2935-2941, 2000
5) Miura M, Kobayashi T, Kaneko T et al:Association of severity of coronary artery aneurysms in patients with Kawasaki disease and risk of later coronary events. JAMA Pediatr 175:e180030, 2018
6) Tsuda E, Hashimoto S:Time course of coronary artery aneurysms in Kawasaki disease. J Pediatr 230:133-139.e2, 2021
P.340 掲載の参考文献
7) Chen S, Lee Y, Crother TR et al:Marked acceleration of atherosclerosis after Lac-tobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease. Arterioscler Thromb Vasc Biol 32:e60-e71, 2012
8) Bekki M, Tahara N, Tahara A et al:Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease. J Nucl Cardiol 26:671-673, 2019
9) Tremoulet AH, Jain S, Jone PN et al:PhaseI/IIa trial of atorvastatin in pa-tients with acute Kawasaki disease with coronary artery aneurysm. J Pediatr 215:107-117. e12, 2019
P.342 掲載の参考文献
1) Ohuchi H:Where is the "Optimal" Fontan hemodynamics? Korean Circ J 47(6):842-857, 2017
2) Stout KK, Daniels CJ, Aboulhosn JA et al:2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease:Executive Summary:A Report of the American College of Cardi-ology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(12):1494-1563, 2019
3) Egbe AC, Banala K, Vojjini R et al:The applications and potential limitations of right ventricular volumes as surrogate marker in tetralogy of Fallot. Int J Cardiol Heart Vasc 26:100430, 2019
4) Ribeiro JM, Teixeira R, Lopes J et al:Transcatheter versus surgical pulmonary valve replacement:A systemic review and meta-analysis. Ann Thorac Surg 110(5):1751-1761, 2020
5) Hascoet S, Martins JD, Baho H et al:Per-cutaneous pulmonary valve implantation in small conduits:A multicenter experi-ence. Int J Cardiol 254:64-68, 2018
P.343 掲載の参考文献
6) Hascoet S, Mauri L, Claude C et al:Infec-tive endocarditis risk after percutaneous pulmonary valve implantation with the melody and sapien valves. JACC Cardio-vasc Interv 10:510-517, 2017
7) Waldmann V, Bouzeman A, Duthoiut G et al:Long-term follow-up of patients with tetralogy of Fallot and implantable cardio-verter defibrillator. Circulation 142:1612-1622, 2020
P.344 掲載の参考文献
8) Zeppenfeld K, Schalij MJ, Bartelings MM et al:Catheter ablation of ventricular tachycardia after repair of congenital heart disease:electroanatomic identifica-tion of the critical right ventricular isth-mus. Circulation 116:2241-2252, 2007
9) Geva T, Mulder B, Gauvreau K et al:Pre-operative predictors of death and sustained ventricular tachycardia after pulmonary valve replacement in patients with repaired tetralogy of Fallot enrolled in the INDICA-TOR cohort. Circulation 138(19):2106-2115, 2018
10) Graham TP Jr, Bernard YD, Mellen BG et al:Long-term outcome in congenitally corrected transposition of the great arter-ies:a multi-institutional study. J Am Coll Cardiol 36(1):255-261, 2000
11) Osakada K, Ohya M, Waki K et al:Con-genitally corrected transposition of the great arteries at age 88 years. CJC Open 2(6):726-728, 2020
12) Shin'oka T, Kurosawa H, Imai Y et al:Outcomes of definitive surgical repair for congenitally corrected transposition of the great arteries or double outlet right ven-tricle with discordant atrioventricular con-nections:Risk analyses in 189 patients. J Thorac Cardiovasc Surg 133(5):1318-1328. e1-4, 2007
13) Barrios PA, Zia A, Pettersson G et al;Members of the ccTGA Working Group:Outcomes of treatment pathways in 240 patients with congenitally corrected trans-position of great arteries. J Thorac Cardio-vasc Surg 161(3):1080-1093. e4, 2021
14) Alghamdi AA, McCrindle BW, Van Arsdell GS:Physiologic versus anatomic repair of congenitally corrected transposition of the great arteries:Meta-analysis of individual patient data. Ann Thorac Surg 81(4):1529-1535, 2006
15) Chatterjee A, Miller NJ, Cribbs MG et al:Systematic review and meta-analysis of outcomes of anatomic repair in congenital-ly corrected transposition of great arteries. World J Cardiol 12(8):427-436, 2020
P.345 掲載の参考文献
16) Kasar T, Ozturk E, Ayyildiz P et al:The assessment of patients with situs inversus and corrected transposition of the great arteries. Rev Port Cardiol(Engl Ed)39(7):391-396, 2020
17) Zandstra TE, Nederend M, Jongbloed MRM et al:Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart, 2021[online ahead of print]
18) van Dissel AC, Winter MM, van der Bom T et al:Long-term clinical outcomes of valsartan in patients with a systemic right ventricle:Follow-up of a multicenter ran-domized controlled trial. Int J Cardiol 278:84-87, 2019
19) Shaddy R, Canter C, Halnon N et al:De-sign for the sacubitril/valsartan(LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction(PAN-ORAMA-HF study). Am Heart J 193:23-34, 2017
20) Hernandez-Madrid A, Paul T, Abrams D et al;ESC Scientific Document Group:Arrhythmias in congenital heart disease:A position paper of the European Heart Rhythm Association(EHRA), Association for European Paediatric and Congenital Cardiology(AEPC), and the European So-ciety of Cardiology(ESC)Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace 20(11):1719-1753, 2018
21) Meyer SL, St Clair N, Powell AJ et al:In-tegrated clinical and magnetic resonance imaging assessments late after fontan op-eration. J Am Coll Cardiol 77(20):2480-2489, 2021
22) Book WM, Gerardin J, Saraf A et al:Clini-cal phenotypes of Fontan failure:Implica-tions for management. Congenit Heart Dis 11(4):296-308, 2016
P.346 掲載の参考文献
23) Ohuchi H, Miyazaki A, Negishi J et al:Hemodynamic determinants of mortality after Fontan operation. Am Heart J 189:9-18, 2017
24) Miike H, Ohuchi H, Hayama Y I et al:Sys-temic artery vasoconstrictor therapy in Fontan patients with high cardiac output-heart failure:A single-center experience. Pediatr Cardiol 42(3):700-706, 2021
25) Munsterman ID, Duijnhouwer AL, Kendall TJ et al;Nijmegen Fontan Initiative:The clinical spectrum of Fontan-associated liver disease:results from a prospective multimodality screening cohort. Eur Heart J 40(13):1057-1068, 2019
26) Yoon JS, Lee DH, Cho EJ et al:Risk of liver cirrhosis and hepatocellular carcinoma after Fontan operation:A need for surveil-lance. Cancers(Basel)12(7):1805, 2020
27) Ohuchi H, Hayama Y, Nakajima K et al:Incidence, predictors, and mortality in patients with liver cancer after Fontan operation. J Am Heart Assoc 10(4):e016617, 2021
28) Ohuchi H, Negishi J, Noritake K et al:Prognostic value of exercise variables in 335 patients after the Fontan operation:a 23-year single-center experience of car-diopulmonary exercisetesting. Congenit Heart Dis 10(2):105-116, 2015
29) Scheffers LE, Berg LEV, Ismailova G et al:Physical exercise training in patients with a Fontan circulation:A systematic review. Eur J Prev Cardiol, 2020[online ahead of print]
30) Ohuchi H, Negishi J, Miike H et al:Posi-tive pediatric exercise capacity trajectory predicts better adult Fontan physiology rationale for early establishment of exer-cise habits. Int J Cardiol 274:80-87, 2019
P.348 掲載の参考文献
1) Baumgartner H, Backer JD, Babu-Narayan SV et al:2020 ESC guidelines for the man-agement of adult congenital heart disease. Eur Heart J 42:563-645, 2021
2) Stout KK, Daniels CJ, Aboulhosn JA et al:2018 AHA/ACC guideline for the man-agement of adults with congenital heart disease. Circulation 139:e698-e800, 2019
3) 市田蕗子, 赤木禎治, 池田智明 他:成人先天性心疾患診療ガイドライン(2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ichida_h.pdf
P.349 掲載の参考文献
4) Zaragoza-Macias E, Zaidi AN, Dendukuri N et al:Medical therapy for systemic right ventricles:a systematic review(Part 1) for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease:a report of the American College og Cardiology/American Heart Association Task Force on Clinical Prac-tice Guidelines. Circulation 139:e801-e813, 2019
P.350 掲載の参考文献
5) Ladouceur M, Segura dela Cal T, Gaye B et al:Effect of medical treatment on heart failure incidence in patients with a sys-temic right ventricle. Heart, 2021[online ahead of print]
6) Maurer SJ, Salvador CP, Schiele S et al:Sacubitril/valsartan for heart failure in adults with complex congenital heart dis-ease. Int J Cardiol 300:137-140, 2020
7) Stout KK, Broberg CS, Book WM et al: Chronic heart failure in congenital heart disease:A scientific statement from the American Heart Association. Circulation 133:770-801, 2016
8) Khairy P, Van Hare GF, Balaji HS et al:PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart dis-ease:developed in partnership between the Pediatric and Congenital Electrophysiology Society(PACES)and the Heart Rhythm Society(HRS). Endorsed by the govern-ing bodies of PACES, HRS, the American College of Cardiology(ACC), the America Heart Association(AHA), the European Heart Rhythm Association(EHRA), the Canadian Heart Rhythm Society(CHRS), and the International Society for Adult Congenital Heart Disease(ISACHD). Heart Rhythm 11:e102-e165, 2014
9) Kharbanda RK, Moore JP, Taverne YJHJ et al:Cardiac resynchronization therapy for the failing systemic right ventricle:A systematic review. Int J Cardiol 318:74-81, 2020
P.351 掲載の参考文献
10) Wang T, Chen L, Yang T et al:Congeni-tal heart disease and risk of cardiovascular disease:a meta-analysis of cohort studies. J Am Heart Assoc 8:e012030, 2019
11) Videbaek J, Laursen HB, Olsen M et al:Long-term nationwide follow-up study of simple congenital heart disease diagnosed in otherwise healthy children. Circulation 133:474-483, 2016
P.352 掲載の参考文献
12) Greenberg JH, Zappitelli M, Devarajan P et al;TRIBE-AKI Consortium:Kidney outcomes 5 years after pediatric cardiac surgery:the TRIBE-AKI Study. JAMA Pediatr 170:1071-1078, 2016
13) Murakami T, Horibata Y, TatenoS et al:Early vascular ageing in adult patients with congenital heart disease. Hypertens Res, 2021[online ahead of print]
X章 生活習慣病
P.354 掲載の参考文献
1) Whelton PK, Carey RM, Aronow WS et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults:A report of the Ameri-can College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 71(19):e127-e248, 2018
2) Khera R, Lu Y, Lu J et al:Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihyper-tensive treatment in United States and China:nationally representative cross-sectional study. BMJ 362:k2357, 2018
3) Son JS, Choi S, Kim K et al:Association of blood pressure classification in Korean young adults according to the 2017 Ameri-can College of Cardiology/American Heart Association guidelines with subsequent cardiovascular disease events. JAMA 320(17):1783-1792, 2018
P.355 掲載の参考文献
4) 日本高血圧学会高血圧治療ガイドライン作成委員会 編:高血圧治療ガイドライン2019. 日本高血圧学会, 2019
5) Banegas JR, Ruilope LM, de la Sierra A et al:Relationship between clinic and ambu-latory blood-pressure measurements and mortality. N Engl J Med 378(16):1509-1520, 2018
P.356 掲載の参考文献
6) Kario K, Hoshide S, Mizuno H et al:Night-time blood pressure phenotype and car-diovascular prognosis:Practitioner-based nationwide JAMP study. Circulation 142(19):1810-1820, 2020
7) Lewis CE, Fine LJ, Beddhu S et al:Final report of a trial of intensive versus stan-dard blood-pressure control. N Engl J Med 384(20):1921-1930, 2021
8) Kazem R, Zeinab B, Milad N et al:Phar-macological blood pressure lowering for primary and secondary prevention of car-diovascular disease across different levels of blood pressure:an individual partici-pant-level data meta-analysis. Lancet 397(10285):1625-1636, 2021
P.357 掲載の参考文献
9) Yang WY, Melgarejo JD, Thijs L et al:Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 322(5):409-420, 2019
10) Hermida RC, Crespo JJ, Dominguez-Sardi-na M et al:Bedtime hypertension treat-ment improves cardiovascular risk reduc-tion:the Hygia Chronotherapy Trial. Eur Heart J 41(48):4565-4576, 2020
11) Azizi M, Schmieder RE, Mahfoud F et al:Endovascular ultrasound renal denerva-tion to treat hypertension(RADIANCE-HTN SOLO):A multicentre, international,single-blind, randomised, sham-controlled trial. Lancet 391(10137):2335-2345, 2018
P.358 掲載の参考文献
12) Bohm M, Kario K, Kandzari DE et al:Efficacy of catheter-based renal denerva-tion in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):A multicentre, randomised, sh-am-controlled trial. Lancet 395(10234):1444-1451, 2020
13) Azizi M, Sanghvi K, Saxena M et al:Ultrasound renal denervation for hyper-tension resistant to a triple medication pill (RADIANCE-HTN TRIO):A randomised, multicentre, single-blind, sham-controlled trial. Lancet 397(10293):2476-2486, 2021
14) Mahfoud F, Townsend RR, Kandzari DE et al:Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol 77(23):2909-2919, 2021
15) Mahfoud F, Mancia G, Schmieder R et al:Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol 75(23):2879-2888, 2020
P.359 掲載の参考文献
16) Krum H, Schlaich MP, Sobotka PA et al:Percutaneous renal denervation in pa-tients with treatment-resistant hyperten-sion:final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622-629, 2014
17) Hughes D, Judge C, Murphy R et al:Asso-ciation of blood pressure lowering with in-cident dementia or cognitive impairment:A systematic review and meta-analysis. JAMA 323(19):1934-1944, 2020
18) Rouch L, Vidal JS, Hoang T et al:Systolic blood pressure postural changes variability is associated with greater dementia risk. Neurology 95(14):e1932-e1940, 2020
19) Wright JT Jr, Williamson JD, Whelton PK et al:A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373(22):2103-2116, 2015
P.362 掲載の参考文献
1) Kitahara S, Kataoka Y, Miura H et al:The feasibility and limitation of coronary com-puted tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo:Findings from near-infrared spec-troscopy analysis. Atherosclerosis 322:1-7, 2021
2) Murai K, Kataoka Y, Nakaoku Y et al:The association between the extent of lipidic burden and delta-fractional flow reserve:analysis from coronary physi-ological and near-infrared spectroscopic measures. Cardiovasc Diagn Ther 11:362-372, 2021
P.363 掲載の参考文献
3) Bayturan O, Kapadia S, Nicholls SJ et al:Clinical predictors of plaque progression despite very low levels of low-density lipo-protein cholesterol. J Am Coll Cardiol 55:2736-2742, 2010
4) Cannon CP, Blazing MA, Giugliano RP et al:Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387-2397, 2015
5) Ouchi Y, Sasaki J, Arai H et al:Ezetimibe lipid-lowering trial on prevention of ath-erosclerotic cardiovascular disease in 75 or older(EWTOPIA 75):A randomized, controlled trial. Circulation 140:992-1003, 2019
6) Tsujita K, Sugiyama S, Sumida H et al:Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percu-taneous coronary intervention:The mul-ticenter randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol 66:495-507, 2015
P.364 掲載の参考文献
7) Abifadel M, Varret M, Rabes JP et al:Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156, 2003
8) Hirayama A, Yamashita S, Ruzza A et al:Long-term treatment with evolocumab among Japanese patients-Final report of the OSLER Open-Label Extension Studies. Circ J 83:971-977, 2019
9) Teramoto T, Kobayashi M, Tasaki H et al:Efficacy and safety of alirocumab in Japanese patients with heterozygous famil-ial hypercholesterolemia or at high cardio-vascular risk with hypercholesterolemia not adequately controlled with statins-ODYSSEY JAPAN Randomized Controlled Trial. Circ J 80:1980-1987, 2016
10) Sabatine MS, Giugliano RP, Keech AC et al:Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713-1722, 2017
11) Schwartz GG, Steg PG, Szarek M et al:Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097-2107, 2018
P.365 掲載の参考文献
12) Nicholls SJ, Puri R, Anderson T et al:Ef-fect of evolocumab on progression of coro-nary disease in statin-treated patients:The GLAGOV randomized clinical trial. JAMA 316:2373-2384, 2016
13) Nicholls SJ, Nissen SE, Prati F et al:As-sessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography:rationale and de-sign of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther 11:120-129, 2021
14) Bergmark BA, O'Donoghue ML, Murphy SA et al:An exploratory analysis of pro-protein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURI-ER Trial. JAMA Cardiol 5:709-713, 2020
15) Marston NA, Gurmu Y, Melloni GEM et al:The effect of PCSK9(proprotein con-vertase subtilisin/kexin type 9)inhibition on the risk of venous thromboembolism. Circulation 141:1600-1607, 2020
16) Ray KK, Bays HE, Catapano AL et al:Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 380:1022-1032, 2019
17) Nicholls S, Lincoff AM, Bays HE et al:Ra-tionale and design of the CLEAR-outcomes trial:Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 235:104-112, 2021
P.366 掲載の参考文献
18) Kataoka Y, Harada-Shiba M, Nakao K et al:Mature proprotein convertase sub-tilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in hetero-zygous familial hypercholesterolemia. J Clin Lipidol 11:413-421. e3, 2017
19) Doi T, Hori M, Harada-Shiba M et al:Patients with LDLR and PCSK9 gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia. J Am Heart Assoc 10:e018263, 2021
20) Santos RD, Gidding SS, Hegele RA et al:Defining severe familial hypercholester-olaemia and the implications for clinical management:a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholester-olemia Panel. Lancet Diabetes Endocrinol 4:850-861, 2016
21) Funabashi S, Kataoka Y, Hori M et al:Substantially elevated athweroscleortic risks in Japanese severe familial hypercho-lesterolemia defined by the International Atherosclerosis Society. JACC Asia, 2021(in press)
P.367 掲載の参考文献
22) Raal FJ, Rosenson RS, Reeskamp LF et al:Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 383:711-720, 2020
P.368 掲載の参考文献
23) Kataoka Y, St John J, Wolski K et al:Ath-eroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol 35:990-995, 2015
24) Kuyama N, Kataoka Y, Takegami M et al:Circulating mature PCSK9 level pre-dicts diminished response to statin thera-py. J Am Heart Assoc 10:e019525, 2021
25) Nochioka K, Sakata Y, Miyata S et al:Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 79:574-582, 2015
26) Scirica BM, Morrow DA, Cannon CP et al:Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47:2326-2331, 2006
27) Sugane H, Kataoka Y, Otsuka F et al:Cardiac outcomes in patients with acute coronary syndrome attributable to calcified nodule. Atherosclerosis 318:70-75, 2020
P.369 掲載の参考文献
28) Shishikura D, Kataoka Y, Di Giovanni G et al:Progression of ultrasound plaque at-tenuation and low echogenicity associates with major adverse cardiovascular events. Eur Heart J 41:2965-2973, 2020
29) Nordestgaard BG, Varbo A:Triglycer-ides and cardiovascular disease. Lancet 384:626-635, 2014
30) Puri R, Nissen SE, Shao M et al:Non-HDL cholesterol and triglycerides:Implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol 36:2220-2228, 2016
P.370 掲載の参考文献
31) Pradhan AD, Paynter NP, Everett BM et al:Rationale and design of the Pemafi-brate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes(PROMINENT)study. Am Heart J 206:80-93, 2018
32) Bhatt DL, Steg PG, Miller M et al:Car-diovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11-22, 2018
33) Nicholls SJ, Lincoff AM, Garcia M et al:Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk:The STRENGTH Randomized Clini-cal Trial. JAMA 324:2268-2280, 2020
34) Kalstad AA, Myhre PL, Laake K et al:Effects of n-3 fatty acid supplements in elderly patients after myocardial infarc-tion:A randomized, controlled trial. Circu-lation 143:528-539, 2020
35) Ridker PM, Everett BM, Thuren T et al:Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 377:1119-1131, 2017
P.371 掲載の参考文献
1) Knuuti J, Wijns W, Saraste A et al:2019 ESC Guidelines for the diagnosis and man-agement of chronic coronary syndromes. Eur Heart J 41(3):407-477, 2020
P.372 掲載の参考文献
2) 日本糖尿病学会:糖尿病診療ガイドライン2019. 2019
3) Kimura K, Kimura T, Ishihara M et al:JCS 2018 Guideline on diagnosis and treat-ment of acute coronary syndrome. Circ J 83(5):1085-1196, 2019
4) Cosentino F, Grant PJ, Aboyans V et al:2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255-323, 2020
P.373 掲載の参考文献
5) Pagidipati NJ, Navar AM, Pieper KS et al:Secondary prevention of cardiovascu-lar disease in patients with type 2 diabetes mellitus:International Insights From the TECOS Trial(Trial Evaluating Car-diovascular Outcomes With Sitagliptin). Circulation 136(13):1193-1203, 2017
6) O'Connor PJ, Sperl-Hillen JAM, Johnson PE et al:Clinical inertia and outpatient medical errors. In:Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety:From Research to Implementation(Volume 2:Concepts and Methodology). Rockville(MD), 2005
7) Zinman B, Wanner C, Lachin JM et al:Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117-2128, 2015
8) Neal B, Perkovic V, Mahaffey KW et al:Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644-657, 2017
9) Wiviott SD, Raz I, Bonaca MP et al:Dapa-gliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347-357, 2019
10) Zelniker TA, Wiviott SD, Raz I et al:SGLT2 inhibitors for primary and second-ary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascu-lar outcome trials. Lancet 393(10166):31-39, 2019
P.374 掲載の参考文献
11) Perkovic V, Jardine MJ, Neal B et al:Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295-2306, 2019
12) McMurray JJV, Solomon SD, Inzucchi SE et al:Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995-2008, 2019
13) Packer M, Anker SD, Butler J et al:Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413-1424, 2020
14) Zannad F, Ferreira JP, Pocock SJ et al:SGLT2 inhibitors in patients with heart failure with reduced ejection fraction:a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819-829, 2020
15) Heerspink HJL, Stefansson BV, Correa-Rotter R et al:Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436-1446, 2020
16) Shimizu W, Kubota Y, Hoshika Y et al:Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus:the EMBODY trial. Cardiovasc Diabetol 19(1):148, 2020
P.375 掲載の参考文献
17) Marso SP, Daniels GH, Brown-Frandsen K et al:Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311-322, 2016
18) Marso SP, Bain SC, Consoli A et al:Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834-1844, 2016
19) Gerstein HC, Colhoun HM, Dagenais GR et al:Dulaglutide and cardiovascular out-comes in type 2 diabetes(REWIND):a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121-130, 2019
20) Husain M, Birkenfeld AL, Donsmark M et al:Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841-851, 2019
21) Yabe D, Nakamura J, Kaneto H et al:Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes(PIONEER 10):an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 8(5):392-406, 2020
22) Pieber TR, Bode B, Mertens A et al:Ef-ficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes(PIONEER 7):a mul-ticentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 7(7):528-539, 2019
P.376 掲載の参考文献
23) Kristensen SL, Rorth R, Jhund PS et al:Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a system-atic review and meta-analysis of cardio-vascular outcome trials. Lancet Diabetes Endocrinol 7(10):776-785, 2019
24) Zelniker TA, Wiviott SD, Raz I et al:Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glu-cose cotransporter 2 inhibitors for preven-tion of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139(17):2022-2031, 2019
P.378 掲載の参考文献
1) Taguchi I, Iimuro S, Iwata H et al:High-dose versus low-dose pitavastatin in Japa-nese patients with stable coronary artery disease(REAL-CAD):A randomized su-periority trial. Circulation 137:1997-2009, 2018
2) Teramoto T, Uno K, Miyoshi I et al:Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world:An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis 251:248-254, 2016
3) Tsujita K, Sugiyama S, Sumida H et al:Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percu-taneous coronary intervention:The mul-ticenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66:495-507, 2015
4) Cannon CP, Blazing MA, Giugliano RP et al:Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387-2397, 2015
5) Nozue T:Lipid lowering therapy and circulating PCSK9 concentration. J Ath-eroscler Thromb 24:895-907, 2017
P.379 掲載の参考文献
6) Nicholls SJ, Puri R, Anderson T et al:Ef-fect of evolocumab on progression of coro-nary disease in statin-treated patients:The GLAGOV randomized clinical trial. JAMA 316:2373-2384, 2016
7) Sabatine MS, Giugliano RP, Keech AC et al:Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713-1722, 2017
8) Ibanez B, James S, Agewall S et al:2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients pre-senting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J 39:119-177, 2018
9) Tada H, Kawashiri MA, Nomura A et al:Serum triglycerides predict first cardio-vascular events in diabetic patients with hypercholesterolemia and retinopathy. Eur J Prev Cardiol 25:1852-1860, 2018
10) Lawler PR, Kotrri G, Koh M et al:Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligi-bility for emerging therapies. Eur Heart J 41:86-94, 2020
11) Miller M, Cannon CP, Murphy SA et al:Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51:724-730, 2008
12) Yamashita S, Masuda D, Matsuzawa Y:Clinical Applications of a novel selective PPAR alpha modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb 26:389-402, 2019
P.380 掲載の参考文献
13) Fruchart JC, Santos RD, Aguilar-Salinas C et al:The selective peroxisome prolif-erator-activated receptor alpha modulator (SPPARMα)paradigm:conceptual frame-work and therapeutic potential:A consen-sus statement from the International Ath-erosclerosis Society(IAS)and the Residual Risk Reduction Initiative(R3i)Foundation. Cardiovasc Diabetol 18:71, 2019
14) Marston NA, Giugliano RP, Im K et al:Association between triglyceride lower-ing and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes:A systematic review and meta-re-gression analysis of randomized controlled trials. Circulation 140:1308-1317, 2019
15) Pradhan AD, Paynter NP, Everett BM et al:Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with dia-betes(PROMINENT)study. Am Heart J 206:80-93, 2018
16) Nozue T, Yamamoto S, Tohyama S et al:Effects of serum n-3 to n-6 polyunsatu-rated fatty acids ratios on coronary ath-erosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol 111:6-11, 2013
17) Nozue T, Yamamoto S, Tohyama S et al:A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol. Am J Car-diovasc Dis 3:255-263, 2013
18) Nozue T, Michishita I:Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipid-emia. Lipids Health Dis14:67, 2015
19) Nozue T, Yamamoto S, Tohyama S et al:Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coro-nary atherosclerosis in patients treated with pitavastatin or pravastatin undergo-ing percutaneous coronary intervention. Am J Cardiol 111:1570-1575, 2013
20) Yokoyama M, Origasa H, Matsuzaki M et al:Effects of eicosapentaenoic acid on major coronary events in hypercholester-olaemic patients(JELIS):A randomised open-label, blinded endpoint analysis. Lan-cet 369:1090-1098, 2007
21) Kita Y, Watanabe M, Kamon D et al:Effects of fatty acid therapy in addition to strong statin on coronary plaques in acute coronary syndrome:An optical coherence tomography study. J Am Heart Assoc 9:e015593, 2020
P.381 掲載の参考文献
22) Bhatt DL, Steg PG, Miller M et al;REDUCE-IT Investigators:Cardiovascu-lar risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11-22, 2019
23) Emdin CA, Khera AV, Natarajan P et al:Phenotypic characterization of genetically lowered human lipoprotein(a)levels. J Am Coll Cardiol 68:2761-2772, 2016
24) Tada, H, Takamura M, Kawashiri MA:Lipoprotein(a)as an old and new causal risk factor of atherosclerotic cardiovascu-lar disease. J Atheroscler Thromb 26:583-591, 2019
25) Nozue T, Yamamoto S, Tohyama S et al:Lipoprotein(a)is associated with necrotic core progression of non-culprit coronary le-sions in statin-treated patients with angina pectoris. Lipids Health Dis13:59, 2014
26) Khera AV, Everett BM, Caulfield MP et al:Lipoprotein(a)concentrations, ro-suvastatin therapy, and residual vascular risk:An analysis from the JUPITER Trial (Justification for the Use of Statins in Pre-vention:an Intervention Trial Evaluating Rosuvastatin). Circulation 129:635-642, 2014
27) Toth PP, Jones SR, Monsalvo ML et al:Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a):A pooled analysis of phase 2 and phase 3 studies. J Am Heart Assoc 9:e014129, 2020
28) O'Donoghue ML, Fazio S, Giugliano RP et al:Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139:1483-1492, 2019
29) Higashioka M, Sakata S, Honda T et al:Small dense low-density lipoprotein cho-lesterol and the risk of coronary heart disease in a Japanese community. J Ath-eroscler Thromb 27:669-682, 2020
30) Sekimoto T, Koba S, Mori H et al:Small dense low-density lipoprotein choles-terol:A residual risk for rapid progression of non-culprit coronary lesion in patients with acute coronary syndrome. J Athero-scler Thromb, 2021
31) Santos HO, Earnest CP, Tinsley GM et al:Small dense low-density lipoprotein-cholesterol(sdLDL-C):Analysis, effects on cardiovascular endpoints and dietary strate-gies. Prog Cardiovasc Dis 63:503-509, 2020
P.382 掲載の参考文献
32) Komiya I, Yamamoto A, Sunakawa S et al:Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hy-pertriglyceridemia:An observational study. Lipids Health Dis 20:17, 2021
33) Elshazly MB, Mani P, Nissen S et al:Rem-nant cholesterol, coronary atheroma pro-gression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol 27:1091-1100, 2020
34) Fujihara Y, Nakamura T, Horikoshi T et al:Remnant lipoproteins are residual risk factor for future cardiovascular events in patients with stable coronary artery dis-ease and on-statin low-density lipoprotein cholesterol levels < 70 mg/dL Circ J 83:1302-1308, 2019
35) Jepsen AM, Langsted A, Varbo A et al:Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart dis-ease Clin Chem 62:593-604, 2016
36) Masuda D, Yamashita S:Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb 24:95-109, 2017
37) Ishibashi S, Yamashita S, Arai H et al;K-877-04 study group:Effects of K-877, a novel selective PPARalpha modulator(SP-PARMalpha), in dyslipidaemic patients:A randomized, double blind, active- and placebo-controlled, phase 2 trial. Athero-sclerosis 249:36-43, 2016
XI章 心肺蘇生術・集中治療・管理
P.384 掲載の参考文献
1) Mancusi C, Carlino MV, Sforza A:Point-of-care ultrasound with pocket-size de-vices in emergency department. Echocar-diography(Mount Kisco, NY)36:1755-1764, 2019
2) Schmidt S, Dieks JK, Quintel M et al:Critical Care Echocardiography as a Rou-tine Procedure for the Detection and Early Treatment of Cardiac Pathologies. Diagnos-tics(Basel, Switzerland)10:671, 2020
P.385 掲載の参考文献
3) Via G, Hussain A, Wells M et al:Interna-tional evidence-based recommendations for focused cardiac ultrasound. J Am Soc Echocardiogr 27:683.e1-683.e33, 2014
4) Nishigami K:Point-of-care echocardiog-raphy for aortic dissection, pulmonary embolism and acute coronary syndrome in patients with killer chest pain:EASY screening focused on the assessment of effusion, aorta, ventricular size and shape and ventricular asynergy. J Echocardiogr 13:141-144, 2015
5) 大手信之, 石津智子, 泉 知里 他:2021年改訂版 循環器超音波検査の適応と判読ガイドライン. 2021
6) Nazerian P, Vanni S, Castelli M et al:Diagnostic performance of emergency transthoracic focus cardiac ultrasound in suspected acute type A aortic dissection. Intern Emerg Med 9:665-670, 2014
7) Daley JI, Dwyer KH, Grunwald Z et al:Increased Sensitivity of Focused Cardiac Ultrasound for Pulmonary Embolism in Emergency Department Patients With Abnormal Vital Signs. Acad Emerg Med 26:1211-1220, 2019
P.386 掲載の参考文献
8) Ghane MR, Gharib MH, Ebrahimi A et al:Accuracy of Rapid Ultrasound in Shock(RUSH) Exam for Diagnosis of Shock in Critically Ill Patients. Trauma Mon 20:e20095, 2015
9) Kedan I, Ciozda W, Palatinus JA et al:Prognostic value of point-of-care ultra-sound during cardiac arrest:a systematic review. Cardiovasc Ultrasound 18:1, 2020
10) Dudek M, Szarpak L, Peacock FW et al:Diagnostic performance of point-of-use ultrasound of resuscitation outcomes:A systematic review and meta-analysis of 3265 patients. Cardiol J 2021[online ahead of print]
11) Reynolds JC, Issa MS, T CN et al:Prognostication with point-of-care echo-cardiography during cardiac arrest:A systematic review. Resuscitation 152:56-68, 2020
12) Soar J, Berg KM, Andersen LW et al:Adult Advanced Life Support:2020 Inter-national Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovas-cular Care Science with Treatment Rec-ommendations. Resuscitation 156:A80-A119, 2020
P.387 掲載の参考文献
13) Medvedofsky D, Mor-Avi V, Amzulescu M et al:Three-dimensional echocardiograph-ic quantification of the left-heart chambers using an automated adaptive analytics algorithm:multicentre validation study. Eur Heart J Cardiovasc Imaging 19:47-58, 2018
14) Kusunose K, Abe T, Haga A et al:A Deep Learning Approach for Assessment of Regional Wall Motion Abnormality From Echocardiographic Images. JACC Cardiovasc Imaging 13:374-381, 2020
15) Filipiak-Strzecka D, Kasprzak JD, Wejner-Mik P et al:Artificial Intelligence-Powered Measurement of Left Ventricular Ejection Fraction Using a Handheld Ultra-sound Device. Ultrasound Med Biol 47:1120-1125, 2021
P.388 掲載の参考文献
16) Nagueh SF, Smiseth OA, Appleton CP et al:Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography:An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart J Cardiovasc Im-aging 17:1321-1360, 2016
17) Ran H, Schneider M, Pistritto AM et al:Echocardiographic evaluation of left ven-tricular filling pressures in patients with pulmonary hypertension. Int J Cardiovasc Imaging 35:861-868, 2019
18) Romano G, Magro S, Agnese V et al:Echocardiography to estimate high filling pressure in patients with heart failure and reduced ejection fraction. ESC Heart Fail-ure 7:2268-2277, 2020
19) Brault C, Marc J, Mercado P et al:Esti-mation of Pulmonary Artery Occlusion Pressure Using Doppler Echocardiogra-phy in Mechanically Ventilated Patients. Crit Care Med 48:e943-e950, 2020
20) Mercado P, Maizel J, Marc J et al:Doppler Echocardiographic Indices Are Specific But Not Sensitive to Predict Pulmonary Artery Occlusion Pressure in Critically Ill Patients Under Mechanical Ventilation. Crit Care Med 49:e1-e10, 2021
P.389 掲載の参考文献
21) Venkateshvaran A, Seidova N, Tureli HO et al:Accuracy of echocardiographic es-timates of pulmonary artery pressures in pulmonary hypertension:insights from the KARUM hemodynamic database. Int J Cardiovasc Imaging, 2021
22) Aashish A, Giridharan S, Karthikeyan S et al:Assessment of Pulmonary Artery Pressures by Various Doppler Echocar-diographic Parameters and its Correlation with Cardiac Catheterization in Patients with Pulmonary Hypertension. Heart Views 21:263-268, 2020
23) Galie N, Humbert M, Vachiery JL et al:2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hyperten-sion:The Joint Task Force for the Diagno-sis and Treatment of Pulmonary Hyperten-sion of the European Society of Cardiology (ESC)and the European Respiratory Soci-ety(ERS):Endorsed by:Association for European Paediatric and Congenital Car-diology(AEPC), International Society for Heart and Lung Transplantation(ISHLT). Eur Heart J 37:67-119, 2016
24) Hussain A, Via G, Melniker L et al:Multi-organ point-of-care ultrasound for CO-VID-19(PoCUS4COVID):international expert consensus. Crit Care(London, Eng-land)24:702, 2020
25) Zanobetti M, Scorpiniti M, Gigli C et al:Point-of-Care Ultrasonography for Evalu-ation of Acute Dyspnea in the ED. Chest 151:1295-1301, 2017
P.390 掲載の参考文献
26) Johri AM, Galen B, Kirkpatrick JN et al:ASE Statement on Point-of-Care Ultra-sound during the 2019 Novel Coronavirus Pandemic. J Am Soc Echocardiogr 33:670-673, 2020
27) Caronia J, Sarzynski A, Tofighi B et al:Resident performed two-point compression ultrasound is inadequate for diagnosis of deep vein thrombosis in the critically III. J Thromb Thrombolysis 37:298-302, 2014
28) Dweck MR, Bularga A, Hahn RT et al:Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Car-diovasc Imaging 21:949-958, 2020
29) Iyengar-Kapuganti RL, Patel N, Anastasius M et al:Point-of-Care Ultrasound Find-ings and Clinical Outcomes in Patients with COVID-19. J Am Soc Echocardiogr 33:1416-1417, 2020
P.391 掲載の参考文献
1) 総務省消防庁ホームページ https://www.jhf.or.jp/pro/info/kyukyu.html
2) 米国心臓協会:CPR およびECCのガイドライン ハイライト版. 2020
3) 日本蘇生協議会:JRC蘇生ガイドライン2020 オンライン版.
P.392 掲載の参考文献
4) Paiva EF, Paxton JH, O'Neil BJ et al:Data supporting the use of end-tidal carbon diox-ide(ETCO2)measurement to guide man-agement of cardiac arrest:A systematic review. Resuscitation 18:1497-1508, 2018
P.393 掲載の参考文献
5) Bougoiun W, Dumas F, Lamhaut L et al:Extracorporeal cardiopulmonary resusci-tation in out-of-hospital cardiac arrest:a registry study. Eur Heart J 41(21):1961-1971, 2020
6) Ohbe H, Isogai S, Jo T et al:Extracorpo-real membrane oxygenation improves out-comes of accidental hypothermia without vital signs:A nationwide observational study. Resuscitation 144:27-32, 2019
7) Miyazaki K, Hikone M, Kuwahara Y et al:Extracorporeal CPR for massive pul-monary embolism in a "hybrid 2136 emer-gency department". Am J Emerg Med 37(12):2132-2135, 2019
8) Nakashima T, Noguchi T, Tahara Y et al:Patients with refractory out-of-cardiac arrest and sustained ventricular fibrilla-tion as candidates for extracorporeal car-diopulmonary resuscitation-Prospective multi-center observational study. Circ J 83(5):1011-1018, 2019
9) Yannopoulos D, Bartos J, Reveendran G et al:Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation(AR-REST):a phase 2, single centre, open-label, randomised controlled trial. Lancet 396(10265):1807-1816, 2020
10) Sakamoto T, Morimura N, Nagao K et al:Extracorporeal cardiopulmonary re-suscitation versus conventional cardiopul-monary resuscitation in adults with out-of-hospital cardiac arrest:a prospective observational study. Resuscitation 85:762-768, 2014
11) Zeiner A, Holzer M, Sterz F et al:Hyper-thermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med 161(16):2007-12, 2001
12) Yokobori S, Frantzen J, Bullock R et al:The use of hypothermia therapy in traumatic ischemic/reperfusional brain injury:Review of the literatures. Ther Hypothermia Temp Manag 1(4):185-192, 2011
P.394 掲載の参考文献
13) Nunnally ME, Jaeschke R, Bellingan GJ et al:Targeted temperature management in critical care:A report and recommenda-tions from five professional societies. Criti-cal Care Med 39(5):1113-1125, 2011
14) Hypothermia after Cardiac Arrest Study Group:Mild therapeutic hypothermia to improve the neurologic outcome after car-diac arrest. N Engl J Med 346(8):549-556, 2002
15) Bernard SA, Gray TW, Buist MD et al:Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 346(8):557-563, 2002
16) Nielsen N, Wetterslev J, Cronberg T et al:Targeted temperature management at 33℃ versus 36℃ after cardiac arrest. N Engl J Med 369(23):2197-2206, 2013
17) Mader TJ, Nathanson BH, Soares WE 3rd et al:Comparative effectiveness of thera-peutic hypothermia after out-of-hospital cardiac arrest:Insight from a large data registry. Ther Hypothermia Temp Manag 4(1):21-31, 2014
18) Perman SM, Grossestreuer AV, Wiebe DJ et al:The utility of therapeutic hypother-mia for post-cardiac arrest syndrome pa-tients with an initial nonshockable rhythm. Circulation 132(22):2146-2151, 2015
19) Chan PS, Berg RA, Tang Y et al:Associa-tion between therapeutic hypothermia and survival after in-hospital cardiac arrest. JAMA 316(13):1375-1382, 2016
20) Yoshida M, Yoshida T, Masui Y et al:As-sociation between therapeutic hypother-mia and outcomes in patients with non-shockable out-of-hospital cardiac arrest developed after emergency medical ser-vice arrival(SOS-KANTO 2012 Analysis Report). Neurocrit Care 30(2):429-439, 2019
21) Dankiewicz J, Cronberg T, Lilja G et al:Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Eng J Med 384:2283-2294, 2021
P.395 掲載の参考文献
22) Taccone FS, Picetti E, Vincent JL et al:High quality targeted temperature man-agement(TTM)after cardiac arrest. Critical Care 24(1):6, 2020
23) Abella BS, Zhao D, Alvarado J et al:Intra-arrest cooling improves outcomes in a murine cardiac arrest model. Circulation 109(22):2786-2791, 2004
24) Cho E, Lee SE, Park E et al:Pilot study on a rewarming rate of 0.15 degrees C/hr versus 0.25 degrees C/hr and outcomes in post cardiac arrest patients. Clin Exp Emerg Med 6:25-30, 2019
25) Hifumi T, Inoue A, Kokubu N et al:Asso-ciation between rewarming duration and neurological outcome in out-of-hospital car-diac arrest patients receiving therapeutic hypothermia. Resuscitation. 146:170-177, 2020
26) Calabro L, Bougouin W, Cariou A et al:Effect of different methods of cooling for targeted temperature management on outcome after cardiac arrest:a systemat-ic review and meta-analysis. Critical Care 23:285, 2019
27) Rossi S, Zanier ER, Mauri I et al:Brain temperature, body core temperature, and intracranial pressure in acute cerebral damage. J Neurol Neurosurg Psychiatry 71:448-454, 2001
28) Shin J, Kim J, Song K et al:Core tem-perature measurement in therapeutic hy-pothermia according to different phases:comparison of bladder, rectal, and tym-panic versus pulmonary artery methods. Resuscitation 84(6):810-817, 2013
29) Kirkegaard H, Soreide E, de Haas I et al:Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest:A random-ized clinical trial. JAMA 318(4):341-350, 2017
P.396 掲載の参考文献
30) Pilcher J, Weatherall M, Shirtcliffe P et al:The effect of hyperoxia following cardiac arrest-A systematic review and meta-analysis of animal trials. Resuscita-tion 83(4):417-422, 2012
31) Roberts BW, Kilgannon JH, Hunter BR et al:Association between early hyperoxia exposure after resuscitation from car-diac arrest and neurological disability:Prospective multicenter protocol-directed cohort study. Circulation 137(20):2114-2124, 2018
32) Sekhon MS, Gooderham P, Menon DK et al:The burden of brain hypoxia and optimal mean arterial pressure in patients with hypoxic ischemic brain injury after cardiac arrest. Crit Care Med 57(7):960-969, 2019
P.397 掲載の参考文献
33) Kishimori T, Matsuyama T, Yamada T et al:Intra-aortic balloon pump and sur-vival with favorable neurological outcome after out-of-hospital cardiac arrest:A multicenter, prospective propensity score-matched study. Resuscitation 143:165-172, 2019
34) Sieweke JT, Akin M, Beheshty JA et al:Unloading in refractory cardiogenic shock after out-of-hospital cardiac arrest due to acute myocardial infarction-a propensity score-matched analysis. Front Cardiovasc Med 24:704312, 2021
35) 江尻健太郎:心肺蘇生後の対応. INTEN-SIVIST 13(1):71-82, 2021
36) Martin M, Reignier J, Le Thuaut A et al:Nutrition during targeted temperature management after cardiac arrest:obser-vational study of neurological outcomes and nutrition tolerance. JPEN J Parenter Enteral Nutr 44(1):138-145, 2020
37) 関根秀介, 横山雄樹, 萩原幸彦 他:体温管理療法の現状. 日臨麻会誌 40(2):172-177, 2020
P.398 掲載の参考文献
38) Francois B, Cariou A, Clere-Jehl R et al:Prevention of early ventilator-associated pneumonia after cardiac arrest. N Engl J Med 381(19):1831-1842, 2019
39) May TL, Riker RR, Fraser GL et al:Variation in sedation and neuromuscular blockade regimens on outcome after car-diac arrest. Critical Care Med 46(10):975-980, 2018
40) Sandroni C, D'Arrigo S, Cacciola S et al:Prediction of poor neurological outcome in comatose survivors of cardiac arrest:a systematic review. Intensive Care Med 46(10):1803-1851, 2020
41) You Y, Park JS, Min J et al:The useful-ness of neuron-specific enolase in cere-brospinal fluid to predict neurological prognosis in cardiac arrest survivors who underwent target temperature manage-ment:A prospective observational study. Resuscitation 145:185-191, 2019
42) Scarpino M, Carrai R, Loll F et al:Neuro-physiology for predicting good and poor neurological outcome at 12 and 72h after cardiac arrest:The ProNeCA multicenter prospective study. Resuscitation 147:95-103, 2020
P.400 掲載の参考文献
1) Henry TD, Tomey MI, Tamis-Holland JE et al:Invasive management of acute myo-cardial infarction complicated by cardio-genic shock:A scientidic statement from the American Heart Association. Circula-tion 143:e815-e829, 2021
2) Hunziker L, Radovanovic D, Jeger R et al:Twenty-year trends in the incidence and outcome of cardiogenic shock in AMIS plus registry. Circ Cardiovasc Interv 12(4):e007293, 2019
P.401 掲載の参考文献
3) Shiraishi Y, Kawana M, Nakata J et al:Time-sensetive approach in the manage-ment of acute heart failure. ESC Heart Fail 8(1):204-221, 2021
4) Baran DA, Long A, Badiye AP et al:Pro-spective validation of the SCAI shock clas-sification:Single center analysis. Catheter Cardiovasc Interv 96(7):1339-1347, 2020
P.402 掲載の参考文献
5) Jentzer J, Diepen S, Barsness G et al:Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol 74(17):2117-2128, 2019
6) Hanson ID, Tagami T, Mando R et al:SCAI shock classification in acute myocar-dial infarction:Insights from the National Cadiogenic Shock Initiative. Catheter Car-diovasc Interv 96(6):1137-1142, 2020
7) 日本循環器学会 他:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018
8) 日本循環器学会 他:急性冠症候群ガイドライン(2018年改訂版). 2019
P.403 掲載の参考文献
9) Thiele H, Zeymer U, Thelemann N et al:Intraaortic balloon pump in cardiogenic shock complicating acute myocardial in-farction:long-term 6-year outcome of the randomized IABP-SHOCK II Trial. Circu-lation 139:395-403, 2019
10) Ponikowski P, Voors AA, Anker SD et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiol-ogy(ESC). Developed with the special contribution of the Heart Failure Associa-tion(HFA)of the ESC. Eur J Heart Fail 18(8):891-975, 2016
11) Link MS, Berkow LC, Kudenchuk PJ et al:Part7:Adult advanced cardiovascu-lar life support:2015 American Heart Association Guidelines update for cardio-pulmonary resuscitation and emergency cardiovascular care. Circulation 132(18 supple 2):S444-S464, 2015
12) Sakamoto T, Morimura N, Nagao K et al:Extracorporeal cardiopulmonary resuscita-tion versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest:a prospective observa-tional study. Resuscitation 85(6):762-768, 2014
P.404 掲載の参考文献
13) 補助人工心臓治療関連学会協議会 インペラ部会:IMPELLA 適正使用指針. http://j-pvad.jp/
P.405 掲載の参考文献
14) Tehrani BN, Truesdell AG, Psotka MA et al:A standardized and comprehensive approach to the management of cardio-genic shock. JACC Heart Fail 8(11):879-891, 2020
15) O'Neill WW, Schreiber T, Wohns DH et al:The current use of Impella 2.5 in acute myocardial infarction complicated by car-digenic shock:results from the USpella Registry. J Interv Cardiol 27(1):1-11, 2014
16) Saku K, Kakino T, Arimura T et al:Left ventricular mechanical unloading by total support of Impella in myocardial infarction reduces infarct size, preserves left ven-tricular function, and revents subsequent heart faiulre in dogs. Circ Heart Fail 11(5):e004397, 2018
17) Kapur NK, Alkhouli MA, DeMartini TJ et al:Unloading the left ventricle before reperfusion in patients with anterior ST-segment-elevation myocardial infarction. Circulation 139(3):337-346, 2019
18) Schrage B, Becher PM, Bernhardt A et al:Left ventricular unloading is associ-ated with lower mortality in patients with cardiogenic shock treated with ve-noarterial extracorporeal membrane oxy-genation:Results from an international, multicenter cohort study. Circulation 142(22):2095-2106, 2020
P.406 掲載の参考文献
19) Tehrani BN, Truesdell AG, Sherwood MW et al:Standardized team-based care for cardiogenic shock. J Am Coll Cardiol 73(13):1659-1669, 2019
20) Basir MB, Kapur NK, Patel K et al:Improved outcome associated with the use of shock protocols:Updates from the National Cardiogenic Shock Initiative. Catheter Cardiovasc Interv 93(7):1173-1183, 2019
P.408 掲載の参考文献
1) Su IL, Wu VC, Chou AH et al:Risk factor analysis of postoperative acute respira-tory distress syndrome after type A aortic dissection repair surgery. Medicine(Balti-more)98(29):e16303, 2019
2) Konstantinides SV, Meyer G, Becattini C et al:2019 ESC Guidelines for the diagno-sis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society(ERS). Eur Heart J 41(4):543-603, 2020
P.409 掲載の参考文献
3) Amato MB, Meade MO, Slutsky AS et al:Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 372(8):747-755, 2015
4) Menk M, Estenssoro E, Sahetya SK et al:Current and evolving standards of care for patients with ARDS. Intensive Care Med 46(12):2157-2167, 2020
5) Gattinoni L, Tonetti T, Cressoni M et al:Ventilator-related causes of lung injury:the mechanical power. Intensive Care Med 42(10):1567-1575, 2016
6) Costa ELV, Slutsky AS, Brochard LJ et al:Ventilatory variables and mechanical power in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med, 2021
7) Billings FT 4th, Lopez MG, Shaw AD:The incidence, risk, presentation, patho-physiology, treatment, and effects of perioperative acute kidney injury. Can J Anaesth 68(3):409-422, 2021
8) Gameiro J, Marques F, Lopes JA:Long-term consequences of acute kidney in-jury:a narrative review. Clin Kidney J 14(3):789-804, 2020
P.410 掲載の参考文献
9) Gaudry S, Hajage D, Schortgen F et al:Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 375(2):122-133, 2016
10) Gaudry S, Hajage D, Martin-Lefevre L et al:Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury(AKIKI 2):a multicentre, open-label, randomised, con-trolled trial. Lancet 397(10281):1293-1300, 2021
11) Ikemura N, Shiraishi Y, Sawano M:Ex-ploring triaging and short-term outcomes of early invasive strategy in non-ST segment elevation acute coronary syndrome:A report from Japanese Multicenter Registry. J Clin Med 9(4):1106, 2020
12) Lun Z, Liu J, Liu L et al:Association of early and late contrast-associated acute kidney injury and long-term mortality in patients undergoing coronary angiogra-phy. J Interv Cardiol 2021
P.411 掲載の参考文献
13) 日本心不全学会ガイドライン委員会 編:心不全患者における栄養評価・管理に関するステートメント.
14) Shiraishi Y, Kohsaka S, Abe T et al:Derivation and validation of clinical predic-tion models for rapid risk stratification for time-sensitive management for acute heart failure. J Clin Med 9(11):3394, 2020
15) Singer P, Blaser AR, Berger MM et al:ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 38(1):48-79, 2019
16) McClave SA, Martindale RG, Vanek VW et al:Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient:Society of Critical Care Medicine(SCCM)and American Society for Parenteral and En-teral Nutrition(A.S.P.E.N.). JPEN J Par-enter Enteral Nutr 40(2):159-211, 2016
17) Critical Care Nutrition:The Canadian clinical practice guidelines(2015). http://www.criticalcarenutrition.com
18) Lambell KJ, Tatucu-Babet OA, Chapple LA et al:Nutrition therapy in critical illness:a review of the literature for clini-cians. Crit Care 24(1):35, 2020
P.412 掲載の参考文献
19) Reignier J, Boisrame-Helms J, Brisard L et al:Enteral versus parenteral early nutrition in ventilated adults with shock:a randomised, controlled, multicentre, open-label, parallel-group study(NUTRI-REA-2). Lancet 391(10116):133-143, 2018
20) Gonzalez-Granda A, Schollenberger A, Haap M et al:Optimization of nutrition therapy with the use of calorimetry to determine and control energy needs in mechanically ventilated critically ill pa-tients:The ONCA Study, a randomized, prospective pilot study. JPEN J Parenter Enteral Nutr 43(4):481-489, 2019
21) Rosenthal MD, Vanzant EL, Moore FA:Chronic critical illness and pics nutritional strategies. J Clin Med 10(11):2294, 2021
P.413 掲載の参考文献
22) Koekkoek WACK, van Setten CHC, Olthof LE et al:Timing of PROTein INtake and clinical outcomes of adult critically ill patients on prolonged mechanical VENTi-lation:The PROTINVENT retrospective study. Clin Nutr 38(2):883-890, 2019
最近チェックした商品履歴
Loading...